{"PMC7112587": [["IntroductionEvidence has been found of an increase in overall suicide rates following reporting of celebrity suicides (Jobes et al., 1996, Phillips, 1974, Stack, 1987, Takahashi, 1998, Tousignant et al., 2005) and non-suicide deaths (Hawton et al., 2000).", [["deaths", "DISEASE", 226, 232], ["increase", "OBSERVATION_MODIFIER", 42, 50]]], ["Furthermore, the impact of suicides of entertainment celebrities appears to have a larger impact than that of other types of celebrity (Stack, 1987, Wasserman, 1984).IntroductionMoreover, young people seem to be more vulnerable to media influences (Hawton and Williams, 2005, Zahl and Hawton, 2004).", [["people", "ORGANISM", 194, 200], ["people", "SPECIES", 194, 200], ["larger", "OBSERVATION_MODIFIER", 83, 89]]], ["People come to learn the details of methods of suicide through media reporting of them, such as asphyxiation from the smoke of burning charcoal, especially in places like Hong Kong and Taiwan (Chan et al., 2005).", [["asphyxiation", "DISEASE", 96, 108], ["People", "ORGANISM", 0, 6], ["People", "SPECIES", 0, 6], ["burning charcoal", "TREATMENT", 127, 143]]], ["Suicide deaths by charcoal burning have increased from 3% in 1997 to 24% in 2002 of the total suicide death (Yip et al., 2005).", [["Suicide", "DISEASE", 0, 7], ["deaths", "DISEASE", 8, 14], ["charcoal", "CHEMICAL", 18, 26], ["death", "DISEASE", 102, 107], ["Suicide deaths", "PROBLEM", 0, 14], ["charcoal burning", "PROBLEM", 18, 34], ["the total suicide death", "PROBLEM", 84, 107], ["increased", "OBSERVATION_MODIFIER", 40, 49]]], ["303; Pirkis and Blood, 2001, p.", [["Pirkis", "TEST", 5, 11], ["Blood", "ANATOMY", 16, 21]]], ["150).IntroductionHowever, few studies have investigated the effects of celebrity suicides and the media reporting of them in Asia (Takahashi, 1998, Au et al., 2004), despite extensive mass media exposure and traditional idolization of celebrities within the region.IntroductionLeslie Cheung, a Hong Kong pop singer and actor who became famous during in the 1980s and 1990s, suffered from depression and committed suicide by jumping from a height on 1st April 2003 in Hong Kong.", [["depression", "DISEASE", 388, 398], ["few studies", "TEST", 26, 37], ["extensive mass media exposure", "TREATMENT", 174, 203], ["depression", "PROBLEM", 388, 398], ["extensive", "OBSERVATION_MODIFIER", 174, 183], ["mass", "OBSERVATION", 184, 188], ["media exposure", "OBSERVATION", 189, 203], ["celebrities", "OBSERVATION", 235, 246], ["region", "ANATOMY_MODIFIER", 258, 264], ["depression", "OBSERVATION", 388, 398]]], ["His funeral was held on 8th April 2003 and there was extensive media coverage of his death.", [["death", "DISEASE", 85, 90], ["his death", "PROBLEM", 81, 90]]], ["According to an electronic news clipping database, which covers all of Hong Kong's newspapers, there were 1243 news articles with his English name or Chinese name during the period between the 2nd April 2003 and 9th April 2003.", [["clipping", "OBSERVATION", 32, 40]]], ["On six of the eight days between the 2nd and 9th April (except 4th April and 5th April) at least one newspaper reported news of Cheung's death on the front page.", [["death", "DISEASE", 137, 142]]], ["Most of the newspaper articles were published in the first 16 days after his death (1701 articles).", [["death", "DISEASE", 77, 82], ["his death", "PROBLEM", 73, 82]]], ["During the subsequent 16 days there were 315 articles, and during the next 16 days only 102 articles.IntroductionThe specific aims of this study were to answer the following questions: (i) Was there a significant increase in suicides following the death of Cheung? (ii) Was there a particularly vulnerable group in the community more likely to be affected by news of Cheung's suicide? and (iii) Was there any difference in the profile of vulnerable people compared to those reported from similar studies in western countries?MethodsMortality data (including suicides) in Hong Kong, SAR during the period 1998 to 2003 were made available by the Census and Statistics Department and the Coroner's Court.", [["death", "DISEASE", 248, 253], ["people", "ORGANISM", 449, 455], ["people", "SPECIES", 449, 455], ["this study", "TEST", 134, 144], ["significant", "OBSERVATION_MODIFIER", 201, 212], ["increase", "OBSERVATION_MODIFIER", 213, 221], ["difference", "OBSERVATION_MODIFIER", 409, 419]]], ["All suicide deaths, coded in the range of E950\u2013E959 were classified and recorded according to the ICD-9 standard (World Health Organization, 1978).", [["deaths", "DISEASE", 12, 18], ["All suicide deaths", "PROBLEM", 0, 18]]], ["With the consent of the Coroner's Court we examined the case files of people who died by suicide in 2003.", [["people", "ORGANISM", 70, 76], ["people", "SPECIES", 70, 76]]], ["The files included information on socio-demographic variables, psychiatric illness, police investigation files and suicide notes (where available).", [["psychiatric illness", "DISEASE", 63, 82]]], ["For comparison, we selected the case files of people who died by suicide during the first six months of each year between 1998 and 2002.MethodsThe suicide rate in Hong Kong has increased markedly in recent years, rising from 13.2 per 100,000 in 1998 to 18.6 per 100,000 in 2003 (Center for Suicide Research and Prevention, 2005).", [["Suicide", "DISEASE", 290, 297], ["people", "ORGANISM", 46, 52], ["people", "SPECIES", 46, 52], ["increased", "OBSERVATION_MODIFIER", 177, 186], ["markedly", "OBSERVATION_MODIFIER", 187, 195]]], ["A chi-square test was used to examine the significance of differences in distribution.", [["A chi-square test", "TEST", 0, 17]]], ["In addition, we also examined the Coroner's death reports as well suicide notes for suicide deaths in 2003, and identified those which mentioned Cheung's death.Monthly distribution of suicide deaths ::: Results", [["death", "DISEASE", 44, 49], ["deaths", "DISEASE", 92, 98], ["death", "DISEASE", 154, 159], ["deaths", "DISEASE", 192, 198], ["Cheung's death", "PROBLEM", 145, 159]]]], "83b84ee9159c3a08c73a3f6d56226dc7bf52c6e2": [["INTRODUCTIONCanine enteritis is a common problem in small animal practice and, of the many causes, infectious viral agents are of considerable significance, Canine parvovirus (CPV), first appeared as a cause of severe, often haemorrhagic gastroenteritis with high mortality in 1978 (Appel and others 1978) .", [["enteritis", "DISEASE", 19, 28], ["Canine parvovirus (CPV)", "DISEASE", 157, 180], ["gastroenteritis", "DISEASE", 238, 253], ["Canine parvovirus", "ORGANISM", 157, 174], ["CPV", "ORGANISM", 176, 179], ["Canine parvovirus", "SPECIES", 157, 174], ["Canine parvovirus", "SPECIES", 157, 174], ["CPV", "SPECIES", 176, 179], ["INTRODUCTIONCanine enteritis", "PROBLEM", 0, 28], ["infectious viral agents", "TREATMENT", 99, 122], ["Canine parvovirus (CPV", "PROBLEM", 157, 179], ["haemorrhagic gastroenteritis", "PROBLEM", 225, 253], ["enteritis", "OBSERVATION", 19, 28], ["small", "OBSERVATION_MODIFIER", 52, 57], ["infectious", "OBSERVATION_MODIFIER", 99, 109], ["severe", "OBSERVATION_MODIFIER", 211, 217], ["haemorrhagic", "OBSERVATION_MODIFIER", 225, 237], ["gastroenteritis", "OBSERVATION", 238, 253]]], ["It has since been shown to have a worldwide distribution, and by early 1980 figures for seroprevalence generally ranged from 25 to 90 per cent (Helfer-Baker and others 1980 , Kramer and others 1980 , Pollock and Carmichael 1981 .", [["seroprevalence", "TEST", 88, 102], ["worldwide", "OBSERVATION_MODIFIER", 34, 43], ["distribution", "OBSERVATION_MODIFIER", 44, 56]]], ["More recently Olson and others (1988) in Sweden have reported seroprevalence rates to CPV of approximately 30 to 40 per cent in both unvaccinated and vaccinated adult dogs.INTRODUCTIONCanine coronavirus (CCV), first isolated from dogs with enteritis in 1971 (Binn and others 1974) , is generally thought to cause mild to moderate enteritis.", [["enteritis", "DISEASE", 240, 249], ["enteritis", "DISEASE", 330, 339], ["CPV", "ORGANISM", 86, 89], ["dogs", "ORGANISM", 167, 171], ["INTRODUCTIONCanine coronavirus", "ORGANISM", 172, 202], ["CCV", "ORGANISM", 204, 207], ["dogs", "ORGANISM", 230, 234], ["dogs", "SPECIES", 167, 171], ["coronavirus", "SPECIES", 191, 202], ["dogs", "SPECIES", 230, 234], ["CPV", "SPECIES", 86, 89], ["INTRODUCTIONCanine coronavirus", "SPECIES", 172, 202], ["CCV", "SPECIES", 204, 207], ["INTRODUCTIONCanine coronavirus", "PROBLEM", 172, 202], ["enteritis", "PROBLEM", 240, 249], ["mild to moderate enteritis", "PROBLEM", 313, 339], ["enteritis", "OBSERVATION", 240, 249], ["mild", "OBSERVATION_MODIFIER", 313, 317], ["moderate", "OBSERVATION_MODIFIER", 321, 329], ["enteritis", "OBSERVATION", 330, 339]]], ["Seroprevalence figures have been reported to range from 4 to 75 per cent in family dogs and 60 to 80 per cent in kennel populations (Cartwright 1973 , Pensaert and Callebaut 1978 , Helfer-Baker and others 1980 , Osterhaus and others 1980 Toma and Moraillon 1980) .INTRODUCTIONCanine distemper virus (CDV) may also cause gastroenteritis in dogs, but other body systems, particularly the upper respiratory tract and CNS are generally also affected (Appel 1987) .", [["body systems", "ANATOMY", 355, 367], ["upper respiratory tract", "ANATOMY", 386, 409], ["CNS", "ANATOMY", 414, 417], ["gastroenteritis", "DISEASE", 320, 335], ["dogs", "ORGANISM", 83, 87], ["INTRODUCTIONCanine distemper virus", "ORGANISM", 264, 298], ["CDV", "ORGANISM", 300, 303], ["dogs", "ORGANISM", 339, 343], ["body", "ORGANISM_SUBDIVISION", 355, 359], ["upper respiratory", "ORGANISM_SUBDIVISION", 386, 403], ["tract", "ORGANISM_SUBDIVISION", 404, 409], ["CNS", "ANATOMICAL_SYSTEM", 414, 417], ["dogs", "SPECIES", 83, 87], ["distemper virus", "SPECIES", 283, 298], ["dogs", "SPECIES", 339, 343], ["INTRODUCTIONCanine distemper virus", "SPECIES", 264, 298], ["CDV", "SPECIES", 300, 303], ["Seroprevalence figures", "TEST", 0, 22], ["INTRODUCTIONCanine distemper virus (CDV", "TREATMENT", 264, 303], ["gastroenteritis in dogs", "PROBLEM", 320, 343], ["other body systems", "TEST", 349, 367], ["the upper respiratory tract", "PROBLEM", 382, 409], ["may also cause", "UNCERTAINTY", 305, 319], ["gastroenteritis", "OBSERVATION", 320, 335], ["upper", "ANATOMY_MODIFIER", 386, 391], ["respiratory tract", "ANATOMY", 392, 409], ["CNS", "ANATOMY", 414, 417]]], ["CDV infection has always been considered to be widespread in dogs [Lauder and others 1954) .", [["CDV infection", "DISEASE", 0, 13], ["CDV", "ORGANISM", 0, 3], ["dogs", "ORGANISM", 61, 65], ["dogs", "SPECIES", 61, 65], ["CDV", "SPECIES", 0, 3], ["CDV infection", "PROBLEM", 0, 13], ["infection", "OBSERVATION", 4, 13], ["widespread", "OBSERVATION_MODIFIER", 47, 57]]], ["However, the only recent survey reported seroprevalence rates to CDV in Sweden of approximately 30 per cent in unvaccinated and approximately 70 per cent in vaccinated adult dogs (Olson and others 1988) .INTRODUCTIONCanine rotavirus (CRV), has been implicated as a cause of neonatal canine enteritis since 1980 (England and Poston 1980) , and seroprevalence has been reported to range from 62 to 84 per cent (McNulty and others 1978, Dagenais and others 1980).", [["canine enteritis", "DISEASE", 283, 299], ["CDV", "ORGANISM", 65, 68], ["dogs", "ORGANISM", 174, 178], ["INTRODUCTIONCanine rotavirus", "ORGANISM", 204, 232], ["CRV", "GENE_OR_GENE_PRODUCT", 234, 237], ["dogs", "SPECIES", 174, 178], ["CDV", "SPECIES", 65, 68], ["CRV", "SPECIES", 234, 237], ["canine", "SPECIES", 283, 289], ["INTRODUCTIONCanine rotavirus (CRV", "TREATMENT", 204, 237], ["neonatal canine enteritis", "PROBLEM", 274, 299], ["enteritis", "OBSERVATION", 290, 299]]], ["As most of the published surveys on the seroprevalence of these four canine viruses took place some years ago or in other countries, a prospective survey to assess their current seroprevalence in urban and suburban family-owned British dogs was carried out, For CPV, it was of particular interest to reassess seroprevalence now infection has to a large extent stabilised in the population.", [["infection", "DISEASE", 328, 337], ["canine", "ORGANISM", 69, 75], ["dogs", "ORGANISM", 236, 240], ["dogs", "SPECIES", 236, 240], ["canine", "SPECIES", 69, 75], ["CPV", "SPECIES", 262, 265], ["CPV", "PROBLEM", 262, 265], ["infection", "PROBLEM", 328, 337], ["infection", "OBSERVATION", 328, 337], ["large", "OBSERVATION_MODIFIER", 347, 352], ["extent", "OBSERVATION_MODIFIER", 353, 359], ["stabilised", "OBSERVATION", 360, 370]]], ["For CCV, an assessment of current UK seroprevalence is important because of the possibility that vaccines may be developed in the near future.", [["UK", "GENE_OR_GENE_PRODUCT", 34, 36], ["CCV", "SPECIES", 4, 7], ["CCV", "PROBLEM", 4, 7], ["an assessment", "TEST", 9, 22], ["vaccines", "TREATMENT", 97, 105]]], ["A number of demographic and other parameters which may influence the prevalence and level of antibody to these viruses were also examined.Data collection and analysisSerum samples were collected from a total of 190 dogs selected from the first-opinion clinic at the University of Liverpool's Small Animal Hospital over a 10-month period.", [["analysisSerum samples", "ANATOMY", 158, 179], ["analysisSerum samples", "CANCER", 158, 179], ["dogs", "ORGANISM", 215, 219], ["dogs", "SPECIES", 215, 219], ["level of antibody to these viruses", "PROBLEM", 84, 118], ["Data collection", "TEST", 138, 153], ["analysisSerum samples", "TEST", 158, 179]]], ["Serum was obtained from the first three dogs presented for any reason, on each of the first four days each week, for four weeks during each of the months of April, July and October 1985 and January 1986; two samples were unobtainable. 'kentyfour of these dogs presented with acute and chronic diarrhoea (15 dogs duration <1 week; five dogs 1 to 3 weeks; four dogs >3 weeks).", [["Serum", "ANATOMY", 0, 5], ["samples", "ANATOMY", 208, 215], ["diarrhoea", "DISEASE", 293, 302], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["dogs", "ORGANISM", 40, 44], ["dogs", "ORGANISM", 255, 259], ["dogs", "SPECIES", 40, 44], ["dogs", "SPECIES", 255, 259], ["Serum", "TEST", 0, 5], ["acute and chronic diarrhoea", "PROBLEM", 275, 302], ["acute", "OBSERVATION_MODIFIER", 275, 280], ["chronic", "OBSERVATION_MODIFIER", 285, 292], ["diarrhoea", "OBSERVATION", 293, 302]]], ["A questionnaire covering a number of demographic parameters was completed for each dog at the time of sampling.", [["dog", "ORGANISM", 83, 86], ["demographic parameters", "TEST", 37, 59], ["sampling", "TEST", 102, 110]]], ["Data requested for each dog included age, breed, sex, Liverpool district (ie suburban or urban) in which the dog resided, vaccination status (ever vaccinated, and up to date vaccination, ie, within the previous two years), diet, whether multidog household and type of exercise.", [["dog", "ORGANISM", 24, 27], ["dog", "ORGANISM", 109, 112], ["dog", "SPECIES", 24, 27], ["dog", "SPECIES", 109, 112]]], ["The influence of these parameters on the presence or absence of serum antibodies to each virus was investigated initially using 2 analysis.", [["serum", "ANATOMY", 64, 69], ["serum", "ORGANISM_SUBSTANCE", 64, 69], ["serum antibodies", "PROTEIN", 64, 80], ["these parameters", "TEST", 17, 33], ["serum antibodies to each virus", "PROBLEM", 64, 94]]], ["Interactive analysis was also carried out using two forms of log-linear modelling.", [["Interactive analysis", "TEST", 0, 20]]], ["Analysis of deviance (logistic regression) further investigated the influence of parameters on presence or absence of antibody, and regression analysis was used to examine the influence of parameters on actual antibody titres.SerologySerum obtained from each dog was heat inactivated at 56' C for 30 minutes and stored in aliquots at -20\u00b0C until used.SerologyVirus neutralising (VN) antibodies to CCV (K378 strain) (Barlough and others 1984) and CDV (Onderstepoort strain) were assayed in a microneutralisation test using 100TCID50 of virus and doubling serial dilutions of serum (Gaskell and others 1982) .", [["serum", "ANATOMY", 574, 579], ["dog", "ORGANISM", 259, 262], ["SerologyVirus neutralising (VN) antibodies", "GENE_OR_GENE_PRODUCT", 351, 393], ["CCV", "ORGANISM", 397, 400], ["K378 strain", "ORGANISM", 402, 413], ["CDV", "ORGANISM", 446, 449], ["Onderstepoort strain", "ORGANISM", 451, 471], ["serum", "ORGANISM_SUBSTANCE", 574, 579], ["SerologyVirus neutralising (VN) antibodies", "PROTEIN", 351, 393], ["dog", "SPECIES", 259, 262], ["dog", "SPECIES", 259, 262], ["CCV", "SPECIES", 397, 400], ["CDV", "SPECIES", 446, 449], ["deviance (logistic regression", "PROBLEM", 12, 41], ["absence of antibody", "PROBLEM", 107, 126], ["regression analysis", "TEST", 132, 151], ["actual antibody titres", "TEST", 203, 225], ["SerologySerum", "TEST", 226, 239], ["SerologyVirus", "TEST", 351, 364], ["antibodies", "TEST", 383, 393], ["CCV", "TEST", 397, 400], ["Barlough", "TEST", 416, 424], ["CDV (Onderstepoort strain", "PROBLEM", 446, 471], ["a microneutralisation test", "TEST", 489, 515], ["virus", "TREATMENT", 535, 540], ["doubling serial dilutions", "TREATMENT", 545, 570]]], ["Viruses were grown on A-72 cells (Binn and others 1980) (CCV) or Vero cells (CDV).", [["A-72 cells", "ANATOMY", 22, 32], ["Vero cells", "ANATOMY", 65, 75], ["A-72 cells", "CELL", 22, 32], ["Binn", "CELL", 34, 38], ["Vero cells", "CELL", 65, 75], ["CDV", "ORGANISM", 77, 80], ["A-72 cells", "CELL_LINE", 22, 32], ["Vero cells", "CELL_LINE", 65, 75], ["A-72", "SPECIES", 22, 26], ["CCV", "SPECIES", 57, 60], ["CDV", "SPECIES", 77, 80], ["Viruses", "PROBLEM", 0, 7], ["Binn", "TEST", 34, 38], ["CCV", "TEST", 57, 60], ["Vero cells", "PROBLEM", 65, 75], ["Vero cells", "OBSERVATION", 65, 75]]], ["Haemagglutination inhibition (HI) tests for CPV antibody were performed with 4-8 HA units of a UK CPV field isolate (kindly supplied by Intervet Laboratories), using a standard microtitre system (Carmichael and others 1980) , with doubling dilutions of serum.", [["serum", "ANATOMY", 253, 258], ["CPV", "ORGANISM", 44, 47], ["serum", "ORGANISM_SUBSTANCE", 253, 258], ["CPV antibody", "PROTEIN", 44, 56], ["CPV", "SPECIES", 44, 47], ["CPV", "SPECIES", 98, 101], ["Haemagglutination inhibition", "TEST", 0, 28], ["HI) tests", "TEST", 30, 39], ["CPV antibody", "TEST", 44, 56], ["a standard microtitre system", "TREATMENT", 166, 194], ["doubling dilutions of serum", "TREATMENT", 231, 258]]], ["An immunofluorescence (IF) test was used to determine rotavirus antibody titres in a microtitre system using Simian rotavirus SA-11 grown in After incubation at 37\u00b0C for one hour the plates were thoroughly washed with phosphate buffered saline.", [["rotavirus SA-11", "CHEMICAL", 116, 131], ["phosphate", "CHEMICAL", 218, 227], ["phosphate", "CHEMICAL", 218, 227], ["rotavirus", "ORGANISM", 54, 63], ["Simian", "ORGANISM", 109, 115], ["phosphate buffered saline", "SIMPLE_CHEMICAL", 218, 243], ["rotavirus antibody", "PROTEIN", 54, 72], ["Simian rotavirus", "SPECIES", 109, 125], ["rotavirus", "SPECIES", 54, 63], ["Simian rotavirus SA-11", "SPECIES", 109, 131], ["An immunofluorescence (IF) test", "TEST", 0, 31], ["rotavirus antibody titres", "PROBLEM", 54, 79], ["a microtitre system", "TREATMENT", 83, 102], ["Simian rotavirus SA", "TREATMENT", 109, 128], ["the plates", "TREATMENT", 179, 189], ["phosphate buffered saline", "TREATMENT", 218, 243]]], ["Fluoroscein labelled rabbit antidog IgG (Sigma) was added to each well and plates were further incubated, washed again and examined under an ultraviolet microscope.", [["Fluoroscein", "CHEMICAL", 0, 11], ["Fluoroscein", "CHEMICAL", 0, 11], ["Fluoroscein", "SIMPLE_CHEMICAL", 0, 11], ["rabbit", "ORGANISM", 21, 27], ["antidog IgG", "GENE_OR_GENE_PRODUCT", 28, 39], ["Fluoroscein labelled rabbit antidog IgG", "PROTEIN", 0, 39], ["Sigma", "PROTEIN", 41, 46], ["rabbit", "SPECIES", 21, 27], ["rabbit", "SPECIES", 21, 27], ["Fluoroscein labelled rabbit antidog IgG", "TREATMENT", 0, 39], ["an ultraviolet microscope", "TREATMENT", 138, 163]]], ["In some cases serum samples were insufficient for all tests to be performed or were toxic, and some data was therefore unavailable.", [["serum samples", "ANATOMY", 14, 27], ["serum samples", "ORGANISM_SUBSTANCE", 14, 27], ["some cases serum samples", "TEST", 3, 27], ["all tests", "TEST", 50, 59]]], ["For rotavirus, only a representative proportion (112) serum samples were assessed.General demography and diarrhoea vs non -diarrh oeaOf the 190 dogs included in the survey 38 per cent were crossbred and 62 per cent purebred.", [["serum samples", "ANATOMY", 54, 67], ["diarrhoea", "DISEASE", 105, 114], ["serum samples", "ORGANISM_SUBSTANCE", 54, 67], ["dogs", "ORGANISM", 144, 148], ["dogs", "SPECIES", 144, 148], ["rotavirus", "SPECIES", 4, 13], ["rotavirus", "PROBLEM", 4, 13], ["serum samples", "TEST", 54, 67], ["General demography", "TEST", 82, 100], ["diarrhoea", "PROBLEM", 105, 114]]], ["Twenty-four per cent of dogs came from multidog (ie, two or more dogs) households.", [["dogs", "ORGANISM", 24, 28], ["dogs", "ORGANISM", 65, 69], ["dogs", "SPECIES", 24, 28], ["dogs", "SPECIES", 65, 69], ["dogs", "TREATMENT", 24, 28]]], ["Of the 190 dogs 15 per cent were fed home produced food only, 50 per cent fed commercial food only and 35 per cent a mixture of these two diets.", [["dogs", "ORGANISM", 11, 15], ["dogs", "SPECIES", 11, 15]]], ["Four exercise regimes were investigated: many dogs were exercised using a combination of regimes, 52 per cent of dogs had access to a garden, 73 per cent were taken out on the lead, 68 per cent were also allowed to run free but accompanied and 11 per cent of dogs roamed fiee.", [["dogs", "ORGANISM", 46, 50], ["dogs", "ORGANISM", 113, 117], ["dogs", "ORGANISM", 259, 263], ["dogs", "SPECIES", 46, 50], ["dogs", "SPECIES", 113, 117], ["dogs", "SPECIES", 259, 263], ["Four exercise regimes", "TREATMENT", 0, 21], ["a combination of regimes", "TREATMENT", 72, 96]]], ["Dogs were evenly distributed throughout the Liverpool area.", [["Dogs", "ORGANISM", 0, 4], ["evenly", "OBSERVATION_MODIFIER", 10, 16], ["distributed", "OBSERVATION_MODIFIER", 17, 28]]], ["There were no significant differences by xz tests with any of these parameters between dogs with or without diarrhoea.General demography and diarrhoea vs non -diarrh oeaThe age distribution of dogs with and without diarrhoea is shown in Fig 1.", [["diarrhoea", "DISEASE", 108, 117], ["diarrhoea", "DISEASE", 141, 150], ["diarrhoea", "DISEASE", 215, 224], ["dogs", "ORGANISM", 87, 91], ["dogs", "ORGANISM", 193, 197], ["dogs", "SPECIES", 87, 91], ["dogs", "SPECIES", 193, 197], ["xz tests", "TEST", 41, 49], ["diarrhoea", "PROBLEM", 108, 117], ["General demography", "PROBLEM", 118, 136], ["diarrhoea", "PROBLEM", 141, 150], ["non -diarrh oea", "PROBLEM", 154, 169], ["diarrhoea", "PROBLEM", 215, 224], ["no", "UNCERTAINTY", 11, 13], ["significant", "OBSERVATION_MODIFIER", 14, 25], ["diarrhoea", "OBSERVATION", 141, 150], ["dogs", "OBSERVATION", 193, 197]]], ["Dogs with diarrhoea were significantly younger (kO.05); 13/24 (54 per cent) of dogs with diarrhoea were under two years of age compared to 251162 (15 per cent) of In spite of the small numbers a model was created for a diarrhoeic dog confirming the findings, which included age and vaccination status (ever vaccinated), but there was no interaction term, ie, both parameters influenced the presence of diarrhoea independently.General demography and diarrhoea vs non -diarrh oeaOf this population 124/149 (83 per cent) of dogs had been vaccinated to CDV and CPV at some time, of which 101/131 (77 per cent) and 75/122 (62 per cent) of dogs had been vaccinated as puppies for CDV and CPV, respectively.", [["diarrhoea", "DISEASE", 10, 19], ["diarrhoea", "DISEASE", 89, 98], ["diarrhoea", "DISEASE", 402, 411], ["diarrhoea", "DISEASE", 449, 458], ["Dogs", "ORGANISM", 0, 4], ["dogs", "ORGANISM", 79, 83], ["dog", "ORGANISM", 230, 233], ["dogs", "ORGANISM", 521, 525], ["CDV", "ORGANISM", 549, 552], ["CPV", "ORGANISM", 557, 560], ["dogs", "ORGANISM", 634, 638], ["puppies", "ORGANISM", 662, 669], ["CDV", "ORGANISM", 674, 677], ["CPV", "ORGANISM", 682, 685], ["Dogs", "SPECIES", 0, 4], ["dogs", "SPECIES", 79, 83], ["dogs", "SPECIES", 521, 525], ["dogs", "SPECIES", 634, 638], ["CDV", "SPECIES", 549, 552], ["CPV", "SPECIES", 557, 560], ["CDV", "SPECIES", 674, 677], ["CPV", "SPECIES", 682, 685], ["diarrhoea", "PROBLEM", 10, 19], ["diarrhoea", "PROBLEM", 89, 98], ["a diarrhoeic dog", "PROBLEM", 217, 233], ["diarrhoea independently", "PROBLEM", 402, 425], ["General demography", "TEST", 426, 444], ["diarrhoea", "PROBLEM", 449, 458], ["CDV", "PROBLEM", 549, 552], ["CPV", "PROBLEM", 557, 560], ["CDV", "PROBLEM", 674, 677], ["CPV", "PROBLEM", 682, 685], ["small", "OBSERVATION_MODIFIER", 179, 184], ["diarrhoea", "OBSERVATION", 449, 458]]], ["Only 34/140 (24 per cent) and 36/139 (26 per cent) of dogs were up to date with CDV and CPV vaccination, respectively.Overall antibody estimationThe range of antibody titres for each virus is shown in Figs 2a-d.", [["dogs", "ORGANISM", 54, 58], ["CDV", "ORGANISM", 80, 83], ["CPV", "ORGANISM", 88, 91], ["dogs", "SPECIES", 54, 58], ["CDV", "SPECIES", 80, 83], ["CPV", "SPECIES", 88, 91], ["CDV", "PROBLEM", 80, 83], ["CPV vaccination", "TREATMENT", 88, 103], ["Overall antibody estimation", "TEST", 118, 145], ["The range of antibody titres", "TREATMENT", 145, 173], ["each virus", "PROBLEM", 178, 188]]], ["Serum samples were considered positive to CCV if VN titres were greater than or equal to 1/4 (Keenan and others 1976); to CPV if HI titres were greater than or equal to 1/80 (Carmichael and others 1980) ; to CDV if VN titres were greater than or equal to 1/20 (Olson and others 1988) ; and to RV if IFA titres were greater than or equal to 1/16 (Johnson and others 1983) .", [["Serum samples", "ANATOMY", 0, 13], ["Serum samples", "ORGANISM_SUBSTANCE", 0, 13], ["CCV", "ORGANISM", 42, 45], ["VN", "GENE_OR_GENE_PRODUCT", 49, 51], ["CPV", "ORGANISM", 122, 125], ["CDV", "ORGANISM", 208, 211], ["VN", "GENE_OR_GENE_PRODUCT", 215, 217], ["VN", "PROTEIN", 49, 51], ["CCV", "SPECIES", 42, 45], ["CPV", "SPECIES", 122, 125], ["CDV", "SPECIES", 208, 211], ["Serum samples", "TEST", 0, 13], ["CCV", "TEST", 42, 45], ["VN titres", "TEST", 49, 58], ["CPV", "TEST", 122, 125], ["HI titres", "TEST", 129, 138], ["VN titres", "TEST", 215, 224], ["RV", "TEST", 293, 295], ["IFA titres", "TEST", 299, 309]]], ["Overall 94/174 (54 per cent) were seropositive to CCV; 146/173 (84 per cent) were seropositive to CDV; 119/170 (70 per cent) were seropositive to CPV; and 97/112 (86 per cent) were seropositive to RV.Factors aflecting antibody prevalenceOn initial xz analysis age and presence of diarrhoea appeared to influence the presence of CCV antibodies.", [["diarrhoea", "DISEASE", 280, 289], ["CCV", "ORGANISM", 50, 53], ["CDV", "ORGANISM", 98, 101], ["CPV", "ORGANISM", 146, 149], ["CCV antibodies", "GENE_OR_GENE_PRODUCT", 328, 342], ["CCV antibodies", "PROTEIN", 328, 342], ["CCV", "SPECIES", 50, 53], ["CDV", "SPECIES", 98, 101], ["CPV", "SPECIES", 146, 149], ["RV", "SPECIES", 197, 199], ["CCV", "SPECIES", 328, 331], ["CCV", "TEST", 50, 53], ["CDV", "TEST", 98, 101], ["CPV", "TEST", 146, 149], ["Factors aflecting antibody", "TEST", 200, 226], ["diarrhoea", "PROBLEM", 280, 289], ["CCV antibodies", "PROBLEM", 328, 342], ["RV", "ANATOMY", 197, 199], ["diarrhoea", "OBSERVATION", 280, 289], ["CCV antibodies", "OBSERVATION", 328, 342]]], ["Significantly fewer young dogs (up to two years of age) were seropositive to CCV as compared to older dogs (P<O*O2); the majority of dogs were seropositive from two years of age onwards (Fig 3) .", [["dogs", "ORGANISM", 26, 30], ["CCV", "ORGANISM", 77, 80], ["dogs", "ORGANISM", 133, 137], ["dogs", "SPECIES", 26, 30], ["dogs", "SPECIES", 102, 106], ["dogs", "SPECIES", 133, 137], ["CCV", "SPECIES", 77, 80], ["Significantly fewer young dogs", "PROBLEM", 0, 30]]], ["Significantly fewer dogs with diarrhoea were seropositive for CCV 6/22 (27 per cent) as compared to 88/152 (58 per cent) without diarrhoea (P<O.O1).Factors aflecting antibody prevalenceThe prevalence of antibodies to CDV appeared to be influenced by age and vaccination status (ever vaccinated).", [["diarrhoea", "DISEASE", 30, 39], ["diarrhoea", "DISEASE", 129, 138], ["CDV", "DISEASE", 217, 220], ["dogs", "ORGANISM", 20, 24], ["CDV", "ORGANISM", 217, 220], ["antibodies", "PROTEIN", 203, 213], ["dogs", "SPECIES", 20, 24], ["CCV", "SPECIES", 62, 65], ["CDV", "SPECIES", 217, 220], ["Significantly fewer dogs", "PROBLEM", 0, 24], ["diarrhoea", "PROBLEM", 30, 39], ["CCV", "TEST", 62, 65], ["diarrhoea", "PROBLEM", 129, 138], ["antibodies to CDV", "PROBLEM", 203, 220]]], ["Significantly fewer dogs (Pc0.02), under the age of six months were seropositive for CDV compared to older dogs (Fig 3) .", [["dogs", "ORGANISM", 20, 24], ["CDV", "ORGANISM", 85, 88], ["dogs", "ORGANISM", 107, 111], ["dogs", "SPECIES", 20, 24], ["dogs", "SPECIES", 107, 111], ["CDV", "SPECIES", 85, 88], ["Significantly fewer dogs", "PROBLEM", 0, 24], ["CDV", "PROBLEM", 85, 88]]], ["For CDV, a disease for which vaccination is practiced in the UK, vaccination status appeared to significantly influence the prevalence where most dogs appear to encounter the virus, as demonstrated by seroconversion, after six of antibody to CDV, with 100/119 (89 per cent) of vaccinated dogs seropositive compared to 13/23 (57 per cent] unvaccinated dogs (P<O.Ol] .Factors aflecting antibody prevalenceThe presence of CPV antibodies was not influenced by any factors including age (Fig 3) or vaccination status.Factors aflecting antibody prevalenceAge appeared to influence the prevalence of antibodies to RV, with dogs under six months of age more likely to be seronegative for RV compared to older dogs (P<O.O1) (Fig 3) .Factors aflecting antibody prevalenceFor all the other factors considered no differences were shown between seronegative and seropositive populations.Factors aflecting antibody prevalenceAnalysis of deviance, which evens out the influence of each parameter, confirmed the influence of presence of diarrhoea on CCV antibody status, and the effect of vaccination status with respect to CDV antibodies.", [["diarrhoea", "DISEASE", 1021, 1030], ["CDV", "ORGANISM", 4, 7], ["dogs", "ORGANISM", 146, 150], ["CDV", "ORGANISM", 242, 245], ["dogs", "ORGANISM", 288, 292], ["dogs", "ORGANISM", 351, 355], ["CPV", "ORGANISM", 419, 422], ["CDV", "ORGANISM", 1108, 1111], ["CPV antibodies", "PROTEIN", 419, 433], ["antibodies", "PROTEIN", 593, 603], ["CCV antibody", "PROTEIN", 1034, 1046], ["CDV antibodies", "PROTEIN", 1108, 1122], ["dogs", "SPECIES", 146, 150], ["dogs", "SPECIES", 288, 292], ["dogs", "SPECIES", 351, 355], ["dogs", "SPECIES", 616, 620], ["dogs", "SPECIES", 701, 705], ["CDV", "SPECIES", 4, 7], ["CDV", "SPECIES", 242, 245], ["CPV", "SPECIES", 419, 422], ["CCV", "SPECIES", 1034, 1037], ["CDV", "SPECIES", 1108, 1111], ["CDV", "PROBLEM", 4, 7], ["a disease", "PROBLEM", 9, 18], ["the virus", "PROBLEM", 171, 180], ["seroconversion", "PROBLEM", 201, 215], ["CDV", "TEST", 242, 245], ["vaccinated dogs seropositive", "PROBLEM", 277, 305], ["CPV antibodies", "PROBLEM", 419, 433], ["vaccination status", "PROBLEM", 493, 511], ["RV", "PROBLEM", 680, 682], ["seronegative and seropositive populations", "PROBLEM", 832, 873], ["Analysis of deviance", "TEST", 911, 931], ["diarrhoea", "PROBLEM", 1021, 1030], ["CCV antibody status", "PROBLEM", 1034, 1053], ["vaccination status", "PROBLEM", 1073, 1091], ["CDV antibodies", "PROBLEM", 1108, 1122], ["disease", "OBSERVATION", 11, 18], ["CPV antibodies", "OBSERVATION", 419, 433], ["seropositive populations", "OBSERVATION", 849, 873], ["diarrhoea", "OBSERVATION", 1021, 1030]]], ["No significant age effect on the presence of antibody for any of the viruses was shown.", [["antibody", "PROBLEM", 45, 53], ["the viruses", "PROBLEM", 65, 76], ["significant", "OBSERVATION_MODIFIER", 3, 14], ["age effect", "OBSERVATION", 15, 25], ["viruses", "OBSERVATION", 69, 76]]], ["Regression analysis showed that levels of antibody titres were also influenced by presence of diarrhoea (CCV) and vaccination status (CDV] .", [["diarrhoea", "DISEASE", 94, 103], ["CCV", "SPECIES", 105, 108], ["CDV", "SPECIES", 134, 137], ["Regression analysis", "TEST", 0, 19], ["levels of antibody titres", "PROBLEM", 32, 57], ["diarrhoea", "PROBLEM", 94, 103], ["antibody titres", "OBSERVATION", 42, 57], ["diarrhoea", "OBSERVATION", 94, 103]]], ["No other influences were seen.DISCUSSIONFIG 3.", [["influences", "OBSERVATION", 9, 19]]], ["Percentage of each age group seropositive to canine coronavirus (CCV), canine distemper virus (CDV), canine parvovirus (CPV) and rotavirus (RV) to take place more gradually over a period of several years.", [["canine coronavirus", "DISEASE", 45, 63], ["canine distemper", "DISEASE", 71, 87], ["canine parvovirus", "DISEASE", 101, 118], ["canine coronavirus", "ORGANISM", 45, 63], ["CCV", "ORGANISM", 65, 68], ["canine distemper virus", "ORGANISM", 71, 93], ["CDV", "ORGANISM", 95, 98], ["canine parvovirus", "ORGANISM", 101, 118], ["CPV", "ORGANISM", 120, 123], ["rotavirus", "ORGANISM", 129, 138], ["canine coronavirus", "SPECIES", 45, 63], ["canine distemper virus", "SPECIES", 71, 93], ["canine parvovirus", "SPECIES", 101, 118], ["canine coronavirus", "SPECIES", 45, 63], ["CCV", "SPECIES", 65, 68], ["canine distemper virus", "SPECIES", 71, 93], ["CDV", "SPECIES", 95, 98], ["canine parvovirus", "SPECIES", 101, 118], ["CPV", "SPECIES", 120, 123], ["rotavirus", "SPECIES", 129, 138], ["RV", "SPECIES", 140, 142], ["canine coronavirus", "PROBLEM", 45, 63], ["canine distemper virus", "PROBLEM", 71, 93], ["canine parvovirus", "PROBLEM", 101, 118], ["rotavirus (RV", "TREATMENT", 129, 142]]], ["This may reflect the age at which field challenge tends to occur.", [["may reflect", "UNCERTAINTY", 5, 16]]], ["It is interesting that in our study most dogs did not seroconvert to RV until over six months of age.", [["dogs", "ORGANISM", 41, 45], ["dogs", "SPECIES", 41, 45], ["our study", "TEST", 26, 35]]], ["In most species rotavirus infection generally seems to be associated with neonatal animals (Woode and Bridger 1975 , McNulty and others 1976 , Snodgrass and others 1976 , England and Poston 1980 .", [["rotavirus infection", "DISEASE", 16, 35], ["rotavirus", "ORGANISM", 16, 25], ["rotavirus", "SPECIES", 16, 25], ["rotavirus infection", "PROBLEM", 16, 35], ["most species", "OBSERVATION_MODIFIER", 3, 15], ["rotavirus infection", "OBSERVATION", 16, 35]]], ["This may be a reflection of the different environments in which different species are reared.DISCUSSIONSeveral factors appeared to be important with respect to diarrhoea.", [["diarrhoea", "DISEASE", 160, 169], ["the different environments", "PROBLEM", 28, 54], ["diarrhoea", "PROBLEM", 160, 169], ["may be", "UNCERTAINTY", 5, 11], ["different", "OBSERVATION_MODIFIER", 32, 41], ["environments", "OBSERVATION_MODIFIER", 42, 54]]], ["Of the dogs with diarrhoea, only 27 per cent were seropositive to CCV compared to 58 per cent of the non-diarrhoea group suggesting that this group of dogs were susceptible to CCV at the time of clinical presentation and may have been undergoing acute CCV infection.", [["diarrhoea", "DISEASE", 17, 26], ["CCV infection", "DISEASE", 252, 265], ["dogs", "ORGANISM", 7, 11], ["dogs", "ORGANISM", 151, 155], ["CCV", "ORGANISM", 176, 179], ["dogs", "SPECIES", 7, 11], ["dogs", "SPECIES", 151, 155], ["CCV", "SPECIES", 66, 69], ["CCV", "SPECIES", 176, 179], ["CCV", "SPECIES", 252, 255], ["diarrhoea", "PROBLEM", 17, 26], ["seropositive to CCV", "PROBLEM", 50, 69], ["CCV", "PROBLEM", 176, 179], ["acute CCV infection", "PROBLEM", 246, 265], ["acute", "OBSERVATION_MODIFIER", 246, 251], ["CCV", "OBSERVATION_MODIFIER", 252, 255], ["infection", "OBSERVATION", 256, 265]]], ["However, diarrhoea mostly occurred in younger dogs whereas the highest seroprevalence to CCV was in older animals.", [["diarrhoea", "DISEASE", 9, 18], ["dogs", "ORGANISM", 46, 50], ["CCV", "ORGANISM", 89, 92], ["dogs", "SPECIES", 46, 50], ["CCV", "SPECIES", 89, 92], ["diarrhoea", "PROBLEM", 9, 18], ["diarrhoea", "OBSERVATION", 9, 18]]], ["Alternatively, other agents may have been responsible for the diarrhoea.", [["diarrhoea", "DISEASE", 62, 71], ["the diarrhoea", "PROBLEM", 58, 71], ["diarrhoea", "OBSERVATION", 62, 71]]], ["Thus the higher prevalence of diarrhoea in unvaccinated animals might suggest involvement of CPV or CDV.", [["diarrhoea", "DISEASE", 30, 39], ["CPV", "ORGANISM", 93, 96], ["CDV", "ORGANISM", 100, 103], ["CPV", "SPECIES", 93, 96], ["CDV", "SPECIES", 100, 103], ["diarrhoea", "PROBLEM", 30, 39], ["CPV", "PROBLEM", 93, 96], ["CDV", "PROBLEM", 100, 103], ["higher prevalence", "OBSERVATION_MODIFIER", 9, 26], ["diarrhoea", "OBSERVATION", 30, 39]]], ["Convalescent sera demonstrating rising titres would have enabled confirmation of these hypotheses, but in this type of first opinion, subsidised clinic such samples were unavailable.", [["sera", "ANATOMY", 13, 17], ["samples", "ANATOMY", 157, 164], ["sera", "ORGANISM_SUBSTANCE", 13, 17], ["samples", "CANCER", 157, 164], ["Convalescent sera", "TEST", 0, 17], ["rising titres", "PROBLEM", 32, 45]]], ["Parallel virus isolation and electron microscopic examination were carried out on a number of faecal samples (Tennant 1989) and CPV was isolated from 1/24 dogs with diarrhoea and from none of the control dogs: with CCV isolation studies faecal samples were unfortunately subject to storage problems.", [["faecal samples", "ANATOMY", 94, 108], ["faecal samples", "ANATOMY", 237, 251], ["diarrhoea", "DISEASE", 165, 174], ["faecal samples", "ORGANISM_SUBSTANCE", 94, 108], ["CPV", "ORGANISM", 128, 131], ["dogs", "ORGANISM", 155, 159], ["dogs", "ORGANISM", 204, 208], ["dogs", "SPECIES", 155, 159], ["dogs", "SPECIES", 204, 208], ["CPV", "SPECIES", 128, 131], ["CCV", "SPECIES", 215, 218], ["Parallel virus isolation", "TREATMENT", 0, 24], ["electron microscopic examination", "TEST", 29, 61], ["faecal samples", "TEST", 94, 108], ["CPV", "PROBLEM", 128, 131], ["diarrhoea", "PROBLEM", 165, 174], ["CCV isolation studies faecal samples", "TEST", 215, 251], ["storage problems", "PROBLEM", 282, 298], ["virus isolation", "OBSERVATION", 9, 24]]], ["Thus we were unable to determine the aetiology of the diarrhoea seen.DISCUSSIONBoth the presence of and level of antibody titre to CDV were influenced by whether the dog had ever been vaccinated or not.", [["diarrhoea", "DISEASE", 54, 63], ["CDV", "ORGANISM", 131, 134], ["dog", "ORGANISM", 166, 169], ["dog", "SPECIES", 166, 169], ["CDV", "SPECIES", 131, 134], ["dog", "SPECIES", 166, 169], ["the diarrhoea", "PROBLEM", 50, 63], ["antibody titre", "TREATMENT", 113, 127], ["CDV", "PROBLEM", 131, 134], ["diarrhoea", "OBSERVATION", 54, 63]]], ["Significantly more dogs vaccinated at some time to CDV had antibody compared to those that had not and similar findings were reported by Olson and others (1988) in Sweden.", [["dogs", "ORGANISM", 19, 23], ["CDV", "ORGANISM", 51, 54], ["dogs", "SPECIES", 19, 23], ["CDV", "SPECIES", 51, 54], ["Significantly more dogs vaccinated", "PROBLEM", 0, 34], ["antibody", "PROBLEM", 59, 67]]], ["It appears that CDV vaccination, rather than widespread infection, plays an Our findings for overall prevalence of antibodies to these four enteric pathogens of dogs broadly confirm the findings of others for this type of pet dog hospital population, although a higher seroprevalence of CPV in vaccinated and non-vaccinated dogs was found than has generally been reported (Cartwright 1973 Olson and others 1988) .", [["infection", "DISEASE", 56, 65], ["CPV", "DISEASE", 287, 290], ["CDV", "ORGANISM", 16, 19], ["dogs", "ORGANISM", 161, 165], ["dog", "ORGANISM", 226, 229], ["CPV", "ORGANISM", 287, 290], ["dogs", "ORGANISM", 324, 328], ["antibodies", "PROTEIN", 115, 125], ["dogs", "SPECIES", 161, 165], ["dogs", "SPECIES", 324, 328], ["CDV", "SPECIES", 16, 19], ["pet dog", "SPECIES", 222, 229], ["CPV", "SPECIES", 287, 290], ["CDV vaccination", "PROBLEM", 16, 31], ["widespread infection", "PROBLEM", 45, 65], ["antibodies", "TREATMENT", 115, 125], ["CPV", "PROBLEM", 287, 290], ["non-vaccinated dogs", "PROBLEM", 309, 328], ["CDV vaccination", "OBSERVATION", 16, 31], ["widespread", "OBSERVATION_MODIFIER", 45, 55], ["infection", "OBSERVATION", 56, 65]]], ["This may be because CPV infection has become more widespread since the earlier surveys were conducted.", [["CPV infection", "DISEASE", 20, 33], ["CPV", "ORGANISM", 20, 23], ["CPV", "SPECIES", 20, 23], ["CPV infection", "PROBLEM", 20, 33], ["may be", "UNCERTAINTY", 5, 11], ["infection", "OBSERVATION", 24, 33]]], ["Of the various demographic parameters examined, breed, sex, exercise pattern, diet, multidog household and urban or suburban district, had no apparent effect on antibody prevalence. xz analysis suggested that age may influence the presence of antibody to CCV, CDV and RV, in that younger dogs were less likely to be seropositive.", [["CCV", "GENE_OR_GENE_PRODUCT", 255, 258], ["CDV", "ORGANISM", 260, 263], ["dogs", "ORGANISM", 288, 292], ["dogs", "SPECIES", 288, 292], ["CCV", "SPECIES", 255, 258], ["CDV", "SPECIES", 260, 263], ["RV", "SPECIES", 268, 270], ["apparent effect on antibody prevalence", "PROBLEM", 142, 180], ["xz analysis", "TEST", 182, 193], ["antibody to CCV", "PROBLEM", 243, 258], ["CDV", "PROBLEM", 260, 263], ["seropositive", "PROBLEM", 316, 328], ["RV", "ANATOMY", 268, 270]]], ["This finding was not confirmed by interactive analysis, but this may be due to the small sizes of the subgroups generated.", [["interactive analysis", "TEST", 34, 54], ["small", "OBSERVATION_MODIFIER", 83, 88], ["sizes", "OBSERVATION_MODIFIER", 89, 94]]], ["The age at which seroconversion occurs depends for all four viruses upon the time of exposure to field virus and, for CDV and CPV alone, on time of vaccination.", [["CDV", "ORGANISM", 118, 121], ["CPV", "ORGANISM", 126, 129], ["CDV", "SPECIES", 118, 121], ["CPV", "SPECIES", 126, 129], ["all four viruses", "PROBLEM", 51, 67], ["field virus", "TREATMENT", 97, 108], ["CDV", "PROBLEM", 118, 121], ["CPV", "PROBLEM", 126, 129], ["vaccination", "TREATMENT", 148, 159]]], ["For CPV, the majority of dogs had antibody by six months of age, in contrast to CDV and RV where most dogs appear to encounter the virus, as demonstrated by seroconversion, after six months of age.", [["CPV", "ORGANISM", 4, 7], ["dogs", "ORGANISM", 25, 29], ["CDV", "ORGANISM", 80, 83], ["dogs", "ORGANISM", 102, 106], ["dogs", "SPECIES", 25, 29], ["dogs", "SPECIES", 102, 106], ["CPV", "SPECIES", 4, 7], ["CDV", "SPECIES", 80, 83], ["RV", "SPECIES", 88, 90], ["CPV", "PROBLEM", 4, 7], ["the virus", "PROBLEM", 127, 136], ["RV", "ANATOMY", 88, 90], ["virus", "OBSERVATION", 131, 136]]], ["For CCV seroconversion appears important role in inducing a significant level of seropositivity to CDV within a population.", [["CDV", "ORGANISM", 99, 102], ["CCV", "SPECIES", 4, 7], ["CDV", "SPECIES", 99, 102], ["CCV seroconversion", "PROBLEM", 4, 22], ["seroconversion", "OBSERVATION", 8, 22]]], ["Also, vaccination, but not up to date, influenced the presence of CDV antibodies supporting the suggestion that CDV antibodies may persist for several years (Krakowka and others 1985, Olson and others 1988) .DISCUSSIONIn contrast to CDV. no factors, including vaccination status, were found to influence the presence or level of CPV antibodies.", [["CDV", "ORGANISM", 66, 69], ["CDV", "ORGANISM", 112, 115], ["CDV", "ORGANISM", 233, 236], ["CPV", "ORGANISM", 329, 332], ["CDV antibodies", "PROTEIN", 66, 80], ["CDV antibodies", "PROTEIN", 112, 126], ["CPV antibodies", "PROTEIN", 329, 343], ["CDV", "SPECIES", 66, 69], ["CDV", "SPECIES", 112, 115], ["CDV", "SPECIES", 233, 236], ["CPV", "SPECIES", 329, 332], ["CDV antibodies", "PROBLEM", 66, 80], ["CDV antibodies", "PROBLEM", 112, 126], ["vaccination status", "PROBLEM", 260, 278], ["CPV antibodies", "PROBLEM", 329, 343]]], ["Olson and others (1988) reported similar findings in a Swedish canine population, where no difference in CPV titres was obtained between vaccinated and unvaccinated adult dogs.", [["canine", "ORGANISM", 63, 69], ["CPV", "ORGANISM", 105, 108], ["dogs", "ORGANISM", 171, 175], ["dogs", "SPECIES", 171, 175], ["canine", "SPECIES", 63, 69], ["CPV", "SPECIES", 105, 108], ["CPV titres", "TEST", 105, 115]]], ["The comparable prevalence of CPV antibodies in all age groups suggests an early exposure of young dogs to CPV and continuous boosting of antibody levels by natural challenge, thus masking any vaccine-derived antibody.", [["CPV", "ORGANISM", 29, 32], ["dogs", "ORGANISM", 98, 102], ["CPV", "ORGANISM", 106, 109], ["CPV antibodies", "PROTEIN", 29, 43], ["vaccine-derived antibody", "PROTEIN", 192, 216], ["dogs", "SPECIES", 98, 102], ["CPV", "SPECIES", 29, 32], ["CPV", "SPECIES", 106, 109], ["CPV antibodies", "PROBLEM", 29, 43], ["CPV", "TREATMENT", 106, 109], ["continuous boosting of antibody levels", "TREATMENT", 114, 152], ["natural challenge", "TREATMENT", 156, 173], ["any vaccine", "TREATMENT", 188, 199], ["CPV antibodies", "OBSERVATION", 29, 43], ["early", "OBSERVATION_MODIFIER", 74, 79]]], ["It is recognised that CPV antibodies arising from natural infection may persist at high levels for several years (Appel 1987) .", [["infection", "DISEASE", 58, 67], ["CPV", "ORGANISM", 22, 25], ["CPV antibodies", "PROTEIN", 22, 36], ["CPV", "SPECIES", 22, 25], ["CPV antibodies", "PROBLEM", 22, 36], ["natural infection", "PROBLEM", 50, 67], ["natural", "OBSERVATION_MODIFIER", 50, 57], ["infection", "OBSERVATION", 58, 67]]]], "ebb38d3df2f22ebae50faa01d7d9c9ab95e6bd3f": [["M a n u s c r i p t BACKGROUND The impact of co-infection with SARS-CoV-2 in people with HIV (PWH) is incompletely understood [1] [2] [3] .", [["co-infection", "DISEASE", 45, 57], ["SARS", "DISEASE", 63, 67], ["HIV", "DISEASE", 89, 92], ["PWH", "DISEASE", 94, 97], ["SARS-CoV-2", "ORGANISM", 63, 73], ["people", "ORGANISM", 77, 83], ["HIV", "ORGANISM", 89, 92], ["people", "SPECIES", 77, 83], ["HIV", "SPECIES", 89, 92], ["SARS-CoV", "SPECIES", 63, 71], ["HIV", "SPECIES", 89, 92], ["co-infection", "PROBLEM", 45, 57], ["SARS", "PROBLEM", 63, 67], ["HIV", "PROBLEM", 89, 92], ["co-infection", "OBSERVATION", 45, 57]]], ["Data on clinical outcomes in large and diverse cohorts of PWH is needed to understand the manifestations, including immunologic outcomes, of this novel co-infection.", [["PWH", "DISEASE", 58, 61], ["co-infection", "DISEASE", 152, 164], ["PWH", "CANCER", 58, 61], ["this novel co-infection", "PROBLEM", 141, 164], ["large", "OBSERVATION_MODIFIER", 29, 34], ["co-infection", "OBSERVATION", 152, 164]]]], "1b7a00b7a4f27b9928775ae1be5378e680913e00": [["Dear Editors,The novel coronavirus SARS-CoV-2 which causes the acute respiratory illness known as COVID-19 has been characterized by the World Health Organization (WHO) as a global pandemic since March 13, 2020.", [["respiratory", "ANATOMY", 69, 80], ["coronavirus SARS", "DISEASE", 23, 39], ["respiratory illness", "DISEASE", 69, 88], ["COVID-19", "CHEMICAL", 98, 106], ["coronavirus SARS-CoV-2", "ORGANISM", 23, 45], ["coronavirus SARS-CoV", "SPECIES", 23, 43], ["SARS-CoV-2", "SPECIES", 35, 45], ["The novel coronavirus SARS", "PROBLEM", 13, 39], ["the acute respiratory illness", "PROBLEM", 59, 88], ["acute", "OBSERVATION_MODIFIER", 63, 68], ["respiratory illness", "OBSERVATION", 69, 88]]], ["Despite a lower case-fatality rate, COVID-19 has resulted in significantly more deaths than SARS in 2003, largely in part due to its higher infectivity.", [["COVID-19", "CHEMICAL", 36, 44], ["deaths", "DISEASE", 80, 86], ["SARS", "DISEASE", 92, 96], ["fatality rate", "TEST", 21, 34], ["COVID", "TEST", 36, 41], ["SARS", "PROBLEM", 92, 96], ["its higher infectivity", "PROBLEM", 129, 151], ["higher", "OBSERVATION_MODIFIER", 133, 139], ["infectivity", "OBSERVATION", 140, 151]]], ["As of May 21, 2020, more than 4,800,000 cases of SARS-CoV-2 infection have been confirmed worldwide, with more than 321,000 fatalities.", [["SARS-CoV-2 infection", "DISEASE", 49, 69], ["fatalities", "DISEASE", 124, 134], ["SARS-CoV-2", "ORGANISM", 49, 59], ["CoV-2", "SPECIES", 54, 59], ["SARS-CoV-2", "SPECIES", 49, 59], ["SARS", "PROBLEM", 49, 53], ["CoV", "PROBLEM", 54, 57], ["2 infection", "PROBLEM", 58, 69]]], ["Singapore confirmed its first case of COVID-19 on January 23, 2020.", [["COVID", "TEST", 38, 43]]], ["Since then, we have had a total of 29,342 cases and 22 fatalities.", [["fatalities", "DISEASE", 55, 65]]], ["Majority of the hospitalized cases were treated at our center, the National Centre of Infectious Diseases (NCID).Dear Editors,Recent studies have shown a decrease in peripheral lymphocytes in COVID-19 patients.", [["peripheral lymphocytes", "ANATOMY", 166, 188], ["Infectious Diseases", "DISEASE", 86, 105], ["NCID", "DISEASE", 107, 111], ["peripheral lymphocytes", "CELL", 166, 188], ["patients", "ORGANISM", 201, 209], ["peripheral lymphocytes", "CELL_TYPE", 166, 188], ["patients", "SPECIES", 201, 209], ["Recent studies", "TEST", 126, 140], ["a decrease in peripheral lymphocytes", "PROBLEM", 152, 188], ["COVID", "TEST", 192, 197], ["Infectious", "OBSERVATION", 86, 96], ["decrease", "OBSERVATION_MODIFIER", 154, 162], ["peripheral lymphocytes", "OBSERVATION", 166, 188]]], ["[1] [2] [3] We sought to assess the lymphocyte subset alterations in COVID-19 patients, in particular the differences between critically ill patients admitted to the intensive care unit (ICU) and general ward patients.", [["lymphocyte", "ANATOMY", 36, 46], ["critically ill", "DISEASE", 126, 140], ["lymphocyte", "CELL", 36, 46], ["patients", "ORGANISM", 78, 86], ["patients", "ORGANISM", 141, 149], ["patients", "ORGANISM", 209, 217], ["patients", "SPECIES", 78, 86], ["patients", "SPECIES", 141, 149], ["patients", "SPECIES", 209, 217]]], ["As the number of SARS-CoV-2 infections increases throughout the world, healthcare systems are being overwhelmed.", [["SARS", "DISEASE", 17, 21], ["infections", "DISEASE", 28, 38], ["SARS-CoV-2", "ORGANISM", 17, 27], ["SARS-CoV", "SPECIES", 17, 25], ["SARS", "PROBLEM", 17, 21], ["2 infections", "PROBLEM", 26, 38], ["infections", "OBSERVATION", 28, 38]]], ["Hence, it is increasingly important to appropriately triage COVID-19 patients and identify those who would need ICU care early.Dear Editors,We retrospectively analyzed 129 samples of ethylenediamine tetraacetic acid (EDTA) anticoagulated peripheral blood samples from a total of 75 patients warded at the NCID, between February 24, 2020, and March 28, 2020.", [["samples", "ANATOMY", 172, 179], ["peripheral blood samples", "ANATOMY", 238, 262], ["ethylenediamine tetraacetic acid", "CHEMICAL", 183, 215], ["EDTA", "CHEMICAL", 217, 221], ["ethylenediamine tetraacetic acid", "CHEMICAL", 183, 215], ["EDTA", "CHEMICAL", 217, 221], ["patients", "ORGANISM", 69, 77], ["ethylenediamine tetraacetic acid", "SIMPLE_CHEMICAL", 183, 215], ["EDTA", "SIMPLE_CHEMICAL", 217, 221], ["peripheral blood samples", "ORGANISM_SUBSTANCE", 238, 262], ["patients", "ORGANISM", 282, 290], ["patients", "SPECIES", 69, 77], ["patients", "SPECIES", 282, 290], ["ICU care", "TREATMENT", 112, 120], ["ethylenediamine tetraacetic acid (EDTA)", "TREATMENT", 183, 222], ["peripheral blood samples", "TEST", 238, 262]]], ["Lymphocyte subsets namely CD3+/ CD4+/CD8+T-cell, CD19+B-cell, and CD16+CD56+ NK cell counts (cells/\u00b5L) were measured by multicolor flow cytometry, using the following reagents: human monoclonal anti-CD3-fluorescein isothiocyanate (FITC), anti-CD8-phycoerythrin (PE), anti-CD4-allophycocyanin (APC), anti-CD19-APC, anti-CD16+CD56 PE, and anti-CD45-peridinin-chlorophyll-protein (PerCP) antibodies.", [["Lymphocyte", "ANATOMY", 0, 10], ["CD3+/ CD4+/CD8+T-cell", "ANATOMY", 26, 47], ["CD19+B-cell", "ANATOMY", 49, 60], ["CD16+CD56+ NK cell", "ANATOMY", 66, 84], ["cells", "ANATOMY", 93, 98], ["fluorescein isothiocyanate", "CHEMICAL", 203, 229], ["fluorescein isothiocyanate", "CHEMICAL", 203, 229], ["FITC", "CHEMICAL", 231, 235], ["Lymphocyte", "CELL", 0, 10], ["CD3", "GENE_OR_GENE_PRODUCT", 26, 29], ["CD4", "GENE_OR_GENE_PRODUCT", 32, 35], ["CD8", "GENE_OR_GENE_PRODUCT", 37, 40], ["CD19", "GENE_OR_GENE_PRODUCT", 49, 53], ["CD16", "GENE_OR_GENE_PRODUCT", 66, 70], ["CD56", "GENE_OR_GENE_PRODUCT", 71, 75], ["human", "ORGANISM", 177, 182], ["anti-CD3-fluorescein isothiocyanate", "SIMPLE_CHEMICAL", 194, 229], ["FITC", "SIMPLE_CHEMICAL", 231, 235], ["anti-CD8-phycoerythrin", "SIMPLE_CHEMICAL", 238, 260], ["PE", "SIMPLE_CHEMICAL", 262, 264], ["anti-CD4-allophycocyanin", "SIMPLE_CHEMICAL", 267, 291], ["APC", "GENE_OR_GENE_PRODUCT", 293, 296], ["anti-CD19", "GENE_OR_GENE_PRODUCT", 299, 308], ["APC", "GENE_OR_GENE_PRODUCT", 309, 312], ["anti-CD16", "GENE_OR_GENE_PRODUCT", 314, 323], ["CD56", "GENE_OR_GENE_PRODUCT", 324, 328], ["PE", "SIMPLE_CHEMICAL", 329, 331], ["anti-CD45-peridinin", "SIMPLE_CHEMICAL", 337, 356], ["chlorophyll-protein", "GENE_OR_GENE_PRODUCT", 357, 376], ["PerCP", "SIMPLE_CHEMICAL", 378, 383], ["Lymphocyte subsets", "CELL_TYPE", 0, 18], ["CD3", "PROTEIN", 26, 29], ["CD4", "PROTEIN", 32, 35], ["CD8", "PROTEIN", 37, 40], ["CD19", "PROTEIN", 49, 53], ["CD16", "PROTEIN", 66, 70], ["CD56", "PROTEIN", 71, 75], ["human monoclonal anti-CD3", "PROTEIN", 177, 202], ["fluorescein isothiocyanate", "PROTEIN", 203, 229], ["FITC", "PROTEIN", 231, 235], ["anti-CD8", "PROTEIN", 238, 246], ["phycoerythrin", "PROTEIN", 247, 260], ["PE", "PROTEIN", 262, 264], ["anti-CD4", "PROTEIN", 267, 275], ["allophycocyanin", "PROTEIN", 276, 291], ["APC", "PROTEIN", 293, 296], ["anti-CD19", "PROTEIN", 299, 308], ["APC", "PROTEIN", 309, 312], ["anti-CD16", "PROTEIN", 314, 323], ["CD56 PE", "PROTEIN", 324, 331], ["anti-CD45", "PROTEIN", 337, 346], ["peridinin", "PROTEIN", 347, 356], ["chlorophyll-protein (PerCP) antibodies", "PROTEIN", 357, 395], ["human", "SPECIES", 177, 182], ["human", "SPECIES", 177, 182], ["Lymphocyte subsets", "TEST", 0, 18], ["CD3", "TEST", 26, 29], ["CD4", "TEST", 32, 35], ["CD8", "TEST", 37, 40], ["T", "TEST", 41, 42], ["cell", "TEST", 43, 47], ["CD19", "TEST", 49, 53], ["B", "TEST", 54, 55], ["cell", "TEST", 56, 60], ["CD16", "TEST", 66, 70], ["CD56", "TEST", 71, 75], ["NK cell counts", "TEST", 77, 91], ["cells", "TEST", 93, 98], ["multicolor flow cytometry", "TEST", 120, 145], ["human monoclonal anti-CD3", "TREATMENT", 177, 202], ["fluorescein isothiocyanate (FITC)", "TREATMENT", 203, 236], ["anti-CD8", "TREATMENT", 238, 246], ["phycoerythrin (PE", "TREATMENT", 247, 264], ["anti-CD4", "TREATMENT", 267, 275], ["allophycocyanin (APC", "TREATMENT", 276, 296], ["anti-CD19", "TREATMENT", 299, 308], ["APC", "TREATMENT", 309, 312], ["anti-CD16", "TREATMENT", 314, 323], ["CD56 PE", "TEST", 324, 331], ["anti-CD45", "TREATMENT", 337, 346], ["peridinin", "TREATMENT", 347, 356], ["chlorophyll", "TREATMENT", 357, 368], ["protein (PerCP) antibodies", "TREATMENT", 369, 395], ["NK", "ANATOMY", 77, 79], ["PE", "OBSERVATION", 262, 264]]], ["Cells were analyzed on a Becton Dickinson FACSCanto TM II Flow analyzer.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5]]], ["A complete blood count (CBC) and differential count were also performed on a Beckman Coulter DxH800 analyzer.", [["blood", "ANATOMY", 11, 16], ["blood", "ORGANISM_SUBSTANCE", 11, 16], ["A complete blood count", "TEST", 0, 22], ["CBC", "TEST", 24, 27], ["differential count", "TEST", 33, 51]]], ["All non-ICU patients had CBC, differential counts, and lymphocyte sub- In mice depleted of CD8+ T cells, RSV replication in the nose appears to be prolonged.", [["lymphocyte", "ANATOMY", 55, 65], ["CD8+ T cells", "ANATOMY", 91, 103], ["nose", "ANATOMY", 128, 132], ["patients", "ORGANISM", 12, 20], ["CBC", "CELL", 25, 28], ["lymphocyte", "CELL", 55, 65], ["mice", "ORGANISM", 74, 78], ["CD8", "GENE_OR_GENE_PRODUCT", 91, 94], ["RSV", "ORGANISM", 105, 108], ["nose", "ORGAN", 128, 132], ["CD8", "PROTEIN", 91, 94], ["T cells", "CELL_TYPE", 96, 103], ["patients", "SPECIES", 12, 20], ["mice", "SPECIES", 74, 78], ["mice", "SPECIES", 74, 78], ["RSV", "SPECIES", 105, 108], ["CBC", "TEST", 25, 28], ["differential counts", "TEST", 30, 49], ["lymphocyte sub", "TEST", 55, 69], ["CD8+ T cells", "TREATMENT", 91, 103], ["RSV replication in the nose", "TREATMENT", 105, 132], ["RSV replication", "OBSERVATION", 105, 120], ["nose", "ANATOMY", 128, 132], ["appears to be", "UNCERTAINTY", 133, 146], ["prolonged", "OBSERVATION", 147, 156]]], ["7 In humans, RSV infection was more severe in immunocompromised children with T-cell defects, and they experienced prolonged viral shedding compared to immunologically normal children.", [["T-cell", "ANATOMY", 78, 84], ["RSV infection", "DISEASE", 13, 26], ["T-cell defects", "DISEASE", 78, 92], ["humans", "ORGANISM", 5, 11], ["RSV", "ORGANISM", 13, 16], ["children", "ORGANISM", 64, 72], ["T-cell", "CELL", 78, 84], ["children", "ORGANISM", 175, 183], ["humans", "SPECIES", 5, 11], ["children", "SPECIES", 64, 72], ["children", "SPECIES", 175, 183], ["humans", "SPECIES", 5, 11], ["RSV", "SPECIES", 13, 16], ["RSV infection", "PROBLEM", 13, 26], ["T-cell defects", "PROBLEM", 78, 92], ["prolonged viral shedding", "PROBLEM", 115, 139], ["RSV", "ANATOMY", 13, 16], ["infection", "OBSERVATION", 17, 26], ["severe", "OBSERVATION_MODIFIER", 36, 42], ["cell defects", "OBSERVATION", 80, 92]]], ["8 Following natural H7N9 infection, the reduction in IFN-\u03b3 + CD8 T cells correlated with clinical recovery.", [["IFN-\u03b3 + CD8 T cells", "ANATOMY", 53, 72], ["H7N9 infection", "DISEASE", 20, 34], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 53, 58], ["IFN", "PROTEIN", 53, 56], ["CD8 T cells", "CELL_TYPE", 61, 72], ["H7N9", "SPECIES", 20, 24], ["natural H7N9 infection", "PROBLEM", 12, 34], ["the reduction", "TREATMENT", 36, 49], ["IFN", "TEST", 53, 56], ["CD8 T cells", "PROBLEM", 61, 72], ["H7N9", "OBSERVATION_MODIFIER", 20, 24], ["infection", "OBSERVATION", 25, 34], ["reduction", "OBSERVATION_MODIFIER", 40, 49]]], ["9 Additionally, we found that NK cells were significantly reduced in ICU patients compared to non-ICU patients and could also be a useful predictor of clinical severity.", [["NK cells", "ANATOMY", 30, 38], ["NK cells", "CELL", 30, 38], ["patients", "ORGANISM", 73, 81], ["patients", "ORGANISM", 102, 110], ["NK cells", "CELL_TYPE", 30, 38], ["patients", "SPECIES", 73, 81], ["patients", "SPECIES", 102, 110], ["NK cells", "PROBLEM", 30, 38], ["clinical severity", "PROBLEM", 151, 168], ["NK cells", "OBSERVATION", 30, 38], ["reduced", "OBSERVATION_MODIFIER", 58, 65]]], ["Our study echoes the findings by Wang F et al, 12 where they described the lymphocyte subsets in COVID-19 and found significantly lower total lymphocytes, CD4+ T cells, CD8+ T cells, and B cells in \"severe cases\" compared to \"mild cases.\"", [["lymphocyte", "ANATOMY", 75, 85], ["lymphocytes", "ANATOMY", 142, 153], ["CD4+ T cells", "ANATOMY", 155, 167], ["CD8+ T cells", "ANATOMY", 169, 181], ["B cells", "ANATOMY", 187, 194], ["lymphocyte", "CELL", 75, 85], ["COVID-19", "CELL", 97, 105], ["lymphocytes", "CELL", 142, 153], ["CD4", "GENE_OR_GENE_PRODUCT", 155, 158], ["CD8", "GENE_OR_GENE_PRODUCT", 169, 172], ["B cells", "CELL", 187, 194], ["lymphocyte subsets", "CELL_TYPE", 75, 93], ["COVID-19", "CELL_LINE", 97, 105], ["lymphocytes", "CELL_TYPE", 142, 153], ["CD4+ T cells", "CELL_TYPE", 155, 167], ["CD8+ T cells", "CELL_TYPE", 169, 181], ["B cells", "CELL_TYPE", 187, 194], ["Our study", "TEST", 0, 9], ["the lymphocyte subsets", "TEST", 71, 93], ["COVID", "TEST", 97, 102], ["significantly lower total lymphocytes", "PROBLEM", 116, 153], ["CD4", "TEST", 155, 158], ["T cells", "TEST", 160, 167], ["CD8", "TEST", 169, 172], ["T cells", "TEST", 174, 181], ["B cells in \"severe cases\"", "PROBLEM", 187, 212], ["mild cases", "PROBLEM", 226, 236], ["lymphocyte subsets", "OBSERVATION", 75, 93], ["significantly", "OBSERVATION_MODIFIER", 116, 129], ["lower", "OBSERVATION_MODIFIER", 130, 135], ["total lymphocytes", "OBSERVATION", 136, 153]]], ["However, in contrast to our study, the CD4/8 ratio and NK cells were not found to be significantly different between the two groups.", [["NK cells", "ANATOMY", 55, 63], ["CD4", "GENE_OR_GENE_PRODUCT", 39, 42], ["8", "GENE_OR_GENE_PRODUCT", 43, 44], ["NK cells", "CELL", 55, 63], ["CD4", "PROTEIN", 39, 42], ["NK cells", "CELL_TYPE", 55, 63], ["our study", "TEST", 24, 33], ["the CD4/8 ratio", "TEST", 35, 50], ["NK cells", "TEST", 55, 63], ["NK cells", "OBSERVATION", 55, 63]]], ["Wan S et al 13 showed only statistically significant differences in CD4+ and CD8+Dear Editors,T cells between the \"severe group\" and \"mild group,\" without any There are several limitations in our study.", [["CD4+", "ANATOMY", 68, 72], ["T cells", "ANATOMY", 94, 101], ["CD4", "GENE_OR_GENE_PRODUCT", 68, 71], ["CD8", "GENE_OR_GENE_PRODUCT", 77, 80], ["T cells", "CELL", 94, 101], ["CD4", "PROTEIN", 68, 71], ["CD8", "PROTEIN", 77, 80], ["T cells", "CELL_TYPE", 94, 101], ["CD4", "TEST", 68, 71], ["our study", "TEST", 192, 201], ["significant", "OBSERVATION_MODIFIER", 41, 52], ["mild", "OBSERVATION_MODIFIER", 134, 138]]], ["Firstly, as it is a retrospective study, blood tests were performed sporadically throughout the admission and not at specified time points.", [["blood", "ANATOMY", 41, 46], ["blood", "ORGANISM_SUBSTANCE", 41, 46], ["a retrospective study", "TEST", 18, 39], ["blood tests", "TEST", 41, 52]]], ["Secondly, we acknowledge that treatments administered such as steroids can influence lymphocyte subsets, and this could potentially confound our results.", [["lymphocyte", "ANATOMY", 85, 95], ["steroids", "CHEMICAL", 62, 70], ["steroids", "CHEMICAL", 62, 70], ["steroids", "SIMPLE_CHEMICAL", 62, 70], ["lymphocyte", "CELL", 85, 95], ["lymphocyte subsets", "CELL_TYPE", 85, 103], ["treatments", "TREATMENT", 30, 40], ["steroids", "TREATMENT", 62, 70], ["lymphocyte subsets", "TREATMENT", 85, 103]]], ["In conclusion, we found statistically significant differences in lymphocyte subsets between ICU and non-ICU patients.", [["lymphocyte", "ANATOMY", 65, 75], ["lymphocyte", "CELL", 65, 75], ["patients", "ORGANISM", 108, 116], ["lymphocyte subsets", "CELL_TYPE", 65, 83], ["patients", "SPECIES", 108, 116], ["significant", "OBSERVATION_MODIFIER", 38, 49], ["differences", "OBSERVATION_MODIFIER", 50, 61], ["lymphocyte subsets", "OBSERVATION", 65, 83]]], ["We also found that peripheral lymphocyte subset alterations are associated with the clinical severity of SARS-CoV-2 infection.", [["peripheral lymphocyte", "ANATOMY", 19, 40], ["SARS-CoV-2 infection", "DISEASE", 105, 125], ["peripheral lymphocyte", "CELL", 19, 40], ["SARS-CoV-2", "ORGANISM", 105, 115], ["peripheral lymphocyte subset", "CELL_TYPE", 19, 47], ["SARS-CoV-2", "SPECIES", 105, 115], ["peripheral lymphocyte subset alterations", "PROBLEM", 19, 59], ["SARS", "PROBLEM", 105, 109], ["CoV", "PROBLEM", 110, 113], ["2 infection", "PROBLEM", 114, 125], ["peripheral lymphocyte", "OBSERVATION", 19, 40], ["subset alterations", "OBSERVATION", 41, 59], ["SARS", "OBSERVATION", 105, 109], ["infection", "OBSERVATION", 116, 125]]], ["Possible predictors of severity include reduction in CD4+ T cells, CD8+ T cells, and NK cells, as well as an increased CD4/8 ratio.ACK N OWLED G EM ENTSWe thank the Department of Haematology and Department of Laboratory Medicine, Tan Tock Seng Hospital for the full support in the laboratory investigations.", [["CD4+ T cells", "ANATOMY", 53, 65], ["CD8+ T cells", "ANATOMY", 67, 79], ["NK cells", "ANATOMY", 85, 93], ["CD4", "GENE_OR_GENE_PRODUCT", 53, 56], ["CD8", "GENE_OR_GENE_PRODUCT", 67, 70], ["NK cells", "CELL", 85, 93], ["CD4", "GENE_OR_GENE_PRODUCT", 119, 122], ["8", "GENE_OR_GENE_PRODUCT", 123, 124], ["CD4", "PROTEIN", 53, 56], ["T cells", "CELL_TYPE", 58, 65], ["CD8+ T cells", "CELL_TYPE", 67, 79], ["NK cells", "CELL_TYPE", 85, 93], ["CD4", "PROTEIN", 119, 122], ["predictors of severity", "PROBLEM", 9, 31], ["CD4+ T cells", "PROBLEM", 53, 65], ["CD8+ T cells", "PROBLEM", 67, 79], ["NK cells", "PROBLEM", 85, 93], ["an increased CD4/8 ratio", "PROBLEM", 106, 130], ["the laboratory investigations", "TEST", 277, 306], ["reduction", "OBSERVATION_MODIFIER", 40, 49], ["NK cells", "OBSERVATION", 85, 93], ["increased", "OBSERVATION_MODIFIER", 109, 118], ["CD4", "OBSERVATION", 119, 122]]], ["Special thanks to Lim Shu Ping and WongACK N OWLED G EM ENTSLai Har for their assistance with specimen collection and processing.", [["specimen", "ANATOMY", 94, 102], ["specimen collection", "TEST", 94, 113]]]], "5bc64dd87cf5c7502eb06d534d15d718c6c02214": [["I nfluenza viruses are contagious zoonotic pathogens that belong to the Orthomyxoviridae family, which consists of 4 genera: Alphainfluenzavirus (influenza A virus), Betainfluenzavirus (influenza B virus), Gammainfluenzavirus (influenza C virus [ICV]), and Deltainfluenzavirus (influenza D virus) (1) (2) (3) (4) .", [["zoonotic pathogens", "DISEASE", 34, 52], ["influenza A virus", "DISEASE", 146, 163], ["influenza B", "DISEASE", 186, 197], ["influenza C", "DISEASE", 227, 238], ["nfluenza viruses", "ORGANISM", 2, 18], ["Orthomyxoviridae", "GENE_OR_GENE_PRODUCT", 72, 88], ["Alphainfluenzavirus (influenza A virus", "ORGANISM", 125, 163], ["Betainfluenzavirus (influenza B virus", "ORGANISM", 166, 203], ["Gammainfluenzavirus (influenza C virus", "ORGANISM", 206, 244], ["ICV]", "ORGANISM", 246, 250], ["influenza D virus", "ORGANISM", 278, 295], ["influenza A virus", "SPECIES", 146, 163], ["influenza B virus", "SPECIES", 186, 203], ["influenza C virus", "SPECIES", 227, 244], ["influenza D virus", "SPECIES", 278, 295], ["I nfluenza viruses", "SPECIES", 0, 18], ["influenza A virus", "SPECIES", 146, 163], ["Betainfluenzavirus (influenza B virus", "SPECIES", 166, 203], ["Gammainfluenzavirus (influenza C virus", "SPECIES", 206, 244], ["Deltainfluenzavirus (influenza D virus", "SPECIES", 257, 295], ["I nfluenza viruses", "PROBLEM", 0, 18], ["contagious zoonotic pathogens", "PROBLEM", 23, 52], ["Alphainfluenzavirus (influenza A virus", "PROBLEM", 125, 163], ["Betainfluenzavirus (influenza B virus", "PROBLEM", 166, 203], ["Gammainfluenzavirus (influenza C virus", "PROBLEM", 206, 244], ["Deltainfluenzavirus (influenza D virus)", "TREATMENT", 257, 296]]], ["Classification of influenza viruses is based on the antigenic differences in the nucleoprotein and matrix protein and supported by intergenic homologies of 20%-30% and intragenic homologies >85% (3) .", [["influenza viruses", "DISEASE", 18, 35], ["influenza viruses", "ORGANISM", 18, 35], ["matrix", "CELLULAR_COMPONENT", 99, 105], ["nucleoprotein and matrix protein", "PROTEIN", 81, 113], ["intergenic homologies", "DNA", 131, 152], ["intragenic homologies", "DNA", 168, 189], ["influenza viruses", "PROBLEM", 18, 35], ["the antigenic differences", "PROBLEM", 48, 73], ["intergenic homologies", "TEST", 131, 152], ["intragenic homologies", "TEST", 168, 189], ["influenza viruses", "OBSERVATION", 18, 35]]]], "PMC7299137": [["BackgroundIn late December 2019, new pneumonia cases have emerged in Wuhan City, China, and reported to the World Health Organization (WHO).", [["pneumonia", "DISEASE", 37, 46], ["new pneumonia cases", "PROBLEM", 33, 52], ["new", "OBSERVATION_MODIFIER", 33, 36], ["pneumonia", "OBSERVATION", 37, 46]]], ["The new cases have presented with respiratory features that resembling viral pneumonia a few months before the declaration of the pandemic by WHO [1].", [["respiratory", "ANATOMY", 34, 45], ["viral pneumonia", "DISEASE", 71, 86], ["respiratory features", "PROBLEM", 34, 54], ["viral pneumonia", "PROBLEM", 71, 86], ["viral", "OBSERVATION_MODIFIER", 71, 76], ["pneumonia", "OBSERVATION", 77, 86]]], ["Those cases were caused by a virus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its disease as 2019 coronavirus disease (COVID-19).", [["acute respiratory syndrome coronavirus", "DISEASE", 48, 86], ["coronavirus disease", "DISEASE", 126, 145], ["SARS-CoV-2", "ORGANISM", 90, 100], ["severe acute respiratory syndrome coronavirus", "SPECIES", 41, 86], ["SARS-CoV-2", "SPECIES", 90, 100], ["a virus", "PROBLEM", 27, 34], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 41, 86], ["SARS", "TEST", 90, 94], ["CoV", "TEST", 95, 98], ["its disease", "PROBLEM", 106, 117], ["coronavirus disease", "PROBLEM", 126, 145], ["COVID", "TEST", 147, 152], ["severe", "OBSERVATION_MODIFIER", 41, 47], ["acute", "OBSERVATION_MODIFIER", 48, 53], ["respiratory syndrome", "OBSERVATION", 54, 74], ["coronavirus disease", "OBSERVATION", 126, 145]]], ["SARS-CoV-2 is a single-stranded RNA virus that belongs to order Nidovirales, family Coronaviridae, a family that also includes other viruses implied in the respiratory illnesses such as severe acute respiratory syndrome (SARS) and the Middle East respiratory syndrome (MERS) [2].", [["respiratory", "ANATOMY", 156, 167], ["SARS", "DISEASE", 0, 4], ["respiratory illnesses", "DISEASE", 156, 177], ["acute respiratory syndrome", "DISEASE", 193, 219], ["SARS", "DISEASE", 221, 225], ["Middle East respiratory syndrome", "DISEASE", 235, 267], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["Nidovirales", "GENE_OR_GENE_PRODUCT", 64, 75], ["Coronaviridae", "GENE_OR_GENE_PRODUCT", 84, 97], ["SARS-CoV-2", "DNA", 0, 10], ["SARS-CoV", "SPECIES", 0, 8], ["Middle East respiratory syndrome (MERS)", "SPECIES", 235, 274], ["a single-stranded RNA virus", "PROBLEM", 14, 41], ["other viruses", "PROBLEM", 127, 140], ["the respiratory illnesses", "PROBLEM", 152, 177], ["severe acute respiratory syndrome", "PROBLEM", 186, 219], ["SARS", "PROBLEM", 221, 225], ["the Middle East respiratory syndrome", "PROBLEM", 231, 267], ["respiratory", "ANATOMY", 156, 167], ["severe", "OBSERVATION_MODIFIER", 186, 192], ["acute", "OBSERVATION_MODIFIER", 193, 198], ["respiratory syndrome", "OBSERVATION", 199, 219], ["Middle", "ANATOMY_MODIFIER", 235, 241], ["respiratory syndrome", "OBSERVATION", 247, 267]]], ["On 24 February 2020, Iraq has confirmed the first case of COVID-19 which subsequently followed by an incremental number that exceeds 1400 on 15 April 2020 [3].", [["COVID", "TEST", 58, 63]]], ["The diagnosis of COVID-19 requires the detection of the specific viral genetic material in the specimens collected from nose, blood, feces or respiratory secretions, however, the variable sensitivity of this test is a problem that threatens the validity [4].", [["specimens", "ANATOMY", 95, 104], ["nose", "ANATOMY", 120, 124], ["blood", "ANATOMY", 126, 131], ["feces", "ANATOMY", 133, 138], ["respiratory secretions", "ANATOMY", 142, 164], ["COVID-19", "CHEMICAL", 17, 25], ["specimens", "TISSUE", 95, 104], ["nose", "ORGANISM_SUBDIVISION", 120, 124], ["blood", "ORGANISM_SUBSTANCE", 126, 131], ["feces", "ORGANISM_SUBSTANCE", 133, 138], ["COVID", "TEST", 17, 22], ["the detection", "TEST", 35, 48], ["the specific viral genetic material", "PROBLEM", 52, 87], ["the specimens", "TEST", 91, 104], ["respiratory secretions", "PROBLEM", 142, 164], ["this test", "TEST", 203, 212], ["nose", "ANATOMY", 120, 124], ["respiratory", "ANATOMY", 142, 153], ["secretions", "OBSERVATION", 154, 164]]], ["Lung injury caused by the COVID-19 infection in the form of acute respiratory distress has been seen in about 30% of cases [5].", [["Lung", "ANATOMY", 0, 4], ["respiratory", "ANATOMY", 66, 77], ["Lung injury", "DISEASE", 0, 11], ["COVID-19", "CHEMICAL", 26, 34], ["infection", "DISEASE", 35, 44], ["respiratory distress", "DISEASE", 66, 86], ["Lung", "ORGAN", 0, 4], ["Lung injury", "PROBLEM", 0, 11], ["the COVID-19 infection", "PROBLEM", 22, 44], ["acute respiratory distress", "PROBLEM", 60, 86], ["injury", "OBSERVATION", 5, 11], ["infection", "OBSERVATION", 35, 44], ["acute", "OBSERVATION_MODIFIER", 60, 65], ["respiratory distress", "OBSERVATION", 66, 86]]], ["Chest computed tomography (CT) plays an essential role in the evaluation of COVID-19 even, sometimes before the clinical symptoms become apparent [6].", [["Chest computed tomography", "TEST", 0, 25], ["the evaluation", "TEST", 58, 72], ["COVID", "TEST", 76, 81], ["the clinical symptoms", "PROBLEM", 108, 129]]], ["Chest CT scan shows 97% and 75% sensitivity for the diagnosis of specimen positive and negative patients respectively but with only 25% specificity [7].", [["specimen", "ANATOMY", 65, 73], ["patients", "ORGANISM", 96, 104], ["patients", "SPECIES", 96, 104], ["Chest CT scan", "TEST", 0, 13], ["specimen positive", "PROBLEM", 65, 82]]], ["There is evidence of the prognostic value of chest CT which has been shown by recent studies, where a specific score by CT scan could predict the mortality of patients with COVID-19 [8].", [["COVID-19", "CHEMICAL", 173, 181], ["chest", "ORGANISM_SUBDIVISION", 45, 50], ["patients", "ORGANISM", 159, 167], ["patients", "SPECIES", 159, 167], ["chest CT", "TEST", 45, 53], ["recent studies", "TEST", 78, 92], ["a specific score", "TEST", 100, 116], ["CT scan", "TEST", 120, 127], ["COVID", "TEST", 173, 178], ["chest", "ANATOMY", 45, 50]]], ["The changes in the lung features on CT follow up have been mentioned in some previous studies [9, 10].", [["lung", "ANATOMY", 19, 23], ["lung", "ORGAN", 19, 23], ["The changes in the lung features", "PROBLEM", 0, 32], ["CT", "TEST", 36, 38], ["some previous studies", "TEST", 72, 93], ["lung", "ANATOMY", 19, 23]]], ["To have a better understanding of the chronological changes of the lung disease in COVID-19, we have performed our study to improve the accuracy of the diagnosis of the disease as no previous studies in Iraq have been performed could assess the progression of the disease on CT scan follow-up.Study population ::: MethodsPatients\u2019 data were collected from seven isolation Iraqi hospitals in Erbil, Baghdad, Babylon, Al-Muthanna, Najaf, and Karbala provinces, between March 10 and April 5, 2020.", [["lung", "ANATOMY", 67, 71], ["lung disease", "DISEASE", 67, 79], ["lung", "ORGAN", 67, 71], ["the lung disease", "PROBLEM", 63, 79], ["our study", "TEST", 111, 120], ["the disease", "PROBLEM", 165, 176], ["previous studies", "TEST", 183, 199], ["the disease", "PROBLEM", 260, 271], ["CT scan", "TEST", 275, 282], ["Babylon", "TREATMENT", 407, 414], ["Najaf", "TREATMENT", 429, 434], ["Karbala", "TREATMENT", 440, 447], ["lung", "ANATOMY", 67, 71], ["disease", "OBSERVATION", 72, 79], ["disease", "OBSERVATION", 169, 176], ["disease", "OBSERVATION", 264, 271]]], ["Ninety-six (61 males and 35 females) with proven COVID-19 infection were enrolled in this study; aged 19\u201382 years, with a mean age of 49.3 \u00b1 8.3 years.", [["COVID-19 infection", "DISEASE", 49, 67], ["COVID-19", "SPECIES", 49, 57], ["proven COVID-19 infection", "PROBLEM", 42, 67], ["infection", "OBSERVATION", 58, 67]]], ["All patients were symptomatic, presented with variable degrees of fever, cough, and dyspnea.", [["fever", "DISEASE", 66, 71], ["cough", "DISEASE", 73, 78], ["dyspnea", "DISEASE", 84, 91], ["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["symptomatic", "PROBLEM", 18, 29], ["fever", "PROBLEM", 66, 71], ["cough", "PROBLEM", 73, 78], ["dyspnea", "PROBLEM", 84, 91], ["symptomatic", "OBSERVATION_MODIFIER", 18, 29], ["variable degrees", "OBSERVATION_MODIFIER", 46, 62], ["fever", "OBSERVATION", 66, 71], ["cough", "OBSERVATION", 73, 78], ["dyspnea", "OBSERVATION", 84, 91]]], ["The patients were divided into two groups according to the duration of symptoms, the first group (70 patients) scanned within the first week of presentation while the second group (26 patients) scanned in the second week.", [["patients", "ORGANISM", 4, 12], ["patients", "ORGANISM", 101, 109], ["patients", "ORGANISM", 184, 192], ["patients", "SPECIES", 4, 12], ["patients", "SPECIES", 101, 109], ["patients", "SPECIES", 184, 192], ["symptoms", "PROBLEM", 71, 79]]], ["The COVID-19 infection was confirmed using the RT-PCR test.Inclusion criteria ::: MethodsProved COVID-19 infection: patients with positive PCR.Inclusion criteria ::: MethodsSymptomatic patients presented with a variable degree of fever, cough, and dyspnea.Exclusion criteria ::: MethodsPatients with preexisting lung disease were excluded from the study.Study design ::: MethodsThis study is a retrospective cross-sectional study.Ethics approval and consent to participate ::: MethodsNo individual data were included in the study.Ethics approval and consent to participate ::: MethodsThe Research Ethics Committee of the Faculty of Medicine at Tikrit University - Iraq, approved this study.Ethics approval and consent to participate ::: MethodsAll patients included in this study gave verbal informed consent to participate in this research.", [["lung", "ANATOMY", 312, 316], ["infection", "DISEASE", 13, 22], ["infection", "DISEASE", 105, 114], ["fever", "DISEASE", 230, 235], ["cough", "DISEASE", 237, 242], ["dyspnea", "DISEASE", 248, 255], ["lung disease", "DISEASE", 312, 324], ["patients", "ORGANISM", 116, 124], ["patients", "ORGANISM", 185, 193], ["lung", "ORGAN", 312, 316], ["patients", "ORGANISM", 748, 756], ["patients", "SPECIES", 116, 124], ["patients", "SPECIES", 185, 193], ["patients", "SPECIES", 748, 756], ["COVID-19", "SPECIES", 4, 12], ["The COVID-19 infection", "PROBLEM", 0, 22], ["the RT-PCR test", "TEST", 43, 58], ["positive PCR", "PROBLEM", 130, 142], ["fever", "PROBLEM", 230, 235], ["cough", "PROBLEM", 237, 242], ["dyspnea", "PROBLEM", 248, 255], ["preexisting lung disease", "PROBLEM", 300, 324], ["the study", "TEST", 344, 353], ["Methods", "TREATMENT", 371, 378], ["This study", "TEST", 378, 388], ["a retrospective cross-sectional study", "TEST", 392, 429], ["Methods", "TREATMENT", 477, 484], ["individual data", "TEST", 487, 502], ["the study", "TEST", 520, 529], ["Methods", "TREATMENT", 577, 584], ["this study", "TEST", 679, 689], ["Methods", "TREATMENT", 737, 744], ["this study", "TEST", 769, 779], ["infection", "OBSERVATION", 13, 22], ["infection", "OBSERVATION", 105, 114], ["variable degree", "OBSERVATION_MODIFIER", 211, 226], ["fever", "OBSERVATION", 230, 235], ["cough", "OBSERVATION", 237, 242], ["dyspnea", "OBSERVATION", 248, 255], ["lung", "ANATOMY", 312, 316], ["disease", "OBSERVATION", 317, 324]]], ["If the patient was unconscious at the time of the study, their next of keen have given written informed consent.Ethics approval and consent to participate ::: MethodsVerbal consent is advised by our medical research ethics committee, particularly in such unusual risky situation to reduce the risk of transmission of the disease by avoiding any unnecessary contact with the positive patients.CT scanning protocol ::: MethodsA high-resolution CT (HRCT) scan was performed in all patients with 64-slice multi-detector row CT scanners (Siemens Sensation-64, Philips Brilliance-64, and GE LightSpeed-64).", [["patient", "ORGANISM", 7, 14], ["patients", "ORGANISM", 383, 391], ["patients", "ORGANISM", 478, 486], ["patient", "SPECIES", 7, 14], ["patients", "SPECIES", 383, 391], ["patients", "SPECIES", 478, 486], ["unconscious", "PROBLEM", 19, 30], ["the study", "TEST", 46, 55], ["the disease", "PROBLEM", 317, 328], ["CT scanning protocol", "TEST", 392, 412], ["MethodsA", "TEST", 417, 425], ["resolution CT (HRCT) scan", "TEST", 431, 456], ["Sensation", "TEST", 541, 550], ["Philips Brilliance", "TEST", 555, 573]]], ["Patients were scanned in the supine position; head first, during breath-hold.", [["head", "ANATOMY", 46, 50], ["Patients", "ORGANISM", 0, 8], ["head", "ORGANISM_SUBDIVISION", 46, 50], ["Patients", "SPECIES", 0, 8], ["head", "ANATOMY", 46, 50]]], ["Scanning parameters were tube voltage 100\u2212120 kV, tube current 110\u2212280 mA, pitch 1.375, FOV 350\u2212400 mm.", [["Scanning parameters", "TEST", 0, 19], ["tube voltage", "TEST", 25, 37], ["tube", "TEST", 50, 54], ["pitch", "TEST", 75, 80], ["FOV", "TEST", 88, 91]]], ["The 1.25-mm or 2.5-mm-thick images were reconstructed using a high-frequency reconstruction algorithm.", [["mm-thick images", "TEST", 19, 34], ["a high-frequency reconstruction algorithm", "TREATMENT", 60, 101]]], ["All examinations were non-enhanced and no intravenous contrast medium was administered.HRCT image analysis ::: MethodsTwo expert radiologists (more than 5-years experience) have evaluated the CT images separately to identify the pulmonary changes.", [["intravenous", "ANATOMY", 42, 53], ["pulmonary", "ANATOMY", 229, 238], ["contrast medium", "CHEMICAL", 54, 69], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 42, 53], ["pulmonary", "ORGAN", 229, 238], ["All examinations", "TEST", 0, 16], ["intravenous contrast medium", "TREATMENT", 42, 69], ["HRCT image analysis", "TEST", 87, 106], ["the CT images", "TEST", 188, 201], ["the pulmonary changes", "PROBLEM", 225, 246], ["pulmonary", "ANATOMY", 229, 238], ["changes", "OBSERVATION", 239, 246]]], ["A detailed evaluation of the images was done and pulmonary changes were identified included ground-glass opacity (GGO), consolidation, crazy paving, tree-in-bud, broncho-vascular thickening, bronchiectasis, pulmonary nodules, cavitation, and pleural effusion.", [["pulmonary", "ANATOMY", 49, 58], ["bud", "ANATOMY", 157, 160], ["broncho", "ANATOMY", 162, 169], ["vascular", "ANATOMY", 170, 178], ["pulmonary nodules", "ANATOMY", 207, 224], ["pleural", "ANATOMY", 242, 249], ["GGO", "DISEASE", 114, 117], ["bronchiectasis", "DISEASE", 191, 205], ["cavitation", "DISEASE", 226, 236], ["pleural effusion", "DISEASE", 242, 258], ["pulmonary", "ORGAN", 49, 58], ["vascular", "MULTI-TISSUE_STRUCTURE", 170, 178], ["pulmonary nodules", "PATHOLOGICAL_FORMATION", 207, 224], ["A detailed evaluation of the images", "TEST", 0, 35], ["pulmonary changes", "PROBLEM", 49, 66], ["ground-glass opacity (GGO)", "PROBLEM", 92, 118], ["consolidation", "PROBLEM", 120, 133], ["broncho-vascular thickening", "PROBLEM", 162, 189], ["bronchiectasis", "PROBLEM", 191, 205], ["pulmonary nodules", "PROBLEM", 207, 224], ["cavitation", "PROBLEM", 226, 236], ["pleural effusion", "PROBLEM", 242, 258], ["pulmonary", "ANATOMY", 49, 58], ["glass opacity", "OBSERVATION", 99, 112], ["GGO", "OBSERVATION_MODIFIER", 114, 117], ["consolidation", "OBSERVATION", 120, 133], ["crazy", "OBSERVATION_MODIFIER", 135, 140], ["tree", "OBSERVATION_MODIFIER", 149, 153], ["bud", "ANATOMY_MODIFIER", 157, 160], ["broncho", "ANATOMY_MODIFIER", 162, 169], ["vascular", "ANATOMY", 170, 178], ["thickening", "OBSERVATION", 179, 189], ["bronchiectasis", "OBSERVATION", 191, 205], ["pulmonary", "ANATOMY", 207, 216], ["nodules", "OBSERVATION", 217, 224], ["cavitation", "OBSERVATION_MODIFIER", 226, 236], ["pleural", "ANATOMY", 242, 249], ["effusion", "OBSERVATION", 250, 258]]], ["The distribution of pulmonary changes was furthermore identified as unilateral vs. bilateral and central vs. peripheral distribution.", [["pulmonary", "ANATOMY", 20, 29], ["pulmonary", "ORGAN", 20, 29], ["peripheral", "TISSUE", 109, 119], ["pulmonary changes", "PROBLEM", 20, 37], ["distribution", "OBSERVATION_MODIFIER", 4, 16], ["pulmonary", "ANATOMY", 20, 29], ["central", "ANATOMY_MODIFIER", 97, 104], ["distribution", "OBSERVATION_MODIFIER", 120, 132]]], ["Lobar distribution was reported as upper, middle/lingular, lower, and multi-lobar distribution (two or more lobes).HRCT image analysis ::: MethodsLung changes were identified as peripheral if limited to the outer one-third and central when confined to the inner two-thirds of the lung.", [["lingular", "ANATOMY", 49, 57], ["lobes", "ANATOMY", 108, 113], ["lung", "ANATOMY", 280, 284], ["upper", "ORGANISM_SUBDIVISION", 35, 40], ["lobes", "ORGAN", 108, 113], ["lung", "ORGAN", 280, 284], ["Lobar distribution", "PROBLEM", 0, 18], ["upper, middle/lingular, lower, and multi-lobar distribution", "PROBLEM", 35, 94], ["HRCT image analysis", "TEST", 115, 134], ["MethodsLung changes", "PROBLEM", 139, 158], ["upper", "ANATOMY_MODIFIER", 35, 40], ["middle", "ANATOMY_MODIFIER", 42, 48], ["lingular", "ANATOMY_MODIFIER", 49, 57], ["lower", "ANATOMY_MODIFIER", 59, 64], ["multi-lobar", "OBSERVATION_MODIFIER", 70, 81], ["distribution", "OBSERVATION_MODIFIER", 82, 94], ["central", "ANATOMY_MODIFIER", 227, 234], ["inner", "ANATOMY_MODIFIER", 256, 261], ["two-", "ANATOMY_MODIFIER", 262, 266], ["thirds", "ANATOMY_MODIFIER", 266, 272], ["lung", "ANATOMY", 280, 284]]], ["Diffuse changes when both peripheral and central zones were affected simultaneously.", [["peripheral", "ANATOMY", 26, 36], ["central zones", "ANATOMY", 41, 54], ["peripheral", "TISSUE", 26, 36], ["central zones", "TISSUE", 41, 54], ["Diffuse changes", "PROBLEM", 0, 15], ["both", "ANATOMY_MODIFIER", 21, 25], ["peripheral", "ANATOMY_MODIFIER", 26, 36], ["central", "ANATOMY_MODIFIER", 41, 48], ["zones", "ANATOMY_MODIFIER", 49, 54]]], ["If there was disagreement concerning the CT analysis, a third radiologist was consulted.Statistical methodology ::: MethodsStatistical analysis was performed using SPSS 22.0.", [["the CT analysis", "TEST", 37, 52], ["MethodsStatistical analysis", "TEST", 116, 143], ["SPSS", "TEST", 164, 168]]], ["Measurement data were expressed as mean \u00b1 standard deviation, and numerical data are described as frequency.", [["Measurement data", "TEST", 0, 16], ["numerical data", "TEST", 66, 80]]], ["Patients were divided into two groups according to the duration of symptoms.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["symptoms", "PROBLEM", 67, 75]]], ["Statistical analysis was done using ANOVA for chi-square calculation to test the significance of results regarding the CT findings across the groups, and the difference was statistically significant with a p value < 0.05.Descriptive data ::: ResultsNinety-six symptomatic patients with proven COVID-19 were enrolled in this study, including 61 males and 35 females; aged 19\u201382 years, with a mean age of 49.3 \u00b1 8.3 years.Descriptive data ::: ResultsPatients were divided into two groups according to the duration of the symptom as follows: the first group included the patients who scanned within the first week after onset of symptoms and the second group included the patients who scanned within the second week after onset of symptoms.Pulmonary CT manifestations ::: ResultsGGO was noted in 73 patients (94.3%) in the first group (Figs.", [["Pulmonary", "ANATOMY", 737, 746], ["patients", "ORGANISM", 272, 280], ["patients", "ORGANISM", 568, 576], ["patients", "ORGANISM", 669, 677], ["patients", "ORGANISM", 796, 804], ["patients", "SPECIES", 272, 280], ["patients", "SPECIES", 568, 576], ["patients", "SPECIES", 669, 677], ["patients", "SPECIES", 796, 804], ["Statistical analysis", "TEST", 0, 20], ["chi-square calculation", "TEST", 46, 68], ["the CT findings", "TEST", 115, 130], ["a p value", "TEST", 204, 213], ["COVID", "TEST", 293, 298], ["this study", "TEST", 319, 329], ["symptoms", "PROBLEM", 626, 634], ["symptoms", "PROBLEM", 728, 736]]], ["1a and 2) and 23 patients (88.5%) of the second group (Fig. 1b) (significant association at p value = 0.05).", [["patients", "ORGANISM", 17, 25], ["patients", "SPECIES", 17, 25]]], ["Consolidation was noted in 18 patients (25.7%) in the first group and 9 patients (34.6%) of the second group (Fig. 1b) (little significance at p value = 0.05).", [["patients", "ORGANISM", 30, 38], ["patients", "ORGANISM", 72, 80], ["patients", "SPECIES", 30, 38], ["patients", "SPECIES", 72, 80], ["Consolidation", "PROBLEM", 0, 13]]], ["Broncho vascular thickening was noted in 13 patients (18.6%) in the first group and 2 patients (7.7%) of the second group (little significance at p value = 0.05).", [["Broncho vascular", "ANATOMY", 0, 16], ["Broncho vascular", "MULTI-TISSUE_STRUCTURE", 0, 16], ["patients", "ORGANISM", 44, 52], ["patients", "ORGANISM", 86, 94], ["patients", "SPECIES", 44, 52], ["patients", "SPECIES", 86, 94], ["Broncho vascular thickening", "PROBLEM", 0, 27], ["vascular", "ANATOMY", 8, 16], ["thickening", "OBSERVATION", 17, 27]]], ["The crazy paving appearance was noted in 11 patients (15.7%) in the first group and 1 patient (3.8%) of the second group (Fig. 3) (significant association at p value = 0.05).", [["patients", "ORGANISM", 44, 52], ["patient", "ORGANISM", 86, 93], ["patients", "SPECIES", 44, 52], ["patient", "SPECIES", 86, 93], ["crazy", "OBSERVATION_MODIFIER", 4, 9]]], ["Tree-in-bud appearance was noted in 3 patients (4.3%) in the first group and 3 patients (10.7%) of the second group (not significant at p value = 0.05).", [["bud", "ANATOMY", 8, 11], ["-bud", "MULTI-TISSUE_STRUCTURE", 7, 11], ["patients", "ORGANISM", 38, 46], ["patients", "ORGANISM", 79, 87], ["patients", "SPECIES", 38, 46], ["patients", "SPECIES", 79, 87], ["Tree", "TEST", 0, 4], ["bud", "ANATOMY_MODIFIER", 8, 11]]], ["Pulmonary nodules were noted in 4 patients (5.1%) in the first group (Figs.", [["Pulmonary nodules", "ANATOMY", 0, 17], ["Pulmonary nodules", "PATHOLOGICAL_FORMATION", 0, 17], ["patients", "ORGANISM", 34, 42], ["patients", "SPECIES", 34, 42], ["Pulmonary nodules", "PROBLEM", 0, 17], ["nodules", "OBSERVATION", 10, 17]]], ["1a and 2a) and 2 patients (7.7%) of the second group (not significant at p value = 0.05).", [["patients", "ORGANISM", 17, 25], ["patients", "SPECIES", 17, 25]]], ["Bronchiectasis was noted in 4 patients (5.5%) seen in the first group and 2 patients (7.7%) of the second group (Fig. 1b) (not significant at p value = 0.05).", [["Bronchiectasis", "DISEASE", 0, 14], ["patients", "ORGANISM", 30, 38], ["patients", "ORGANISM", 76, 84], ["patients", "SPECIES", 30, 38], ["patients", "SPECIES", 76, 84], ["Bronchiectasis", "PROBLEM", 0, 14]]], ["Pleural effusion was noted in 2 patients (2.9%) seen in the first group.", [["Pleural", "ANATOMY", 0, 7], ["Pleural effusion", "DISEASE", 0, 16], ["Pleural", "PATHOLOGICAL_FORMATION", 0, 7], ["patients", "ORGANISM", 32, 40], ["patients", "SPECIES", 32, 40], ["Pleural effusion", "PROBLEM", 0, 16], ["effusion", "OBSERVATION", 8, 16]]], ["Cavitation was noted in only one patient (1.4%) of the first group.", [["patient", "ORGANISM", 33, 40], ["patient", "SPECIES", 33, 40], ["Cavitation", "PROBLEM", 0, 10]]], ["Halo signs, reversed halo sign, pneumothorax, and lymphadenopathy were seen neither in the first nor in the second group (Table 1).", [["pneumothorax", "DISEASE", 32, 44], ["lymphadenopathy", "DISEASE", 50, 65], ["Halo signs", "TEST", 0, 10], ["reversed halo sign", "PROBLEM", 12, 30], ["pneumothorax", "PROBLEM", 32, 44], ["lymphadenopathy", "PROBLEM", 50, 65], ["reversed", "OBSERVATION_MODIFIER", 12, 20], ["halo sign", "OBSERVATION", 21, 30], ["pneumothorax", "OBSERVATION", 32, 44], ["lymphadenopathy", "OBSERVATION", 50, 65]]]], "0d1e55a32451582bed1424fda389028deb96e711": [["1.IntroductionThe development of a field effect transistor (FET), allowing signal enhancement of biological binding events with an applied electric field, is a lab-on-a-chip approach with short assay times down to seconds in the best cases [1] [2] [3] [4] .", [["[1] [2] [3] [4]", "SIMPLE_CHEMICAL", 240, 255], ["a field effect transistor (FET)", "TREATMENT", 33, 64], ["signal enhancement of biological binding events", "PROBLEM", 75, 122], ["a-chip approach", "TREATMENT", 167, 182], ["short assay", "TEST", 188, 199]]], ["It represents an attractive sensing platform due to its fast response time, ease to use, possibility of miniaturization together with sensitive and selective detection.", [["selective detection", "TEST", 148, 167]]], ["Selective sensing is achieved by anchoring specific probes on the conducting rGO channel of the transistor, which remains a critical factor for FET sensor performance, of particular importance when used as a biosensor.", [["rGO channel", "PROTEIN", 77, 88], ["the transistor", "TREATMENT", 92, 106]]], ["The golden standard of viral detection in clinical settings remains the polymerase chain reaction (PCR) or the advanced quantitative real-time reverse transcription PCR (qRT-PCR) [5, 6] .", [["viral detection", "TEST", 23, 38], ["the polymerase chain reaction", "PROBLEM", 68, 97], ["PCR", "TEST", 99, 102], ["reverse transcription PCR", "TEST", 143, 168], ["golden", "OBSERVATION_MODIFIER", 4, 10]]], ["The typical turnaround time for screening and diagnosing patients is > 24 h.", [["patients", "ORGANISM", 57, 65], ["patients", "SPECIES", 57, 65], ["screening", "TEST", 32, 41]]], ["Additional drawback is the fact that the positive rate of qRT-PCR assays is often reported to vary from 30 to 60%.", [["qRT", "DNA", 58, 61], ["qRT", "TEST", 58, 61], ["PCR assays", "TEST", 62, 72]]], ["Therefore, more accurate and sensitive methods are urgently needed to support the quality assurance of the qRT-PCR.", [["the qRT-PCR", "TEST", 103, 114]]], ["In order to be applicable for viral infection diagnosis, the FET biosensor should have a sensitivity close to that of PCR, a lower per-test cost, and minimum investment in the necessary laboratory hardware.", [["viral infection", "DISEASE", 30, 45], ["viral infection", "PROBLEM", 30, 45], ["the FET biosensor", "TEST", 57, 74], ["a sensitivity", "PROBLEM", 87, 100], ["PCR", "TEST", 118, 121], ["infection", "OBSERVATION", 36, 45], ["hardware", "OBSERVATION", 197, 205]]], ["For these reasons, graphenebased FET sensors for viral infection screening are still at their early phase of development [4, [7] [8] [9] [10] [11] .", [["viral infection", "DISEASE", 49, 64], ["[7] [8] [9] [10] [11]", "SIMPLE_CHEMICAL", 125, 146], ["graphenebased FET sensors", "TEST", 19, 44], ["viral infection screening", "TEST", 49, 74]]], ["The use of rGO-based FET for the evaluation of Ebola glycoproteins suspended in Published in the topical collection 2D Nanomaterials for Electroanalysis with guest editor Sabine Szunerits. human serum and plasma with a sensitivity down to 1 ng mL \u22121 was reported by Chen et al. [4] .", [["serum", "ANATOMY", 195, 200], ["plasma", "ANATOMY", 205, 211], ["rGO", "CHEMICAL", 11, 14], ["Ebola", "DISEASE", 47, 52], ["rGO", "CHEMICAL", 11, 14], ["rGO", "SIMPLE_CHEMICAL", 11, 14], ["Ebola", "ORGANISM", 47, 52], ["human", "ORGANISM", 189, 194], ["serum", "ORGANISM_SUBSTANCE", 195, 200], ["plasma", "ORGANISM_SUBSTANCE", 205, 211], ["rGO", "PROTEIN", 11, 14], ["Ebola glycoproteins", "PROTEIN", 47, 66], ["human", "SPECIES", 189, 194], ["Ebola", "SPECIES", 47, 52], ["human", "SPECIES", 189, 194], ["rGO-based FET", "TREATMENT", 11, 24], ["the evaluation", "TEST", 29, 43], ["Ebola glycoproteins", "TREATMENT", 47, 66], ["human serum", "TEST", 189, 200], ["plasma", "TEST", 205, 211], ["a sensitivity", "TEST", 217, 230]]], ["The rapid detection of COVID-19 causative virus in the human nasopharynx was just reported on a graphene field effect transistor [11] .", [["nasopharynx", "ANATOMY", 61, 72], ["graphene", "CHEMICAL", 96, 104], ["COVID-19", "ORGANISM", 23, 31], ["human", "ORGANISM", 55, 60], ["nasopharynx", "ORGAN", 61, 72], ["human", "SPECIES", 55, 60], ["COVID-19 causative virus", "SPECIES", 23, 47], ["human", "SPECIES", 55, 60], ["The rapid detection", "TEST", 0, 19], ["COVID", "TEST", 23, 28], ["causative virus in the human nasopharynx", "PROBLEM", 32, 72], ["a graphene field effect transistor", "TREATMENT", 94, 128], ["virus", "OBSERVATION", 42, 47], ["human nasopharynx", "ANATOMY", 55, 72]]], ["The sensor was produced by coating graphene sheets of the FET with specific antibodies against SARS-CoV-2 spike protein.1.IntroductionDetection limits of 1 fg mL \u22121 in PBS and 100 fg mL \u22121 in universal transport medium (UMT) were achieved for the SARS-CoV-2 spike protein.", [["graphene", "CHEMICAL", 35, 43], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 95, 105], ["SARS-CoV-2 spike protein", "PROTEIN", 95, 119], ["SARS-CoV-2 spike protein", "PROTEIN", 247, 271], ["SARS-CoV", "SPECIES", 95, 103], ["SARS-CoV", "SPECIES", 247, 255], ["the FET", "TEST", 54, 61], ["specific antibodies", "TEST", 67, 86], ["SARS", "PROBLEM", 95, 99], ["CoV", "TEST", 100, 103], ["2 spike protein", "PROBLEM", 104, 119], ["PBS", "TEST", 168, 171], ["the SARS", "TEST", 243, 251], ["CoV", "TEST", 252, 255]]], ["Field effect biosensing with monoclonal antibodies covalently linked to graphene was proposed for the quantitative detection of native Zika virus (ZIKV), with a detection of antigen in buffer at concentrations as low as 450 pM [9] .", [["graphene", "CHEMICAL", 72, 80], ["graphene", "CHEMICAL", 72, 80], ["graphene", "SIMPLE_CHEMICAL", 72, 80], ["Zika virus", "ORGANISM", 135, 145], ["ZIKV", "ORGANISM", 147, 151], ["monoclonal antibodies", "PROTEIN", 29, 50], ["Zika virus", "SPECIES", 135, 145], ["Zika virus", "SPECIES", 135, 145], ["ZIKV", "SPECIES", 147, 151], ["monoclonal antibodies covalently", "PROBLEM", 29, 61], ["native Zika virus", "PROBLEM", 128, 145], ["antigen in buffer", "TREATMENT", 174, 191], ["Zika virus", "OBSERVATION", 135, 145]]], ["Additionally, good linearity and large dynamic range of label-free protein detection allow the use of graphene FETs as biosensors in a wide range of applications [12] .1.IntroductionIn this work, we investigate the potential of reduced graphene oxide-based FET (rGO-FET) for the detection of human papillomavirus (HPV) [13] .", [["graphene FETs", "CHEMICAL", 102, 115], ["graphene oxide", "CHEMICAL", 236, 250], ["rGO-FET", "CHEMICAL", 262, 269], ["human papillomavirus (HPV)", "DISEASE", 292, 318], ["graphene", "CHEMICAL", 102, 110], ["graphene oxide", "CHEMICAL", 236, 250], ["graphene FETs", "SIMPLE_CHEMICAL", 102, 115], ["graphene oxide", "SIMPLE_CHEMICAL", 236, 250], ["human", "ORGANISM", 292, 297], ["papillomavirus", "ORGANISM", 298, 312], ["HPV", "ORGANISM", 314, 317], ["human", "SPECIES", 292, 297], ["papillomavirus", "SPECIES", 298, 312], ["human papillomavirus", "SPECIES", 292, 312], ["HPV", "SPECIES", 314, 317], ["graphene FETs", "TREATMENT", 102, 115], ["a wide range of applications", "TREATMENT", 133, 161], ["reduced graphene oxide", "TREATMENT", 228, 250], ["FET (rGO-FET)", "TREATMENT", 257, 270], ["human papillomavirus", "PROBLEM", 292, 312], ["good", "OBSERVATION_MODIFIER", 14, 18], ["linearity", "OBSERVATION_MODIFIER", 19, 28], ["large", "OBSERVATION_MODIFIER", 33, 38], ["dynamic", "OBSERVATION_MODIFIER", 39, 46]]], ["More than 100 types of human papillomaviruses (HPVs) have been identified and approximately half of them infect the genital tract.", [["genital tract", "ANATOMY", 116, 129], ["human papillomaviruses (HPVs", "DISEASE", 23, 51], ["human", "ORGANISM", 23, 28], ["papillomaviruses", "ORGANISM", 29, 45], ["HPVs", "CANCER", 47, 51], ["genital tract", "ORGANISM_SUBDIVISION", 116, 129], ["human", "SPECIES", 23, 28], ["human papillomaviruses", "SPECIES", 23, 45], ["human papillomaviruses (HPVs", "PROBLEM", 23, 51], ["papillomaviruses", "OBSERVATION", 29, 45], ["approximately half", "OBSERVATION_MODIFIER", 78, 96], ["infect", "OBSERVATION", 105, 111], ["genital tract", "ANATOMY", 116, 129]]], ["All papillomaviruses share a common genetic structure: a doublestranded circular DNA genome encoding approximately eight open reading frames (ORFs).", [["papillomaviruses", "ORGANISM", 4, 20], ["DNA", "CELLULAR_COMPONENT", 81, 84], ["doublestranded circular DNA genome", "DNA", 57, 91], ["open reading frames", "DNA", 121, 140], ["ORFs", "DNA", 142, 146], ["a doublestranded circular DNA genome", "TREATMENT", 55, 91], ["papillomaviruses", "OBSERVATION", 4, 20]]], ["As only 1% of the infected people present symptomatology, early diagnosis relies currently on molecular diagnosis tools, notably nucleic acid hybridization assays and PCR [14] .1.IntroductionOne of the first works on using a biosensor-based platform for HPV sensing is the electrochemical sensor proposed by the group of O'Sullivan for the detection of HPV-16 E6 DNA with a detection limit of 490 pM [15] .", [["nucleic acid", "CHEMICAL", 129, 141], ["O'Sullivan", "CHEMICAL", 321, 331], ["people", "ORGANISM", 27, 33], ["HPV", "ORGANISM", 254, 257], ["O'Sullivan", "SIMPLE_CHEMICAL", 321, 331], ["HPV", "ORGANISM", 353, 356], ["E6", "ORGANISM", 360, 362], ["DNA", "CELLULAR_COMPONENT", 363, 366], ["HPV-16 E6 DNA", "DNA", 353, 366], ["people", "SPECIES", 27, 33], ["HPV-16 E6", "SPECIES", 353, 362], ["nucleic acid hybridization assays", "TEST", 129, 162], ["PCR", "TEST", 167, 170], ["a biosensor", "TREATMENT", 223, 234], ["HPV sensing", "TREATMENT", 254, 265], ["HPV", "TEST", 353, 356]]], ["One of the currently best performing HPV sensors is based on the use of HPV-16 DNA-modified AuNPs/single-walled carbon nanotubes with a detection limit of 1 aM and a linear range between 1 aM and 1 pM for HPV-16 DNA [16] .", [["AuNPs", "CHEMICAL", 92, 97], ["carbon nanotubes", "CHEMICAL", 112, 128], ["carbon", "CHEMICAL", 112, 118], ["HPV", "ORGANISM", 37, 40], ["HPV", "ORGANISM", 72, 75], ["DNA", "CELLULAR_COMPONENT", 79, 82], ["AuNPs", "SIMPLE_CHEMICAL", 92, 97], ["single-walled carbon nanotubes", "SIMPLE_CHEMICAL", 98, 128], ["HPV-16 DNA", "DNA", 72, 82], ["HPV sensors", "TREATMENT", 37, 48], ["HPV", "TEST", 72, 75], ["DNA", "TEST", 79, 82], ["modified AuNPs/single-walled carbon nanotubes", "TREATMENT", 83, 128], ["HPV", "TEST", 205, 208]]], ["Our group has recently demonstrated the interest of aptamer-modified electrodes for the sensitive and selective detection of the E7 major capsid protein of human papillomavirus (HPV) [17] .", [["E7", "GENE_OR_GENE_PRODUCT", 129, 131], ["human papillomavirus", "ORGANISM", 156, 176], ["HPV", "ORGANISM", 178, 181], ["E7 major capsid protein", "PROTEIN", 129, 152], ["human", "SPECIES", 156, 161], ["papillomavirus", "SPECIES", 162, 176], ["human papillomavirus", "SPECIES", 156, 176], ["HPV", "SPECIES", 178, 181], ["aptamer-modified electrodes", "TREATMENT", 52, 79], ["selective detection", "TEST", 102, 121]]], ["Here, we show that rGO-FET with adapted surface architecture allows for the sensing of HPV-16 E7 protein, with a linear sensing regime between 30 and 1000 nM.", [["surface", "ANATOMY", 40, 47], ["rGO", "CHEMICAL", 19, 22], ["rGO-FET", "SIMPLE_CHEMICAL", 19, 26], ["HPV-16 E7", "ORGANISM", 87, 96], ["rGO", "PROTEIN", 19, 22], ["HPV-16 E7 protein", "PROTEIN", 87, 104], ["HPV", "TEST", 87, 90], ["a linear sensing regime", "TREATMENT", 111, 134]]], ["Microelectrodes (ED-IDE1-Au w/o SU8) were purchased from Micrux Technologies, Spain.2.Materials and methodsThe 5\u2032-amine-modified HPV-16 E7 aptamer with spacer (NH 2 -5\u2032-(TTT) 8 GGG AGG ACG AUG CGG AAG CAT CAA GGG TGA TCG TTT GAC CCT CCC CAG ACG ACU CGC CCG A-3) [18] was purchased from Integrated DNA Technologies (IDT Corporation).2.Materials and methodsThe scrambled aptamer sequence used was NH 2 -5\u2032-(TTT) 8 GG GAG GAC GAU GCG GGT AAT AAA CAC GAC AAC GCT TTA TTG CCC CCA GAC GAC UCG CCC GA-3 (Integrated DNA Technologies, IDT Corporation).2.Materials and methodsThe HPV recombinant HPV-16 E7 (M W = 15 kDa) was obtained from LifeSpan BioSciences.", [["5\u2032-amine", "CHEMICAL", 111, 119], ["NH 2 -5\u2032", "CHEMICAL", 160, 168], ["NH 2 -5\u2032-", "CHEMICAL", 395, 404], ["Au", "CHEMICAL", 25, 27], ["5\u2032-amine", "CHEMICAL", 111, 119], ["CCG A-3", "CHEMICAL", 253, 260], ["NH", "CHEMICAL", 395, 397], ["5\u2032-amine", "SIMPLE_CHEMICAL", 111, 119], ["HPV", "ORGANISM", 129, 132], ["E7", "ORGANISM", 136, 138], ["DNA", "CELLULAR_COMPONENT", 297, 300], ["NH 2 -5\u2032-(TTT) 8 GG GAG", "SIMPLE_CHEMICAL", 395, 418], ["DNA", "CELLULAR_COMPONENT", 508, 511], ["HPV", "ORGANISM", 570, 573], ["HPV-16 E7", "ORGANISM", 586, 595], ["SU8", "DNA", 32, 35], ["AAG CAT CAA GGG TGA TCG TTT GAC CCT CCC CAG ACG ACU CGC CCG A-3", "DNA", 197, 260], ["scrambled aptamer sequence", "DNA", 359, 385], ["NH 2 -5\u2032-(TTT) 8 GG GAG GAC GAU GCG GGT AAT AAA CAC GAC AAC GCT TTA TTG CCC CCA GAC GAC UCG CCC GA-3", "DNA", 395, 495], ["E7", "PROTEIN", 593, 595], ["Microelectrodes", "TEST", 0, 15], ["methods", "TEST", 100, 107], ["modified HPV", "TEST", 120, 132], ["E7 aptamer with spacer (NH", "TREATMENT", 136, 162], ["TTT", "TEST", 170, 173], ["GGG AGG", "TEST", 177, 184], ["ACG", "TEST", 185, 188], ["AUG", "TEST", 189, 192], ["CGG", "TEST", 193, 196], ["AAG", "TEST", 197, 200], ["CAT", "TEST", 201, 204], ["CAA", "TEST", 205, 208], ["GGG", "TEST", 209, 212], ["TGA", "TEST", 213, 216], ["TCG", "TEST", 217, 220], ["TTT", "TEST", 221, 224], ["GAC", "TEST", 225, 228], ["CCT", "TEST", 229, 232], ["CCC", "TEST", 233, 236], ["CAG", "TEST", 237, 240], ["ACG", "TEST", 241, 244], ["CCG", "TEST", 253, 256], ["The scrambled aptamer sequence", "TEST", 355, 385], ["NH", "TEST", 395, 397], ["TTT", "TEST", 405, 408], ["GG", "TEST", 412, 414], ["GAG GAC", "TEST", 415, 422], ["GAU", "TEST", 423, 426], ["GCG", "TEST", 427, 430], ["GGT", "TEST", 431, 434], ["AAT", "TEST", 435, 438], ["AAA", "TEST", 439, 442], ["CAC", "TEST", 443, 446], ["GAC", "TEST", 447, 450], ["AAC", "TEST", 451, 454], ["GCT", "TEST", 455, 458], ["TTA", "TEST", 459, 462], ["TTG", "TEST", 463, 466], ["CCC", "TEST", 467, 470], ["CCA", "TEST", 471, 474], ["GAC", "TEST", 475, 478], ["GAC", "TEST", 479, 482], ["UCG", "TEST", 483, 486], ["CCC GA", "TEST", 487, 493], ["methods", "TEST", 559, 566], ["The HPV recombinant HPV", "TEST", 566, 589], ["E7", "TEST", 593, 595]]], ["Human insulin for control experiments was obtained from Sigma-Aldrich.2.Materials and methodsSaliva samples were kindly provided by the Centre Hospitalier Universitaire (CHU), Lille.2.Materials and methodsThe blocking agent PEG was pre-conjugated with a PBSE linker (PyPEG) for later \u03c0-\u03c0 immobilization on the rGO surface [19] .2.1.Fabrication of reduced graphene oxide-based FETBefore modification with rGO, the microelectrodes were cleaned by submerging them in a solution of 5 parts deionized water, 1 part ammonia solution (30% NH 4 OH), and 1 part hydrogen peroxide (30% H 2 O 2 ) and heating to 80\u00b0C, followed by rinsing with deionized water and absolute EtOH, before being blow-dried with compressed air, and stored for later use in a plastic Petri dish.", [["Saliva samples", "ANATOMY", 93, 107], ["PEG", "CHEMICAL", 224, 227], ["PyPEG", "CHEMICAL", 267, 272], ["graphene oxide", "CHEMICAL", 355, 369], ["ammonia", "CHEMICAL", 510, 517], ["NH 4 OH", "CHEMICAL", 532, 539], ["hydrogen peroxide", "CHEMICAL", 553, 570], ["H 2 O", "CHEMICAL", 576, 581], ["EtOH", "CHEMICAL", 661, 665], ["PEG", "CHEMICAL", 224, 227], ["PBSE", "CHEMICAL", 254, 258], ["rGO", "CHEMICAL", 310, 313], ["graphene oxide", "CHEMICAL", 355, 369], ["ammonia", "CHEMICAL", 510, 517], ["NH", "CHEMICAL", 532, 534], ["OH", "CHEMICAL", 537, 539], ["hydrogen peroxide", "CHEMICAL", 553, 570], ["H 2 O 2", "CHEMICAL", 576, 583], ["EtOH", "CHEMICAL", 661, 665], ["Human", "ORGANISM", 0, 5], ["insulin", "GENE_OR_GENE_PRODUCT", 6, 13], ["Sigma-Aldrich", "ORGANISM", 56, 69], ["Saliva samples", "ORGANISM_SUBSTANCE", 93, 107], ["PEG", "SIMPLE_CHEMICAL", 224, 227], ["PBSE linker", "SIMPLE_CHEMICAL", 254, 265], ["PyPEG", "SIMPLE_CHEMICAL", 267, 272], ["\u03c0-\u03c0", "SIMPLE_CHEMICAL", 284, 287], ["graphene oxide", "SIMPLE_CHEMICAL", 355, 369], ["FETBefore", "SIMPLE_CHEMICAL", 376, 385], ["rGO", "SIMPLE_CHEMICAL", 404, 407], ["ammonia", "SIMPLE_CHEMICAL", 510, 517], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 553, 570], ["EtOH", "SIMPLE_CHEMICAL", 661, 665], ["PBSE linker", "PROTEIN", 254, 265], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["Human insulin", "TREATMENT", 0, 13], ["methodsSaliva samples", "TREATMENT", 86, 107], ["The blocking agent PEG", "TREATMENT", 205, 227], ["a PBSE linker (PyPEG", "TREATMENT", 252, 272], ["later \u03c0-\u03c0 immobilization", "TREATMENT", 278, 302], ["the rGO surface", "TEST", 306, 321], ["Fabrication of reduced graphene oxide", "TREATMENT", 332, 369], ["FETBefore modification with rGO", "TREATMENT", 376, 407], ["the microelectrodes", "TREATMENT", 409, 428], ["a solution of 5 parts deionized water", "TREATMENT", 464, 501], ["1 part ammonia solution", "TREATMENT", 503, 526], ["1 part hydrogen peroxide", "TREATMENT", 546, 570], ["a plastic Petri dish", "TREATMENT", 740, 760], ["PEG", "OBSERVATION", 224, 227], ["reduced", "OBSERVATION_MODIFIER", 347, 354], ["graphene oxide", "OBSERVATION", 355, 369], ["plastic", "OBSERVATION", 742, 749], ["Petri dish", "OBSERVATION", 750, 760]]], ["Before graphene oxide (GO) transfer, the glass part between the interdigitated electrodes (IDE) was functionalized with 3-amino-propyltriethoxysilane (APTES) by using a 2% APTES in absolute EtOH for 1 h, followed by rinsing with water and absolute EtOH to remove excess silane.2.1.Fabrication of reduced graphene oxide-based FETAll chips are placed in a glass Petri dish and annealed at 120\u00b0C for 2 h.", [["graphene oxide", "CHEMICAL", 7, 21], ["3-amino-propyltriethoxysilane", "CHEMICAL", 120, 149], ["APTES", "CHEMICAL", 151, 156], ["APTES", "CHEMICAL", 172, 177], ["EtOH", "CHEMICAL", 190, 194], ["EtOH", "CHEMICAL", 248, 252], ["silane", "CHEMICAL", 270, 276], ["graphene oxide", "CHEMICAL", 304, 318], ["graphene oxide", "CHEMICAL", 7, 21], ["3-amino-propyltriethoxysilane", "CHEMICAL", 120, 149], ["APTES", "CHEMICAL", 151, 156], ["EtOH", "CHEMICAL", 190, 194], ["EtOH", "CHEMICAL", 248, 252], ["silane", "CHEMICAL", 270, 276], ["graphene oxide", "CHEMICAL", 304, 318], ["graphene oxide", "SIMPLE_CHEMICAL", 7, 21], ["3-amino-propyltriethoxysilane", "SIMPLE_CHEMICAL", 120, 149], ["APTES", "SIMPLE_CHEMICAL", 151, 156], ["APTES", "SIMPLE_CHEMICAL", 172, 177], ["EtOH", "SIMPLE_CHEMICAL", 190, 194], ["water", "SIMPLE_CHEMICAL", 229, 234], ["EtOH", "SIMPLE_CHEMICAL", 248, 252], ["silane", "SIMPLE_CHEMICAL", 270, 276], ["graphene oxide", "SIMPLE_CHEMICAL", 304, 318], ["graphene oxide", "TREATMENT", 7, 21], ["the interdigitated electrodes (IDE)", "TREATMENT", 60, 95], ["3-amino-propyltriethoxysilane (APTES", "TREATMENT", 120, 156], ["a 2% APTES", "TREATMENT", 167, 177], ["excess silane", "TREATMENT", 263, 276], ["Fabrication of reduced graphene oxide", "TREATMENT", 281, 318], ["FETAll chips", "TREATMENT", 325, 337], ["a glass Petri dish", "TREATMENT", 352, 370], ["reduced", "OBSERVATION_MODIFIER", 296, 303], ["graphene oxide", "OBSERVATION", 304, 318]]], ["GO (12.5 \u03bcg mL \u22121 ) was transferred to the silanized IDE by drop casting of 15 \u03bcL.", [["IDE", "GENE_OR_GENE_PRODUCT", 53, 56]]], ["After 2 h, the excess GO suspension is rinsed off with deionized dH 2 O and carefully blow-dried with compressed air.2.1.Fabrication of reduced graphene oxide-based FETReduction of GO to rGO was performed by placing the electrodes into a glass Petri dish and adding 1 mL of hydrazine into the corners of the glass dish, while the chips are all placed in the center.", [["dH 2 O", "CHEMICAL", 65, 71], ["graphene oxide", "CHEMICAL", 144, 158], ["hydrazine", "CHEMICAL", 274, 283], ["dH 2 O", "CHEMICAL", 65, 71], ["graphene oxide", "CHEMICAL", 144, 158], ["hydrazine", "CHEMICAL", 274, 283], ["graphene oxide", "SIMPLE_CHEMICAL", 144, 158], ["rGO", "SIMPLE_CHEMICAL", 187, 190], ["hydrazine", "SIMPLE_CHEMICAL", 274, 283], ["the excess GO suspension", "TREATMENT", 11, 35], ["Fabrication of reduced graphene oxide", "TREATMENT", 121, 158], ["a glass Petri dish", "TREATMENT", 236, 254], ["hydrazine", "TREATMENT", 274, 283], ["the chips", "TREATMENT", 326, 335], ["air", "OBSERVATION", 113, 116], ["reduced", "OBSERVATION_MODIFIER", 136, 143], ["graphene oxide", "OBSERVATION", 144, 158], ["glass Petri dish", "OBSERVATION", 238, 254], ["corners", "ANATOMY_MODIFIER", 293, 300], ["glass dish", "OBSERVATION", 308, 318]]], ["Immediately, the lid is sealed air-tight with Kapton tape right afterwards and the dish is placed in an oven inside the fume hood at 80\u00b0C for 4 h.", [["Kapton tape", "TREATMENT", 46, 57], ["lid", "ANATOMY", 17, 20], ["sealed", "OBSERVATION_MODIFIER", 24, 30], ["air", "OBSERVATION", 31, 34], ["dish", "OBSERVATION", 83, 87]]], ["After reduction, the Petri dish remains in the fume hood without lid for 1 h to evaporate the remaining hydrazine before rinsing each chip with dH 2 O and subsequently with isopropanol to remove hydrazine residues, then gently blow-dry with nitrogen and store the chips in a desiccator or directly perform the thermal reduction.", [["hydrazine", "CHEMICAL", 104, 113], ["dH 2 O", "CHEMICAL", 144, 150], ["isopropanol", "CHEMICAL", 173, 184], ["hydrazine", "CHEMICAL", 195, 204], ["nitrogen", "CHEMICAL", 241, 249], ["hydrazine", "CHEMICAL", 104, 113], ["dH 2 O", "CHEMICAL", 144, 150], ["isopropanol", "CHEMICAL", 173, 184], ["hydrazine", "CHEMICAL", 195, 204], ["nitrogen", "CHEMICAL", 241, 249], ["hydrazine", "SIMPLE_CHEMICAL", 104, 113], ["dH 2 O", "SIMPLE_CHEMICAL", 144, 150], ["isopropanol", "SIMPLE_CHEMICAL", 173, 184], ["hydrazine residues", "SIMPLE_CHEMICAL", 195, 213], ["nitrogen", "SIMPLE_CHEMICAL", 241, 249], ["reduction", "TREATMENT", 6, 15], ["the remaining hydrazine", "TREATMENT", 90, 113], ["isopropanol", "TREATMENT", 173, 184], ["hydrazine residues", "TREATMENT", 195, 213], ["nitrogen", "TREATMENT", 241, 249], ["the chips", "TREATMENT", 260, 269], ["the thermal reduction", "TREATMENT", 306, 327], ["reduction", "OBSERVATION_MODIFIER", 6, 15], ["Petri dish", "OBSERVATION", 21, 31]]], ["These slides were furthermore annealed at 200\u00b0C under vacuum for 2 h, resulting in stable and highly conducting electrical interfaces.2.2.Surface modification towards an HPV-16 E7 aptasensorThe rGO-FET was immersed into a mixture of PyPEG (5 mM) and 1-pyrenecarboxylic acid (PCA, 500 \u03bcM, linker) in DMSO for 12 h at room temperature to obtain a 10:1 ratio of blocking and linking agents and subsequently rinsed thoroughly with DMSO and dH 2 O. Then, HPV-16 E7 aptamers were immobilized by first activating the carboxyl groups by immersion into a solution of EDC (15 mM)/NHS (15 mM) in PBS (0.1 M, pH 7.4) for 30 min, followed by covalent coupling of the 5\u2032-NH 2 -modified aptamer (15 \u03bcL, 100 nM in RNase-free water) by incubating for 40 min at room temperature and washing (3 times) with PBS.2.3.CharacterizationScanning electron microscopy Scanning electron microscopy (SEM) images were obtained using an electron microscope ULTRA 55 (Zeiss, France) equipped with a thermal field emission emitter and three different detectors (EsB detector with filter grid, high-efficiency In-lens SE detector, and Everhart-Thornley secondary electron detector).2.3.CharacterizationMicro-Raman analysis Micro-Raman spectroscopy measurements were performed on a LabRam HR micro-Raman system (Horiba Jobin Yvon, France) combined with a 473-nm laser diode as an excitation source.", [["rGO", "CHEMICAL", 194, 197], ["PyPEG", "CHEMICAL", 233, 238], ["1-pyrenecarboxylic acid", "CHEMICAL", 250, 273], ["PCA", "CHEMICAL", 275, 278], ["DMSO", "CHEMICAL", 299, 303], ["DMSO", "CHEMICAL", 427, 431], ["EDC", "CHEMICAL", 558, 561], ["NHS", "CHEMICAL", 570, 573], ["5\u2032-NH", "CHEMICAL", 654, 659], ["PyPEG", "CHEMICAL", 233, 238], ["1-pyrenecarboxylic acid", "CHEMICAL", 250, 273], ["PCA", "CHEMICAL", 275, 278], ["DMSO", "CHEMICAL", 299, 303], ["DMSO", "CHEMICAL", 427, 431], ["carboxyl", "CHEMICAL", 510, 518], ["EDC", "CHEMICAL", 558, 561], ["NH", "CHEMICAL", 657, 659], ["E7", "ORGANISM", 177, 179], ["rGO-FET", "SIMPLE_CHEMICAL", 194, 201], ["PyPEG", "SIMPLE_CHEMICAL", 233, 238], ["1-pyrenecarboxylic acid", "SIMPLE_CHEMICAL", 250, 273], ["PCA", "SIMPLE_CHEMICAL", 275, 278], ["DMSO", "SIMPLE_CHEMICAL", 299, 303], ["DMSO", "SIMPLE_CHEMICAL", 427, 431], ["HPV-16", "ORGANISM", 450, 456], ["E7", "ORGANISM", 457, 459], ["EDC", "SIMPLE_CHEMICAL", 558, 561], ["NHS", "SIMPLE_CHEMICAL", 570, 573], ["5\u2032-NH 2 -modified aptamer", "SIMPLE_CHEMICAL", 654, 679], ["rGO", "PROTEIN", 194, 197], ["RNase", "PROTEIN", 698, 703], ["HPV-16", "SPECIES", 450, 456], ["Surface modification", "TREATMENT", 138, 158], ["an HPV", "TEST", 167, 173], ["PyPEG", "TEST", 233, 238], ["1-pyrenecarboxylic acid (PCA", "TREATMENT", 250, 278], ["DMSO", "TREATMENT", 299, 303], ["blocking and linking agents", "TREATMENT", 359, 386], ["DMSO", "TREATMENT", 427, 431], ["HPV", "TEST", 450, 453], ["E7 aptamers", "TREATMENT", 457, 468], ["a solution of EDC", "TREATMENT", 544, 561], ["pH", "TEST", 597, 599], ["modified aptamer", "TREATMENT", 663, 679], ["RNase-free water)", "TREATMENT", 698, 715], ["PBS", "TREATMENT", 788, 791], ["CharacterizationScanning electron microscopy", "TEST", 796, 840], ["Scanning electron microscopy (SEM) images", "TEST", 841, 882], ["an electron microscope ULTRA", "TEST", 903, 931], ["a thermal field emission emitter", "TREATMENT", 965, 997], ["EsB detector", "TEST", 1029, 1041], ["filter grid", "TEST", 1047, 1058], ["Raman analysis", "TEST", 1174, 1188], ["Raman spectroscopy measurements", "TEST", 1195, 1226], ["a 473-nm laser diode", "TREATMENT", 1318, 1338], ["vacuum", "OBSERVATION", 54, 60], ["stable", "OBSERVATION_MODIFIER", 83, 89], ["electrical interfaces", "OBSERVATION", 112, 133]]], ["The scattered light is collected by the same objective in backscattering configuration, dispersed by an 1800mm focal length monochromator and detected by a CCD.2.3.CharacterizationX-ray photoelectron spectroscopy All measurements were carried out on a Thermo Fisher Microlab 310/350spectrometer equipped with a twin anode Al/Mg-K\u03b1 X-ray source (XR3) and a hemispherical analyzer.", [["Al", "CHEMICAL", 322, 324], ["Mg", "CHEMICAL", 325, 327], ["K", "CHEMICAL", 328, 329], ["Al", "CHEMICAL", 322, 324], ["Mg", "CHEMICAL", 325, 327], ["K", "CHEMICAL", 328, 329], ["Mg-K\u03b1", "SIMPLE_CHEMICAL", 325, 330], ["an 1800mm focal length monochromator", "TREATMENT", 101, 137], ["CharacterizationX", "TEST", 164, 181], ["ray photoelectron spectroscopy", "TEST", 182, 212], ["All measurements", "TEST", 213, 229], ["a twin anode Al", "TREATMENT", 309, 324], ["a hemispherical analyzer", "TEST", 354, 378], ["scattered", "OBSERVATION_MODIFIER", 4, 13], ["light", "OBSERVATION_MODIFIER", 14, 19], ["backscattering configuration", "OBSERVATION", 58, 86], ["1800mm", "OBSERVATION_MODIFIER", 104, 110], ["focal", "OBSERVATION_MODIFIER", 111, 116]]], ["Samples were mounted onto the sample holders using double-sided carbon tape.2.3.CharacterizationPass energies of 100 eV and 20 eV as well as energy resolutions of 1 eV and 100 meV were used for survey and detail spectra respectively (excitation energy: 1486.6 eV/ 1253.6 eV, beam power: 100 W, angle, base pressure: 3 \u00d7 10 \u22129 mbar, pressure during measurements: 7 \u00d7 10 \u22129 mbar).", [["Samples", "ANATOMY", 0, 7], ["carbon", "CHEMICAL", 64, 70], ["Samples", "TEST", 0, 7], ["double-sided carbon tape", "TREATMENT", 51, 75], ["beam power", "TEST", 275, 285], ["angle", "TEST", 294, 299], ["base pressure", "TEST", 301, 314], ["mbar", "TEST", 326, 330], ["pressure during measurements", "TEST", 332, 360], ["sided", "ANATOMY_MODIFIER", 58, 63], ["carbon tape", "OBSERVATION", 64, 75], ["base", "ANATOMY_MODIFIER", 301, 305], ["pressure", "OBSERVATION_MODIFIER", 306, 314]]], ["All measurements were carried out with the sample in normal emission angle with respect to the analyzer.", [["All measurements", "TEST", 0, 16], ["the analyzer", "TEST", 91, 103]]], ["The analysis area was around 7 \u00d7 7 mm 2 .", [["The analysis area", "TEST", 0, 17]]], ["Data analysis was done using the CASA XPS and Thermo Fisher Avantage software packages employing Shirley/Tougaard backgrounds [20] and Scofield sensitivity factors [21] .", [["Data analysis", "TEST", 0, 13], ["the CASA XPS", "TEST", 29, 41], ["Shirley/Tougaard backgrounds", "TREATMENT", 97, 125]]], ["Charge correction was applied to the spectra so the C 1s signal of adventitious carbon was shifted to 284.6-284.8 eV throughout the measurements.", [["carbon", "CHEMICAL", 80, 86], ["C 1s", "PROTEIN", 52, 56], ["Charge correction", "TREATMENT", 0, 17], ["the C 1s signal", "TEST", 48, 63], ["adventitious carbon", "TEST", 67, 86], ["adventitious", "OBSERVATION_MODIFIER", 67, 79], ["carbon", "OBSERVATION_MODIFIER", 80, 86]]], ["Curve fits using combined Gaussian-Lorentzian peak shapes (GL(0)-GL(70)) were used to discern the components.2.4.Electrical measurementsElectrical measurements were conducted using a probe s t a t i o n s o u r c e m e t e r u n i t U 2 4 2 2 A ( K e y s i g h t Technologies, USA).", [["Curve fits", "TEST", 0, 10], ["combined Gaussian-Lorentzian peak shapes", "TEST", 17, 57], ["Electrical measurements", "TEST", 113, 136], ["Electrical measurements", "TEST", 136, 159], ["a probe s", "TEST", 181, 190], ["U", "TEST", 233, 234], ["A", "TEST", 243, 244], ["y s", "TEST", 251, 254], ["t Technologies", "TEST", 261, 275], ["USA", "TEST", 277, 280]]], ["All measurements were performed using a custom-made flow cell made of PMMA with fixed flow channel geometry (16 \u03bcL), ensuring a defined flow rate of 100 \u03bcL/min to minimize mass transport limitation of the analyte to the sensor surface in all experiments.", [["cell", "ANATOMY", 57, 61], ["PMMA", "CHEMICAL", 70, 74], ["PMMA", "CHEMICAL", 70, 74], ["cell", "CELL", 57, 61], ["PMMA", "SIMPLE_CHEMICAL", 70, 74], ["All measurements", "TEST", 0, 16], ["PMMA", "TREATMENT", 70, 74], ["fixed flow channel geometry", "TEST", 80, 107], ["a defined flow rate", "TEST", 126, 145], ["mass transport limitation", "PROBLEM", 172, 197], ["mass", "OBSERVATION", 172, 176]]], ["Furthermore, electrode drilling for constants gateelectrode distance (100 \u03bcm) and a hollow with FET dimensions for fixed positioning of the sensor chip were incorporated to the flow cell.", [["cell", "ANATOMY", 182, 186], ["cell", "CELL", 182, 186], ["electrode drilling", "TREATMENT", 13, 31], ["a hollow with FET dimensions", "TREATMENT", 82, 110], ["fixed positioning of the sensor chip", "TREATMENT", 115, 151], ["flow cell", "OBSERVATION", 177, 186]]], ["A silver chloride wire (diameter 1 mm, Sigma-Aldrich) was used to operate the rGO-FET device in liquid gate configuration, with a constant gate bias of \u2212 0.3 V and a constant source drain bias of 0.05 V. The verification of the electrical signal was carried out on a surface plasmon resonance device Indicator-G (Sensia S.L.).2.4.Electrical measurementsThe general procedure of the sensing experiment started with continuously flushing the pure buffer (PBS, 1 mM) until a stable baseline of drain current was established, followed by injection of the analyte at a constant flow rate of 100 \u03bcL min \u22121 .2.5.Electrical output characteristicsElectrical parameters of the rGO-FET were determined using gate-source voltage vs. drain-source current (I D V G ) relations.", [["silver chloride", "CHEMICAL", 2, 17], ["silver chloride", "CHEMICAL", 2, 17], ["silver chloride", "SIMPLE_CHEMICAL", 2, 17], ["rGO", "SIMPLE_CHEMICAL", 667, 670], ["rGO", "PROTEIN", 78, 81], ["rGO", "PROTEIN", 667, 670], ["A silver chloride wire (diameter", "TREATMENT", 0, 32], ["Sigma-Aldrich)", "TREATMENT", 39, 53], ["the rGO-FET device in liquid gate configuration", "TREATMENT", 74, 121], ["a constant gate bias", "TEST", 128, 148], ["a constant source drain bias", "TREATMENT", 164, 192], ["the electrical signal", "TEST", 224, 245], ["a surface plasmon resonance device", "TREATMENT", 265, 299], ["Electrical measurements", "TEST", 330, 353], ["The general procedure", "TREATMENT", 353, 374], ["the sensing experiment", "TREATMENT", 378, 400], ["continuously flushing the pure buffer (PBS", "TREATMENT", 414, 456], ["drain", "TREATMENT", 491, 496], ["the analyte", "TREATMENT", 547, 558], ["a constant flow rate", "TEST", 562, 582], ["Electrical output characteristics", "TEST", 605, 638], ["the rGO-FET", "TREATMENT", 663, 674], ["drain", "TREATMENT", 721, 726], ["current (I D V G )", "TREATMENT", 734, 752], ["chloride wire", "OBSERVATION", 9, 22], ["FET device", "OBSERVATION", 82, 92], ["liquid gate configuration", "OBSERVATION", 96, 121], ["stable", "OBSERVATION_MODIFIER", 472, 478], ["drain", "OBSERVATION", 491, 496]]], ["1) was determined from the linear regime in the I D V G graph according to Eq.", [["the linear regime", "TREATMENT", 23, 40], ["the I D V G graph", "TREATMENT", 44, 61]]], ["1 [22] :2.5.Electrical output characteristicswhere \u03b1 is the induced carrier density by the gate voltage (V G ) change of 1 V and e is the electron charge.", [["\u03b1", "PROTEIN", 51, 52], ["Electrical output", "TEST", 12, 29], ["the induced carrier density", "PROBLEM", 56, 83], ["the gate voltage", "TEST", 87, 103], ["carrier density", "OBSERVATION", 68, 83]]], ["From the expression for the linear regimes in the I D V G graph, the electron/hole mobility is obtained after considering the device properties according to Eq.", [["electron", "SIMPLE_CHEMICAL", 69, 77], ["the linear regimes", "TREATMENT", 24, 42], ["the I D V G graph", "TREATMENT", 46, 63], ["the electron/hole mobility", "TREATMENT", 65, 91], ["the device properties", "TREATMENT", 122, 143], ["hole mobility", "OBSERVATION", 78, 91]]], ["2:2.5.Electrical output characteristicswhere m lin is the slope from the linear fit (in A V \u22121 ), L and W are the channel length and width (in m), respectively, V DS is the applied drain-source voltage (in V), and C i is the gate capacitance (in F).", [["Electrical output", "TEST", 6, 23], ["the applied drain", "TREATMENT", 169, 186], ["output", "OBSERVATION_MODIFIER", 17, 23], ["characteristicswhere", "OBSERVATION_MODIFIER", 24, 44], ["m lin", "OBSERVATION", 45, 50], ["slope", "OBSERVATION_MODIFIER", 58, 63], ["linear", "OBSERVATION_MODIFIER", 73, 79], ["fit", "OBSERVATION_MODIFIER", 80, 83], ["L", "ANATOMY_MODIFIER", 98, 99], ["channel", "OBSERVATION_MODIFIER", 114, 121], ["length", "OBSERVATION_MODIFIER", 122, 128], ["width", "OBSERVATION_MODIFIER", 133, 138], ["drain", "OBSERVATION", 181, 186]]], ["The values for L, W, and C i are considered for the particular interdigitated electrodes and the designed flow cell.", [["cell", "ANATOMY", 111, 115], ["cell", "CELL", 111, 115], ["The values", "TEST", 0, 10], ["L, W, and C i", "PROBLEM", 15, 28], ["the particular interdigitated electrodes", "PROBLEM", 48, 88], ["flow cell", "OBSERVATION", 106, 115]]], ["The geometric design of the IDE results in a channel length of 10 \u03bcm and width of 490 mm over 90 parallel electrode pairs.", [["IDE", "PROTEIN", 28, 31], ["a channel length", "TEST", 43, 59], ["width", "TEST", 73, 78], ["length", "OBSERVATION_MODIFIER", 53, 59], ["490 mm", "OBSERVATION_MODIFIER", 82, 88]]], ["The capacity C i is 3.3 \u03bcF, evaluated from cyclic voltammetry measurements from the IDT to the gate electrode in the present flow cell design.3.1.Fabrication of HPV-16 E7 sensitive rGO-FETThe experimental setup of an individual rGO-FET device is shown in Fig. 1a .", [["cell", "ANATOMY", 130, 134], ["cell", "CELL", 130, 134], ["E7", "ORGANISM", 168, 170], ["cyclic voltammetry measurements", "TEST", 43, 74], ["the gate electrode", "TREATMENT", 91, 109], ["HPV", "TEST", 161, 164], ["FETThe experimental setup", "TREATMENT", 185, 210], ["an individual rGO", "TREATMENT", 214, 231], ["FET device", "TREATMENT", 232, 242], ["gate electrode", "OBSERVATION", 95, 109], ["flow cell design", "OBSERVATION", 125, 141]]], ["The interdigitated electrode chip with the functionalized rGO layer is placed into the sample holder and a sealed flow cell with inlet, outlet, and gating wire encloses the measurement chamber.", [["sample", "ANATOMY", 87, 93], ["cell", "ANATOMY", 119, 123], ["cell", "CELL", 119, 123], ["The interdigitated electrode chip", "TREATMENT", 0, 33], ["the functionalized rGO layer", "TREATMENT", 39, 67], ["a sealed flow cell with inlet, outlet, and gating wire", "TREATMENT", 105, 159], ["interdigitated", "OBSERVATION_MODIFIER", 4, 18], ["electrode chip", "OBSERVATION", 19, 33], ["functionalized", "OBSERVATION_MODIFIER", 43, 57], ["rGO layer", "OBSERVATION", 58, 67], ["sealed", "OBSERVATION_MODIFIER", 107, 113], ["flow cell", "OBSERVATION", 114, 123], ["inlet", "OBSERVATION_MODIFIER", 129, 134], ["outlet", "OBSERVATION_MODIFIER", 136, 142], ["gating wire", "OBSERVATION", 148, 159], ["chamber", "OBSERVATION_MODIFIER", 185, 192]]], ["The two terminals of the IDE and the gate electrode are electrically connected as shown in Fig. 1b and the signal is recorded with the source meter unit U2722A (Keysight Technologies).", [["IDE", "GENE_OR_GENE_PRODUCT", 25, 28], ["IDE", "PROTEIN", 25, 28], ["the IDE and the gate electrode", "TREATMENT", 21, 51], ["two", "OBSERVATION_MODIFIER", 4, 7], ["terminals", "OBSERVATION_MODIFIER", 8, 17], ["gate electrode", "OBSERVATION", 37, 51]]], ["While chemical vapordeposited graphene (CVD graphene) allows for the exact material positioning of high-quality graphene with little defects [23] , the advantage of using liquid-dispersed graphene oxide (GO) flakes facilitates the fabrication but comes with the disadvantage of a practically random and uncontrolled distribution of the GO flakes, resulting in random localization during the adsorption from the liquid onto the gate surface.", [["vapordeposited graphene", "CHEMICAL", 15, 38], ["CVD graphene", "CHEMICAL", 40, 52], ["graphene", "CHEMICAL", 112, 120], ["graphene oxide", "CHEMICAL", 188, 202], ["graphene", "CHEMICAL", 30, 38], ["graphene", "CHEMICAL", 44, 52], ["graphene", "CHEMICAL", 112, 120], ["graphene oxide", "CHEMICAL", 188, 202], ["vapordeposited graphene", "SIMPLE_CHEMICAL", 15, 38], ["graphene", "SIMPLE_CHEMICAL", 112, 120], ["graphene oxide", "SIMPLE_CHEMICAL", 188, 202], ["surface", "CELLULAR_COMPONENT", 432, 439], ["chemical vapordeposited graphene (CVD graphene", "TREATMENT", 6, 52], ["high-quality graphene", "TREATMENT", 99, 120], ["little defects", "PROBLEM", 126, 140], ["liquid-dispersed graphene oxide (GO) flakes", "TREATMENT", 171, 214], ["the fabrication", "TREATMENT", 227, 242]]], ["Figure 1c depicts an SEM image of the drain-source channel of the interdigitated electrodes (IDE) coated with rGO, where a full drain-source channel coverage can be observed.", [["IDE", "PROTEIN", 93, 96], ["rGO", "PROTEIN", 110, 113], ["an SEM image", "TEST", 18, 30], ["the drain", "TREATMENT", 34, 43], ["the interdigitated electrodes (IDE) coated with rGO", "TREATMENT", 62, 113], ["a full drain", "TREATMENT", 121, 133], ["source channel coverage", "TREATMENT", 134, 157], ["drain", "OBSERVATION", 38, 43]]], ["The dimensions of the IDE chip are 6 mm in width and 10 mm in length, with a circular sensing area of 3 mm in diameter.", [["IDE", "GENE_OR_GENE_PRODUCT", 22, 25], ["IDE", "PROTEIN", 22, 25], ["the IDE chip", "TREATMENT", 18, 30], ["width", "TEST", 43, 48], ["length", "TEST", 62, 68], ["a circular sensing area", "PROBLEM", 75, 98], ["dimensions", "OBSERVATION_MODIFIER", 4, 14], ["chip", "OBSERVATION_MODIFIER", 26, 30], ["6 mm", "OBSERVATION_MODIFIER", 35, 39], ["width", "OBSERVATION_MODIFIER", 43, 48], ["10 mm", "OBSERVATION_MODIFIER", 53, 58], ["length", "OBSERVATION_MODIFIER", 62, 68], ["circular", "OBSERVATION_MODIFIER", 77, 85], ["area", "OBSERVATION_MODIFIER", 94, 98], ["3 mm", "ANATOMY_MODIFIER", 102, 106], ["diameter", "OBSERVATION_MODIFIER", 110, 118]]], ["The rGO sheets, obtained by sequential GO transfer and 4-h hydrazine reduction [3] , followed by thermal annealing, were further characterized by Raman microscopy.", [["rGO sheets", "ANATOMY", 4, 14], ["hydrazine", "CHEMICAL", 59, 68], ["4-h hydrazine", "CHEMICAL", 55, 68], ["rGO", "SIMPLE_CHEMICAL", 4, 7], ["4-h hydrazine", "SIMPLE_CHEMICAL", 55, 68], ["The rGO sheets", "TEST", 0, 14], ["4-h hydrazine reduction", "TREATMENT", 55, 78], ["thermal annealing", "TREATMENT", 97, 114], ["Raman microscopy", "TEST", 146, 162]]], ["The Raman spectrum (Fig. 1d) consists of two main bands at 1597 and 1341 cm \u22121 related to sp 2 carbon (graphenic) and defects in the rGO sheets [24] .", [["sp 2 carbon", "CHEMICAL", 90, 101], ["carbon", "CHEMICAL", 95, 101], ["rGO", "CHEMICAL", 133, 136], ["defects in the rGO sheets", "PROBLEM", 118, 143], ["defects", "OBSERVATION", 118, 125]]], ["The low-intensity D+D\u2032 contribution at \u2248 2900 cm \u22121 appears due to the impurities of rGO.3.1.Fabrication of HPV-16 E7 sensitive rGO-FETThe surface characterization to validate the presence of rGO is documented in Fig. 2a , which shows a series of C1s high-resolution X-ray photoelectron spectroscopy (XPS) spectra of the transferred GO films before and after hydrazine/thermal annealing.", [["surface", "ANATOMY", 139, 146], ["rGO", "CHEMICAL", 192, 195], ["hydrazine", "CHEMICAL", 359, 368], ["rGO", "CHEMICAL", 85, 88], ["hydrazine", "CHEMICAL", 359, 368], ["D+D\u2032", "SIMPLE_CHEMICAL", 18, 22], ["rGO", "SIMPLE_CHEMICAL", 85, 88], ["E7", "ORGANISM", 115, 117], ["rGO", "SIMPLE_CHEMICAL", 192, 195], ["C1s", "GENE_OR_GENE_PRODUCT", 247, 250], ["hydrazine", "SIMPLE_CHEMICAL", 359, 368], ["rGO", "PROTEIN", 85, 88], ["E7", "PROTEIN", 115, 117], ["rGO", "PROTEIN", 128, 131], ["rGO", "PROTEIN", 192, 195], ["C1s", "PROTEIN", 247, 250], ["the impurities of rGO", "PROBLEM", 67, 88], ["HPV", "TEST", 108, 111], ["FETThe surface characterization", "TEST", 132, 163], ["C1s high-resolution X-ray photoelectron spectroscopy", "TREATMENT", 247, 299], ["the transferred GO films", "TEST", 317, 341], ["hydrazine/thermal annealing", "TREATMENT", 359, 386], ["low-intensity", "OBSERVATION_MODIFIER", 4, 17]]], ["The initial scan of GOdeposited films displays strong bands at 284.3, 285.0, and 286.7 eV, indicating the presence of both sp 2 C-C, C-C/C-H, and C-O bonds, respectively.", [["C", "CHEMICAL", 128, 129], ["C", "CHEMICAL", 130, 131], ["C", "CHEMICAL", 133, 134], ["C", "CHEMICAL", 135, 136], ["C-H", "CHEMICAL", 137, 140], ["C-O", "CHEMICAL", 146, 149], ["2 C-C", "SIMPLE_CHEMICAL", 126, 131], ["C-C", "SIMPLE_CHEMICAL", 133, 136], ["C-H", "SIMPLE_CHEMICAL", 137, 140], ["C-O bonds", "SIMPLE_CHEMICAL", 146, 155], ["The initial scan of GOdeposited films", "TEST", 0, 37], ["strong bands", "PROBLEM", 47, 59], ["C", "TEST", 133, 134], ["strong", "OBSERVATION_MODIFIER", 47, 53]]], ["The broad band at 288.3 eV indicates the presence of C=O groups.", [["C=O", "CHEMICAL", 53, 56], ["C=O", "SIMPLE_CHEMICAL", 53, 56], ["The broad band", "PROBLEM", 0, 14]]], ["After reduction, a relative decrease in the intensity of the C-O bonds is observed, along with a strong removal of the sp 3 C-C component as would be expected as the carbon becomes more graphitic [25] .3.1.Fabrication of HPV-16 E7 sensitive rGO-FETElectrical measurements of the rGO-FET are displayed in Fig. 2b .", [["C-O", "CHEMICAL", 61, 64], ["C-C", "CHEMICAL", 124, 127], ["carbon", "CHEMICAL", 166, 172], ["C-O", "SIMPLE_CHEMICAL", 61, 64], ["C-C", "SIMPLE_CHEMICAL", 124, 127], ["carbon", "SIMPLE_CHEMICAL", 166, 172], ["HPV", "ORGANISM", 221, 224], ["E7", "ORGANISM", 228, 230], ["rGO-FETElectrical", "SIMPLE_CHEMICAL", 241, 258], ["rGO-FET", "SIMPLE_CHEMICAL", 279, 286], ["sp 3 C-C component", "PROTEIN", 119, 137], ["E7", "PROTEIN", 228, 230], ["rGO", "PROTEIN", 241, 244], ["rGO", "DNA", 279, 282], ["FET", "DNA", 283, 286], ["reduction", "TREATMENT", 6, 15], ["a relative decrease", "PROBLEM", 17, 36], ["the C-O bonds", "PROBLEM", 57, 70], ["a strong removal", "TREATMENT", 95, 111], ["the sp 3 C-C component", "PROBLEM", 115, 137], ["HPV", "TEST", 221, 224], ["FETElectrical measurements", "TEST", 245, 271], ["the rGO", "TEST", 275, 282], ["reduction", "OBSERVATION_MODIFIER", 6, 15], ["relative", "OBSERVATION_MODIFIER", 19, 27], ["decrease", "OBSERVATION_MODIFIER", 28, 36], ["intensity", "OBSERVATION_MODIFIER", 44, 53], ["strong", "OBSERVATION_MODIFIER", 97, 103], ["removal", "OBSERVATION", 104, 111], ["sp 3", "OBSERVATION_MODIFIER", 119, 123]]], ["The drain-source current (I DS ) dependency to the gate voltage (V G ) of the rGO-FET can be seen in this The examined devices show an ambipolar nature, with a linear regime for both charge carrier types below \u00b1 1 V G (Fig. 2b) .", [["rGO", "PROTEIN", 78, 81], ["FET", "PROTEIN", 82, 85], ["The drain", "TREATMENT", 0, 9], ["the rGO-FET", "TREATMENT", 74, 85], ["a linear regime", "TREATMENT", 158, 173], ["both charge carrier types", "TREATMENT", 178, 203], ["drain", "OBSERVATION", 4, 9], ["ambipolar nature", "OBSERVATION", 135, 151]]], ["From the linear fit of the slopes negative and positive to Fig. 2 Reduced graphene oxidebased FET (rGO-FET) used for HPV-16 E7 sensing. a XPS spectra of GO-FET before (top) and after (bottom) reduction, by treating the GO layer for 4 h with hydrazine followed by thermal annealing. b Transfer characteristics of a solution-gated rGO-FET before and after surface modification with a PCA linker, leading to a Dirac point shift of 50 mV Fig. 3 Modification of the rGO-FET with RNA HVP-16 E7 aptamer. a XPS spectra of the rGO surface before and after modification with a pyrene linker for aptamer immobilization.", [["surface", "ANATOMY", 354, 361], ["rGO surface", "ANATOMY", 518, 529], ["graphene oxidebased", "CHEMICAL", 74, 93], ["rGO-FET", "CHEMICAL", 99, 106], ["hydrazine", "CHEMICAL", 241, 250], ["rGO", "CHEMICAL", 329, 332], ["pyrene", "CHEMICAL", 567, 573], ["graphene", "CHEMICAL", 74, 82], ["hydrazine", "CHEMICAL", 241, 250], ["rGO", "CHEMICAL", 518, 521], ["pyrene", "CHEMICAL", 567, 573], ["graphene oxidebased FET", "SIMPLE_CHEMICAL", 74, 97], ["E7", "ORGANISM", 124, 126], ["hydrazine", "SIMPLE_CHEMICAL", 241, 250], ["rGO", "SIMPLE_CHEMICAL", 461, 464], ["pyrene", "SIMPLE_CHEMICAL", 567, 573], ["rGO", "DNA", 461, 464], ["FET", "DNA", 465, 468], ["RNA HVP-16 E7 aptamer", "DNA", 474, 495], ["the slopes", "TEST", 23, 33], ["Reduced graphene oxidebased FET (rGO-FET)", "TREATMENT", 66, 107], ["HPV", "TEST", 117, 120], ["a XPS spectra of GO-FET before (top)", "TREATMENT", 136, 172], ["bottom) reduction", "TREATMENT", 184, 201], ["hydrazine", "TREATMENT", 241, 250], ["thermal annealing", "TREATMENT", 263, 280], ["a solution-gated rGO-FET", "TREATMENT", 312, 336], ["surface modification", "TREATMENT", 354, 374], ["a PCA linker", "TREATMENT", 380, 392], ["a Dirac point shift", "TEST", 405, 424], ["the rGO", "TEST", 457, 464], ["RNA HVP", "TEST", 474, 481], ["a XPS spectra of the rGO surface", "TREATMENT", 497, 529], ["a pyrene linker", "TREATMENT", 565, 580], ["aptamer immobilization", "TREATMENT", 585, 607], ["linear", "OBSERVATION_MODIFIER", 9, 15], ["positive to Fig", "OBSERVATION_MODIFIER", 47, 62]]], ["Green represents the XPS spectrum of the aptamer-modified rGO surface, while the black spectrum corresponds to the surface functionalized with only PyPEG/PCA molecules. b High-resolution XPS spectra in the P2p region of the rGO surface before and after aptamer immobilization to investigate the uptake of phosphate, present in the aptamer backbone. c Transfer characteristics of an HPV-16 E7 RNA aptamer-modified rGO-FET with the standard linker mixture of 10:1 PyPEG/PCA. d Change of the drain-source current I DS over time at an applied V G = 500 mV in PBS (0.1 M, pH 7.4) to demonstrate the baseline drift within 4 h of the modified gFET surface the Dirac point, the charge carrier mobility was found in the range of 725 cm 2 (Vs) \u22121 for electrons and 680 cm 2 (Vs) \u22121 for the hole mobility for the rGO-FETs.", [["rGO surface", "ANATOMY", 58, 69], ["surface", "ANATOMY", 115, 122], ["rGO surface", "ANATOMY", 224, 235], ["gFET surface", "ANATOMY", 636, 648], ["phosphate", "CHEMICAL", 305, 314], ["rGO", "CHEMICAL", 413, 416], ["PyPEG", "CHEMICAL", 462, 467], ["rGO", "CHEMICAL", 58, 61], ["PyPEG", "CHEMICAL", 148, 153], ["rGO", "CHEMICAL", 224, 227], ["phosphate", "CHEMICAL", 305, 314], ["rGO", "CHEMICAL", 802, 805], ["PyPEG", "SIMPLE_CHEMICAL", 148, 153], ["PCA molecules", "SIMPLE_CHEMICAL", 154, 167], ["rGO surface", "CELLULAR_COMPONENT", 224, 235], ["phosphate", "SIMPLE_CHEMICAL", 305, 314], ["HPV-16 E7", "ORGANISM", 382, 391], ["rGO-FET", "SIMPLE_CHEMICAL", 413, 420], ["PyPEG", "SIMPLE_CHEMICAL", 462, 467], ["rGO-FETs", "SIMPLE_CHEMICAL", 802, 810], ["PyPEG", "PROTEIN", 148, 153], ["PCA molecules", "PROTEIN", 154, 167], ["P2p region", "DNA", 206, 216], ["rGO", "PROTEIN", 413, 416], ["rGO", "PROTEIN", 802, 805], ["FETs", "PROTEIN", 806, 810], ["HPV-16", "SPECIES", 382, 388], ["the aptamer-modified rGO surface", "TREATMENT", 37, 69], ["the black spectrum", "PROBLEM", 77, 95], ["the surface functionalized", "TREATMENT", 111, 137], ["PyPEG/PCA molecules", "TREATMENT", 148, 167], ["aptamer immobilization", "TREATMENT", 253, 275], ["the uptake of phosphate", "PROBLEM", 291, 314], ["an HPV", "TEST", 379, 385], ["E7 RNA aptamer", "TREATMENT", 389, 403], ["modified rGO-FET", "TREATMENT", 404, 420], ["the standard linker mixture", "TREATMENT", 426, 453], ["PyPEG/PCA", "TREATMENT", 462, 471], ["the drain", "TREATMENT", 485, 494], ["V G", "TEST", 539, 542], ["mV in PBS", "TEST", 549, 558], ["pH", "TEST", 567, 569], ["the baseline drift", "PROBLEM", 590, 608], ["the charge carrier mobility", "TEST", 666, 693], ["electrons", "TEST", 741, 750], ["Vs", "TEST", 765, 767], ["the hole mobility", "TREATMENT", 776, 793], ["the rGO-FETs", "TREATMENT", 798, 810], ["PCA molecules", "OBSERVATION", 154, 167], ["High", "OBSERVATION_MODIFIER", 171, 175], ["PCA", "ANATOMY", 468, 471], ["drain", "OBSERVATION", 489, 494]]], ["The values are low, compared with previous reports (5000 cm 2 (Vs) \u22121 [26] to 200.000 cm 2 (Vs) \u22121 [27] ), while others report low mobilities of 1 cm 2 (Vs) \u22121 [28] in literature, but the absolute changes in current I DS are by three orders of magnitude higher than other reports, hence yield a better signal-to-noise ratio.3.2.Surface modification of rGO-FET for HPV-16 E7 sensingTo create a functional surface for preferential HPV-16 E7 binding, the rGO-FET chip was functionalized with 1-pyrenebutyric acid (PCA), followed by EDC/NHS activation for covalent linking of the aptamer comprising an NH 2 end group and a spacer of eight repetitions of TTT units.", [["surface", "ANATOMY", 404, 411], ["rGO", "CHEMICAL", 352, 355], ["1-pyrenebutyric acid", "CHEMICAL", 489, 509], ["EDC", "CHEMICAL", 529, 532], ["1-pyrenebutyric acid", "CHEMICAL", 489, 509], ["PCA", "CHEMICAL", 511, 514], ["NH", "CHEMICAL", 598, 600], ["rGO-FET", "SIMPLE_CHEMICAL", 352, 359], ["HPV-16 E7", "ORGANISM", 364, 373], ["surface", "CELLULAR_COMPONENT", 404, 411], ["HPV-16 E7", "ORGANISM", 429, 438], ["rGO", "SIMPLE_CHEMICAL", 452, 455], ["1-pyrenebutyric acid", "SIMPLE_CHEMICAL", 489, 509], ["PCA", "SIMPLE_CHEMICAL", 511, 514], ["EDC", "SIMPLE_CHEMICAL", 529, 532], ["NHS", "SIMPLE_CHEMICAL", 533, 536], ["rGO", "PROTEIN", 352, 355], ["E7", "PROTEIN", 436, 438], ["rGO", "PROTEIN", 452, 455], ["NH 2 end group", "PROTEIN", 598, 612], ["The values", "TEST", 0, 10], ["Vs", "TEST", 63, 65], ["Vs", "TEST", 92, 94], ["low mobilities", "PROBLEM", 127, 141], ["Vs", "TEST", 153, 155], ["the absolute changes", "PROBLEM", 184, 204], ["rGO", "TEST", 352, 355], ["HPV", "TEST", 364, 367], ["preferential HPV", "PROBLEM", 416, 432], ["the rGO-FET chip", "TREATMENT", 448, 464], ["1-pyrenebutyric acid (PCA", "TREATMENT", 489, 514], ["the aptamer", "TREATMENT", 572, 583], ["an NH 2 end group", "TREATMENT", 595, 612], ["a spacer of eight repetitions of TTT units", "TREATMENT", 617, 659], ["low", "OBSERVATION_MODIFIER", 15, 18], ["low mobilities", "OBSERVATION_MODIFIER", 127, 141], ["absolute", "OBSERVATION", 188, 196]]], ["The success of the surface functionalization was assessed using XPS (Fig. 3a) .3.2.Surface modification of rGO-FET for HPV-16 E7 sensingThe PCA was mixed with a blocking agent of pre-conjugated pyrene-PEG units (PyPEG) in a ratio of 1:10, a ratio experimentally verified to be optimal for having an anti-fouling character and good sensing sensitivity (Fig. 3a inset) .", [["surface", "ANATOMY", 19, 26], ["rGO", "CHEMICAL", 107, 110], ["pre-conjugated pyrene-PEG", "CHEMICAL", 179, 204], ["PyPEG", "CHEMICAL", 212, 217], ["pyrene", "CHEMICAL", 194, 200], ["PEG", "CHEMICAL", 201, 204], ["PyPEG", "CHEMICAL", 212, 217], ["surface", "CELLULAR_COMPONENT", 19, 26], ["rGO-FET", "SIMPLE_CHEMICAL", 107, 114], ["HPV-16 E7", "ORGANISM", 119, 128], ["PCA", "SIMPLE_CHEMICAL", 140, 143], ["pre-conjugated pyrene-PEG units", "SIMPLE_CHEMICAL", 179, 210], ["PyPEG", "SIMPLE_CHEMICAL", 212, 217], ["rGO", "PROTEIN", 107, 110], ["the surface functionalization", "TREATMENT", 15, 44], ["XPS", "TEST", 64, 67], ["Surface modification of rGO", "TREATMENT", 83, 110], ["HPV", "TEST", 119, 122], ["E7 sensingThe PCA", "TREATMENT", 126, 143], ["a blocking agent", "TREATMENT", 159, 175], ["pre-conjugated pyrene", "TREATMENT", 179, 200], ["PEG units (PyPEG", "TREATMENT", 201, 217], ["an anti-fouling character", "PROBLEM", 296, 321]]], ["It was reported that this RNA E7 aptamer has an affinity with a low dissociation constant K d = 2 \u03bcM [29] .", [["E7", "GENE_OR_GENE_PRODUCT", 30, 32], ["this RNA E7 aptamer", "PROBLEM", 21, 40], ["an affinity", "PROBLEM", 45, 56], ["a low dissociation", "PROBLEM", 62, 80], ["K d", "TEST", 90, 93]]], ["This indicates that the sensor is in the ligand-depletion regime, where experimental conditions, including probe density and surface area as well as sample volume, are important parameters [30] .", [["surface area", "ANATOMY", 125, 137], ["sample", "ANATOMY", 149, 155], ["the ligand-depletion regime", "TREATMENT", 37, 64], ["experimental conditions", "PROBLEM", 72, 95], ["probe density and surface area", "TREATMENT", 107, 137], ["sample volume", "TEST", 149, 162], ["depletion regime", "OBSERVATION", 48, 64], ["surface", "OBSERVATION_MODIFIER", 125, 132]]], ["The success of the surface modification steps was validated by XPS analysis (Fig. 3b) , with the presence of phosphate after RNA immobilization.", [["surface", "ANATOMY", 19, 26], ["phosphate", "CHEMICAL", 109, 118], ["phosphate", "CHEMICAL", 109, 118], ["phosphate", "SIMPLE_CHEMICAL", 109, 118], ["the surface modification steps", "TREATMENT", 15, 45], ["XPS analysis", "TEST", 63, 75], ["phosphate", "TREATMENT", 109, 118], ["RNA immobilization", "TREATMENT", 125, 143]]], ["The I DS vs. V G curves of the aptamer-functionalized device are shown in Fig. 3c .", [["V G", "GENE_OR_GENE_PRODUCT", 13, 16], ["the aptamer-functionalized device", "TREATMENT", 27, 60]]], ["The Dirac point after RNA immobilization is stabilized at 130 \u00b1 10 mV vs. AgCl wire without affecting the transconductance with the addition of PCA via non-covalent \u03c0-\u03c0 stacking interactions.3.2.Surface modification of rGO-FET for HPV-16 E7 sensingNext to the electrical transfer characteristic of the rGO-FET device after aptamer immobilization, the baseline drift over Fig. 4 FET-based sensing of HPV-16 E7 proteins. a Protein sensing in real time using aptamer-modified rGO-FET when the device is exposed to increasing concentrations of HPV-16 E7 proteins (7.5, 15, 31, 62, 100, 125, 250, 500 , and 1000 nM) in PBS (0.1 M, pH 7.4).", [["AgCl", "CHEMICAL", 74, 78], ["rGO", "CHEMICAL", 219, 222], ["rGO", "CHEMICAL", 473, 476], ["AgCl", "CHEMICAL", 74, 78], ["AgCl", "SIMPLE_CHEMICAL", 74, 78], ["PCA", "SIMPLE_CHEMICAL", 144, 147], ["rGO", "SIMPLE_CHEMICAL", 219, 222], ["HPV-16 E7", "ORGANISM", 231, 240], ["rGO", "SIMPLE_CHEMICAL", 302, 305], ["HPV-16 E7", "ORGANISM", 399, 408], ["rGO-FET", "SIMPLE_CHEMICAL", 473, 480], ["E7", "ORGANISM", 547, 549], ["rGO", "PROTEIN", 219, 222], ["rGO", "PROTEIN", 302, 305], ["HPV-16 E7 proteins", "PROTEIN", 399, 417], ["rGO", "PROTEIN", 473, 476], ["HPV-16 E7 proteins", "PROTEIN", 540, 558], ["RNA immobilization", "TREATMENT", 22, 40], ["AgCl wire", "TREATMENT", 74, 83], ["PCA", "TREATMENT", 144, 147], ["Surface modification of rGO", "TREATMENT", 195, 222], ["HPV", "TEST", 231, 234], ["the rGO-FET device", "TREATMENT", 298, 316], ["aptamer immobilization", "TREATMENT", 323, 345], ["HPV", "TEST", 399, 402], ["a Protein sensing", "TREATMENT", 419, 436], ["aptamer-modified rGO", "TREATMENT", 456, 476], ["the device", "TREATMENT", 486, 496], ["HPV", "TEST", 540, 543], ["E7 proteins", "TEST", 547, 558], ["PBS", "TEST", 614, 617], ["pH", "TEST", 626, 628], ["wire", "OBSERVATION", 79, 83]]], ["Additionally, insulin was exposed to the sensor surface to verify the blocking of nonspecific proteins.", [["insulin", "GENE_OR_GENE_PRODUCT", 14, 21], ["insulin", "PROTEIN", 14, 21], ["nonspecific proteins", "PROTEIN", 82, 102], ["insulin", "TREATMENT", 14, 21], ["nonspecific proteins", "PROBLEM", 82, 102]]], ["The aptasensor exhibits minute response to non-specific concentrations of 1 \u03bcM, proving the repelling due to the PyPEG coating of the sensing area. b Effective response extracted from the I DS current, generated by different HPV-16 E7 protein concentrations and fitted to a Langmuir isotherm.", [["PyPEG", "SIMPLE_CHEMICAL", 113, 118], ["E7", "ORGANISM", 232, 234], ["E7", "PROTEIN", 232, 234], ["the PyPEG coating", "TREATMENT", 109, 126], ["E7 protein concentrations", "TREATMENT", 232, 257], ["a Langmuir isotherm", "TREATMENT", 272, 291], ["non-specific concentrations", "OBSERVATION_MODIFIER", 43, 70]]], ["The K d at half saturation equals 200 nM. c Signal generation of an aptamer unfolding upon specific binding to HPV-16 E7 (black) compared with non-specific binding of insulin to the surface. d SPR experiments using HPV aptamer (black) and scrambled aptamer (red) surface linker incorporated in the same manner as on the rGO-FET sensors to investigate the specificity of the aptamers for HPV-16 E7 sensing time is an important parameter for any sensor application.", [["surface", "ANATOMY", 182, 189], ["surface", "ANATOMY", 263, 270], ["K", "CHEMICAL", 4, 5], ["HPV-16 E7", "ORGANISM", 111, 120], ["insulin", "GENE_OR_GENE_PRODUCT", 167, 174], ["surface", "CELLULAR_COMPONENT", 182, 189], ["HPV", "ORGANISM", 215, 218], ["rGO", "SIMPLE_CHEMICAL", 320, 323], ["HPV-16 E7", "ORGANISM", 387, 396], ["E7", "PROTEIN", 118, 120], ["insulin", "PROTEIN", 167, 174], ["rGO", "PROTEIN", 320, 323], ["E7", "PROTEIN", 394, 396], ["The K d at half saturation", "TEST", 0, 26], ["an aptamer unfolding", "PROBLEM", 65, 85], ["HPV", "TEST", 111, 114], ["insulin", "TREATMENT", 167, 174], ["d SPR experiments", "TREATMENT", 191, 208], ["HPV aptamer", "TREATMENT", 215, 226], ["scrambled aptamer (red) surface linker", "TREATMENT", 239, 277], ["the rGO", "TEST", 316, 323], ["FET sensors", "TEST", 324, 335], ["HPV", "TEST", 387, 390], ["any sensor application", "TREATMENT", 440, 462], ["Signal generation", "OBSERVATION", 44, 61], ["aptamer unfolding", "OBSERVATION", 68, 85]]], ["Due to the linear characteristic of the current decay in the observed time frame, it can be corrected with a linear regression after an established baseline.", [["a linear regression", "PROBLEM", 107, 126], ["linear", "OBSERVATION_MODIFIER", 11, 17]]], ["The baseline was subtracted from the recorded sensor output to obtain the sensing response, \u0394I DS .3.3.Specific sensing of HPV-16 E7The functionalized rGO-FET devices were used to electronically monitor aptamer-protein binding in real time by exposing it to increasing concentrations of HPV recombinant HPV-16 E7 protein (Fig. 4a) .", [["HPV", "ORGANISM", 123, 126], ["rGO", "SIMPLE_CHEMICAL", 151, 154], ["HPV", "ORGANISM", 287, 290], ["HPV-16 E7", "ORGANISM", 303, 312], ["rGO", "PROTEIN", 151, 154], ["HPV recombinant HPV-16 E7 protein", "PROTEIN", 287, 320], ["\u0394I DS", "TEST", 92, 97], ["HPV", "TEST", 123, 126], ["E7The functionalized rGO", "TREATMENT", 130, 154], ["FET devices", "TREATMENT", 155, 166], ["protein binding", "PROBLEM", 211, 226], ["HPV recombinant HPV", "TEST", 287, 306]]], ["A large change in current is observed for the target solution due to preferential binding of the protein to the aptamer.", [["A large change", "PROBLEM", 0, 14], ["the target solution", "TREATMENT", 42, 61], ["large", "OBSERVATION_MODIFIER", 2, 7], ["change", "OBSERVATION", 8, 14]]], ["The equilibrium value and the kinetic on-and off-rates are useful parameters for determining the dissociation constant K d of the binding reaction.", [["The equilibrium value", "TEST", 0, 21], ["the kinetic", "TEST", 26, 37], ["the binding reaction", "PROBLEM", 126, 146]]], ["Figure 4b illustrates the saturation levels of the aptasensor for different concentrations, normalized to its maximum possible response, when all binding sites are occupied, and the binding curve follows a Langmuir isotherm model (Eq.", [["the saturation levels", "TEST", 22, 43], ["the aptasensor", "TEST", 47, 61], ["different concentrations", "PROBLEM", 66, 90], ["all binding sites", "PROBLEM", 142, 159], ["the binding curve", "TEST", 178, 195], ["a Langmuir isotherm model", "TREATMENT", 204, 229]]], ["3).3.3.Specific sensing of HPV-16 E7Fitting Eq.", [["HPV", "ORGANISM", 27, 30], ["HPV", "TEST", 27, 30]]], ["3 to the data points yields a K d of 200 nM at half saturation, consistent with previous reports of aptamer-protein binding reactions.3.3.Specific sensing of HPV-16 E7To underline specific binding, the change in electrical signal upon binding to insulin, a protein of comparable size, was recorded at comparable concentrations (Fig. 4c ).", [["K", "CHEMICAL", 30, 31], ["HPV-16 E7To", "ORGANISM", 158, 169], ["insulin", "GENE_OR_GENE_PRODUCT", 246, 253], ["insulin", "PROTEIN", 246, 253], ["HPV-16", "SPECIES", 158, 164], ["a K d", "TEST", 28, 33], ["protein binding reactions", "PROBLEM", 108, 133], ["HPV", "TEST", 158, 161], ["the change in electrical signal", "PROBLEM", 198, 229], ["insulin", "TREATMENT", 246, 253], ["consistent with", "UNCERTAINTY", 64, 79], ["size", "OBSERVATION_MODIFIER", 279, 283]]], ["The addition of 100 nM and 1000 nM insulin leads to a minute gFET response.", [["insulin", "GENE_OR_GENE_PRODUCT", 35, 42], ["insulin", "PROTEIN", 35, 42], ["1000 nM insulin", "TREATMENT", 27, 42]]], ["The net charge of insulin is negative at a pH of 7.4 due to the isoelectric point at 5.3 [31] .", [["insulin", "GENE_OR_GENE_PRODUCT", 18, 25], ["insulin", "PROTEIN", 18, 25], ["The net charge of insulin", "TREATMENT", 0, 25], ["a pH", "TEST", 41, 45], ["the isoelectric point", "TEST", 60, 81]]], ["Upon non-specific interaction with the surface, it increases the negative charge at the semiconductor surface and counteracts the applied electric field.", [["surface", "ANATOMY", 39, 46], ["surface", "CELLULAR_COMPONENT", 39, 46], ["non-specific", "OBSERVATION_MODIFIER", 5, 17], ["interaction", "OBSERVATION", 18, 29], ["negative charge", "OBSERVATION", 65, 80]]], ["On the other hand, the electric field will increase upon specific binding of the aptamer to HPV-16 E7 proteins, due to the conformational change and increased distance of the negatively charged RNA from the surface [32, 33] .3.3.Specific sensing of HPV-16 E7Additionally, the titration of the HPV-16 E7 protein was performed on a graphene surface in an optical measurement device (SPR) with a scrambled aptamer sequence (Fig. 4d) .", [["surface", "ANATOMY", 207, 214], ["graphene", "CHEMICAL", 330, 338], ["HPV-16 E7", "ORGANISM", 92, 101], ["HPV-16 E7Additionally", "ORGANISM", 249, 270], ["HPV-16 E7", "ORGANISM", 293, 302], ["HPV-16 E7 proteins", "PROTEIN", 92, 110], ["HPV-16 E7 protein", "PROTEIN", 293, 310], ["HPV", "TEST", 92, 95], ["E7 proteins", "TEST", 99, 110], ["the conformational change", "PROBLEM", 119, 144], ["HPV", "TEST", 249, 252], ["the HPV", "TEST", 289, 296], ["E7 protein", "TEST", 300, 310], ["a graphene surface", "TREATMENT", 328, 346], ["a scrambled aptamer sequence", "TREATMENT", 391, 419], ["increased", "OBSERVATION_MODIFIER", 149, 158]]], ["The response of the surface plasmon resonance experiment on graphene-coated gold substrates indicates that the aptamer is specifically binding to the protein, while the scrambled sequence shows minute non-specific interactions at 1000 nM.3.3.Specific sensing of HPV-16 E7The detection limit for the E7 protein was determined to be about 1.75 nM (100 pg mL \u22121 ) from five blank noise signals (95% confidence level) in PBS (Fig. 5) .", [["graphene", "CHEMICAL", 60, 68], ["graphene", "CHEMICAL", 60, 68], ["graphene", "SIMPLE_CHEMICAL", 60, 68], ["HPV-16 E7The", "ORGANISM", 262, 274], ["E7", "ORGANISM", 299, 301], ["E7 protein", "PROTEIN", 299, 309], ["the surface plasmon resonance", "TEST", 16, 45], ["the scrambled sequence", "TEST", 165, 187], ["minute non-specific interactions", "PROBLEM", 194, 226], ["HPV", "TEST", 262, 265], ["the E7 protein", "TEST", 295, 309], ["five blank noise signals", "TEST", 366, 390], ["PBS", "TEST", 417, 420]]], ["The eventual feasibility of the use of the sensor in biological relevant media was evaluated by establishing a calibration curve of E7 protein in saliva samples spiked with different concentrations of E7.", [["samples", "ANATOMY", 153, 160], ["E7", "GENE_OR_GENE_PRODUCT", 132, 134], ["saliva samples", "ORGANISM_SUBSTANCE", 146, 160], ["E7", "GENE_OR_GENE_PRODUCT", 201, 203], ["E7 protein", "PROTEIN", 132, 142], ["E7", "PROTEIN", 201, 203], ["a calibration curve", "TEST", 109, 128], ["E7 protein", "TEST", 132, 142], ["saliva samples", "TEST", 146, 160], ["different concentrations of E7", "TREATMENT", 173, 203]]], ["Indeed, one widely accepted detection scenario is based on HPV-16 E7 detection in saliva [34] .", [["HPV-16 E7", "ORGANISM", 59, 68], ["saliva", "ORGANISM_SUBSTANCE", 82, 88], ["E7", "PROTEIN", 66, 68], ["HPV-16", "SPECIES", 59, 65], ["HPV", "TEST", 59, 62]]], ["Saliva, which is 90.5% composed of water, is in addition composed of a variety of electrolytes, including sodium, potassium, calcium, magnesium, chloride, bicarbonate, and phosphate.", [["sodium", "CHEMICAL", 106, 112], ["potassium", "CHEMICAL", 114, 123], ["calcium", "CHEMICAL", 125, 132], ["magnesium", "CHEMICAL", 134, 143], ["chloride", "CHEMICAL", 145, 153], ["bicarbonate", "CHEMICAL", 155, 166], ["phosphate", "CHEMICAL", 172, 181], ["sodium", "CHEMICAL", 106, 112], ["potassium", "CHEMICAL", 114, 123], ["calcium", "CHEMICAL", 125, 132], ["magnesium", "CHEMICAL", 134, 143], ["chloride", "CHEMICAL", 145, 153], ["bicarbonate", "CHEMICAL", 155, 166], ["phosphate", "CHEMICAL", 172, 181], ["Saliva", "ORGANISM_SUBSTANCE", 0, 6], ["electrolytes", "SIMPLE_CHEMICAL", 82, 94], ["sodium", "SIMPLE_CHEMICAL", 106, 112], ["potassium", "SIMPLE_CHEMICAL", 114, 123], ["calcium", "SIMPLE_CHEMICAL", 125, 132], ["magnesium", "SIMPLE_CHEMICAL", 134, 143], ["chloride", "SIMPLE_CHEMICAL", 145, 153], ["bicarbonate", "SIMPLE_CHEMICAL", 155, 166], ["phosphate", "SIMPLE_CHEMICAL", 172, 181], ["a variety of electrolytes", "TREATMENT", 69, 94], ["sodium", "TREATMENT", 106, 112], ["potassium", "TREATMENT", 114, 123], ["calcium", "TREATMENT", 125, 132], ["magnesium", "TREATMENT", 134, 143], ["chloride", "TREATMENT", 145, 153], ["bicarbonate", "TREATMENT", 155, 166], ["phosphate", "TREATMENT", 172, 181]]], ["It also contains immunoglobulins, enzymes, mucus, and proteins.", [["immunoglobulins", "GENE_OR_GENE_PRODUCT", 17, 32], ["mucus", "GENE_OR_GENE_PRODUCT", 43, 48], ["immunoglobulins", "PROTEIN", 17, 32], ["enzymes", "PROTEIN", 34, 41], ["mucus, and proteins", "PROTEIN", 43, 62], ["immunoglobulins", "TEST", 17, 32], ["enzymes", "TEST", 34, 41], ["immunoglobulins", "OBSERVATION", 17, 32]]], ["The calibration curves in PBS and spiked saliva are shown in Fig. 5 .", [["saliva", "ORGANISM_SUBSTANCE", 41, 47], ["The calibration curves in PBS and spiked saliva", "TEST", 0, 47]]], ["Both curves are comparable, with a minute reduction in sensitivity.", [["a minute reduction", "TREATMENT", 33, 51], ["curves", "OBSERVATION_MODIFIER", 5, 11], ["reduction", "OBSERVATION_MODIFIER", 42, 51]]], ["The response to HPV-16 E7 in spiked saliva decreased due to increased ion concentrations in saliva, reducing the Debye length for the biorecognition in real time [35] .", [["saliva", "ANATOMY", 36, 42], ["HPV-16 E7", "CHEMICAL", 16, 25], ["HPV-16 E7", "ORGANISM", 16, 25], ["saliva", "ORGANISM_SUBSTANCE", 36, 42], ["ion", "SIMPLE_CHEMICAL", 70, 73], ["saliva", "ORGANISM_SUBSTANCE", 92, 98], ["HPV-16", "SPECIES", 16, 22], ["HPV", "TEST", 16, 19], ["increased ion concentrations in saliva", "PROBLEM", 60, 98]]], ["The linear regime of the sensor remains and is suitable for biosensing applications, and the signal is reduced by approximately 9% compared with PBS buffer.3.3.Specific sensing of HPV-16 E7The reproducibility of the electrode fabrication and use for HPV-16 E7 sensing is expressed in terms of the relative standard deviation and is found to be 9.3% at HPV-16 E7 concentration of 1 ng mL \u22121 .", [["HPV-16 E7", "ORGANISM", 180, 189], ["HPV-16 E7", "ORGANISM", 250, 259], ["HPV-16 E7", "ORGANISM", 352, 361], ["E7", "PROTEIN", 187, 189], ["E7", "PROTEIN", 359, 361], ["biosensing applications", "TREATMENT", 60, 83], ["PBS buffer", "TREATMENT", 145, 155], ["HPV", "TEST", 180, 183], ["the electrode fabrication", "TREATMENT", 212, 237], ["HPV", "TEST", 250, 253], ["HPV", "TEST", 352, 355], ["E7 concentration", "TREATMENT", 359, 375], ["linear", "OBSERVATION_MODIFIER", 4, 10], ["regime", "OBSERVATION_MODIFIER", 11, 17], ["reduced", "OBSERVATION_MODIFIER", 103, 110], ["standard deviation", "OBSERVATION", 306, 324]]], ["The long-term stability of the sensor exhibited a loss of 5% when tested in HPV-16 E7 (1 ng mL \u22121 ) after the electrode was stored at 4\u00b0C for a month.4.ConclusionIn conclusion, sensing on reduced graphene oxide-modified FET of HPV-16 E7 protein was demonstrated.", [["graphene oxide", "CHEMICAL", 196, 210], ["graphene oxide", "CHEMICAL", 196, 210], ["HPV-16 E7", "ORGANISM", 76, 85], ["graphene oxide", "SIMPLE_CHEMICAL", 196, 210], ["HPV", "ORGANISM", 227, 230], ["E7", "ORGANISM", 234, 236], ["HPV-16 E7 protein", "PROTEIN", 227, 244], ["HPV-16", "SPECIES", 76, 82], ["a loss", "PROBLEM", 48, 54], ["HPV", "TEST", 76, 79], ["E7", "TEST", 83, 85], ["the electrode", "TREATMENT", 106, 119], ["reduced graphene oxide", "TREATMENT", 188, 210], ["HPV", "TEST", 227, 230], ["E7 protein", "TEST", 234, 244], ["long-term stability", "OBSERVATION_MODIFIER", 4, 23]]], ["An important aspect in any sensing device is the way the ligand is attached to the interface.", [["any sensing device", "TREATMENT", 23, 41]]], ["In our case, integration of a HPV-16 E7- Fig. 5 Sensing characteristics of gFET for HPV-16 E7 proteins.", [["HPV-16 E7", "ORGANISM", 30, 39], ["gFET", "GENE_OR_GENE_PRODUCT", 75, 79], ["HPV-16 E7", "ORGANISM", 84, 93], ["E7", "PROTEIN", 37, 39], ["gFET", "PROTEIN", 75, 79], ["HPV-16 E7 proteins", "PROTEIN", 84, 102], ["HPV-16", "SPECIES", 84, 90], ["a HPV", "TEST", 28, 33], ["HPV", "TEST", 84, 87]]], ["Calibration curve of the HPV-16 E7 protein sensor in PBS (black) and in saliva (red).", [["HPV-16 E7", "ORGANISM", 25, 34], ["saliva", "ORGANISM_SUBSTANCE", 72, 78], ["E7", "PROTEIN", 32, 34], ["HPV-16", "SPECIES", 25, 31], ["Calibration curve", "TEST", 0, 17], ["the HPV", "TEST", 21, 28], ["E7 protein sensor", "TEST", 32, 49], ["saliva", "ANATOMY", 72, 78]]], ["Protein sensing in real time using aptamer-modified rGO-FET when the device is exposed to increasing concentrations of HPV-16 E7 proteins (7.5, 15, 31, 62, 100, 125, 250, 500, and 1000 nM) specific aptamer was achieved by covalent EDC/NHS coupling to rGO-FET pre-modified with 1-pyrenebutyric acid/ pyrene-PEG in a ratio of 1:10.", [["rGO", "CHEMICAL", 52, 55], ["EDC", "CHEMICAL", 231, 234], ["rGO", "CHEMICAL", 251, 254], ["1-pyrenebutyric acid", "CHEMICAL", 277, 297], ["pyrene", "CHEMICAL", 299, 305], ["PEG", "CHEMICAL", 306, 309], ["1-pyrenebutyric acid", "CHEMICAL", 277, 297], ["pyrene", "CHEMICAL", 299, 305], ["PEG", "CHEMICAL", 306, 309], ["rGO-FET", "SIMPLE_CHEMICAL", 52, 59], ["HPV-16 E7", "ORGANISM", 119, 128], ["EDC", "SIMPLE_CHEMICAL", 231, 234], ["NHS", "SIMPLE_CHEMICAL", 235, 238], ["rGO-FET", "SIMPLE_CHEMICAL", 251, 258], ["1-pyrenebutyric acid", "SIMPLE_CHEMICAL", 277, 297], ["pyrene-PEG", "SIMPLE_CHEMICAL", 299, 309], ["rGO", "PROTEIN", 52, 55], ["HPV-16 E7 proteins", "PROTEIN", 119, 137], ["Protein sensing", "TEST", 0, 15], ["aptamer-modified rGO", "TREATMENT", 35, 55], ["the device", "TREATMENT", 65, 75], ["HPV", "TEST", 119, 122], ["E7 proteins", "TEST", 126, 137], ["specific aptamer", "TEST", 189, 205], ["rGO", "TEST", 251, 254], ["FET", "TEST", 255, 258], ["1-pyrenebutyric acid/ pyrene", "TREATMENT", 277, 305], ["PEG", "TREATMENT", 306, 309], ["PEG", "OBSERVATION", 306, 309]]], ["Monitoring the aptamerprotein binding in real time revealed preferential binding of HPV-16 E7 with a detection limit of about 100 pg mL \u22121 (1.75 nM) for HPV-16 E7 from five blank noise signals (95% confidence level).", [["aptamerprotein", "SIMPLE_CHEMICAL", 15, 29], ["HPV-16 E7", "ORGANISM", 84, 93], ["E7", "ORGANISM", 160, 162], ["E7", "PROTEIN", 91, 93], ["E7", "PROTEIN", 160, 162], ["Monitoring the aptamerprotein binding", "TEST", 0, 37], ["HPV", "TEST", 84, 87], ["a detection limit", "TEST", 99, 116], ["HPV", "TEST", 153, 156], ["blank noise signals", "TEST", 173, 192]]], ["The dissociation constant K d of the binding reaction was determined as 200 nM, consistent with previous reports of aptamer-protein binding reactions.", [["K", "CHEMICAL", 26, 27], ["The dissociation", "PROBLEM", 0, 16], ["the binding reaction", "PROBLEM", 33, 53], ["protein binding reactions", "PROBLEM", 124, 149], ["consistent with", "UNCERTAINTY", 80, 95]]]], "PMC4986582": [["IntroductionDuring the last week of April 2009, a laboratory\u2010confirmed outbreak of pandemic A/H1N1 [A(H1N1)pdm09] influenza was reported in an elementary school in a rural community of British Columbia (BC), Canada.", [["influenza", "DISEASE", 114, 123], ["pandemic", "ORGANISM", 83, 91], ["A/H1N1 [A(H1N1)pdm09] influenza", "ORGANISM", 92, 123], ["pandemic A/H1N1 [A(H1N1)pdm09", "SPECIES", 83, 112], ["H1N1", "PROBLEM", 94, 98], ["A(H1N1)pdm", "TREATMENT", 100, 110], ["influenza", "PROBLEM", 114, 123]]], ["The school includes students of Aboriginal and non\u2010Aboriginal backgrounds drawn from the local town and surrounding First Nations reserves.", [["Aboriginal backgrounds", "TEST", 51, 73]]], ["Because A(H1N1)pdm09 had recently emerged in mid\u2010April as a novel virus and in order to characterize its transmission, clinical profile, risk factors, and impact, an outbreak investigation was organized by public health authorities through household telephone survey between May 15 and June 5, 2009.IntroductionInitial findings from this investigation have previously been published.1Of note, this outbreak investigation provided first detection of an association between prior 2008\u20132009 trivalent influenza vaccine (TIV) receipt and A(H1N1)pdm09 risk that was subsequently confirmed in at least four other studies conducted during the summer, 2009 in Canada.2In this paper, we report additional epidemiologic features of influenza\u2010like illness (ILI) experience during this outbreak including characteristics such as medical care, risk factors, and duration of illness both on\u2010 and off\u2010reserve.", [["influenza", "DISEASE", 498, 507], ["influenza\u2010like illness", "DISEASE", 722, 744], ["ILI", "DISEASE", 746, 749], ["illness", "DISEASE", 861, 868], ["A(H1N1)pdm09", "ORGANISM", 8, 20], ["A(H1N1)pdm09", "ORGANISM", 534, 546], ["TIV", "SPECIES", 517, 520], ["pdm09", "PROBLEM", 15, 20], ["a novel virus", "PROBLEM", 58, 71], ["an outbreak investigation", "TEST", 163, 188], ["this investigation", "TEST", 333, 351], ["prior 2008\u20132009 trivalent influenza vaccine", "TREATMENT", 472, 515], ["A(H1N1)pdm09 risk", "PROBLEM", 534, 551], ["influenza\u2010like illness", "PROBLEM", 722, 744], ["risk factors", "PROBLEM", 831, 843], ["illness", "PROBLEM", 861, 868], ["mid", "ANATOMY_MODIFIER", 45, 48]]], ["As a further main objective, we evaluate transmission patterns such as the household secondary attack rate (SAR) and serial interval (SI: interval between the index and secondary case), both of which are relevant in planning for and responding to novel influenza virus emergence.Outbreak investigation ::: Materials and MethodsAs previously described,1an elementary school (school A) in a rural BC community identified a >10% absenteeism rate owing to respiratory illness among students.", [["respiratory illness", "DISEASE", 452, 471], ["influenza virus", "ORGANISM", 253, 268], ["novel influenza virus emergence", "PROBLEM", 247, 278], ["respiratory illness", "PROBLEM", 452, 471]]], ["Local health authorities were notified on April 28, 2009, and nasopharyngeal specimens confirmed A(H1N1)pdm09 as the cause on May 3, 2009.", [["nasopharyngeal specimens", "ANATOMY", 62, 86], ["nasopharyngeal specimens", "CANCER", 62, 86], ["nasopharyngeal specimens", "TEST", 62, 86], ["A(H1N1)pdm09", "PROBLEM", 97, 109], ["nasopharyngeal", "ANATOMY", 62, 76]]], ["The school was closed on May 1, 2009 and re\u2010opened May 11, 2009.Outbreak investigation ::: Materials and MethodsTo characterize clinical and epidemiologic features of A(H1N1)pdm09 illness and spread in the community, a telephone survey of households with at least one child enrolled in any of the community schools was conducted May 15 through June 5, 2009.", [["A(H1N1)pdm09", "ORGANISM", 167, 179], ["A(H1N1)pdm09", "SPECIES", 167, 179], ["A(H1N1)pdm09 illness", "PROBLEM", 167, 187]]], ["Among consenting households, an adult respondent provided information about household characteristics and illness among all household members.", [["illness", "DISEASE", 106, 113]]], ["Household information included the number of household members and sleeping rooms, self\u2010identification as Aboriginal/non\u2010Aboriginal, and among Aboriginal participants residency on\u2010/off\u2010reserve.", [["participants", "SPECIES", 154, 166]]], ["Individual\u2010level information included age, flu\u2010like symptoms and related dates of onset, days spent in bed, health care visits, comorbidity (corresponding to high\u2010risk categories specified by the National Advisory Committee on Immunization), and receipt of 2008\u20132009 and/or 2007\u20132008 TIV.3", [["flu\u2010like symptoms", "PROBLEM", 43, 60], ["comorbidity", "PROBLEM", 128, 139], ["TIV", "TREATMENT", 284, 287]]]], "0c0b76bdde85404eef39575005d64289ec29aa1b": [["In this chapter we focus on the bioinformatics strategies for translating genome-wide expression analyses into clinically useful cancer markers with a specific focus on breast cancer with a perspective on new diagnostic device tools coming from the field of nanobiotechnology and the challenges related to high-throughput data integration, analysis, and assessment from multiple sources.", [["cancer", "ANATOMY", 129, 135], ["breast cancer", "ANATOMY", 169, 182], ["cancer", "DISEASE", 129, 135], ["breast cancer", "DISEASE", 169, 182], ["cancer", "CANCER", 129, 135], ["breast cancer", "CANCER", 169, 182], ["useful cancer markers", "PROBLEM", 122, 143], ["breast cancer", "PROBLEM", 169, 182], ["analysis", "TEST", 340, 348], ["assessment", "TEST", 354, 364], ["cancer", "OBSERVATION", 129, 135], ["breast", "ANATOMY", 169, 175], ["cancer", "OBSERVATION", 176, 182]]]], "50fcac9b23fc8196eedc3616117c4d5a535806f1": [["IntroductionInfectious bronchitis virus is the type species of the family Coronaviridae, and is part of the Gammacoronavirus genus (Woo et al., 2009) .", [["IntroductionInfectious bronchitis virus", "DISEASE", 0, 39], ["IntroductionInfectious bronchitis virus", "ORGANISM", 0, 39], ["Coronaviridae", "GENE_OR_GENE_PRODUCT", 74, 87], ["IntroductionInfectious bronchitis virus", "SPECIES", 0, 39], ["IntroductionInfectious bronchitis virus", "PROBLEM", 0, 39], ["bronchitis", "OBSERVATION", 23, 33]]], ["Within the Coronaviridae, individual species are able to infect a wide array of animals, including but not limited to humans, dogs, cats, pigs, cows, birds, bats, and whales.", [["humans", "ORGANISM", 118, 124], ["dogs", "ORGANISM", 126, 130], ["cats", "ORGANISM", 132, 136], ["pigs", "ORGANISM", 138, 142], ["cows", "ORGANISM", 144, 148], ["humans", "SPECIES", 118, 124], ["dogs", "SPECIES", 126, 130], ["cats", "SPECIES", 132, 136], ["pigs", "SPECIES", 138, 142], ["cows", "SPECIES", 144, 148], ["humans", "SPECIES", 118, 124], ["pigs", "SPECIES", 138, 142], ["individual species", "PROBLEM", 26, 44]]], ["IBV mainly infects chickens, and globally causes great economic loss for the poultry industry every year (Saif, 2003) .", [["IBV", "ORGANISM", 0, 3], ["chickens", "ORGANISM", 19, 27], ["chickens", "SPECIES", 19, 27], ["IBV", "SPECIES", 0, 3], ["chickens", "SPECIES", 19, 27], ["IBV", "PROBLEM", 0, 3], ["infects chickens", "OBSERVATION", 11, 27], ["great", "OBSERVATION_MODIFIER", 49, 54], ["economic loss", "OBSERVATION", 55, 68]]], ["Although IBV mainly infects the ciliated epithelia in the respiratory tract of chickens and causes respiratory disease, many studies have discovered that IBV can also spread to other organs of the chicken and can cause pathology in other issues, such as alimentary tract, testes, oviduct, and Harderian gland (Bezuidenhout et al., 2011; Raj and Jones, 1997) .", [["ciliated epithelia", "ANATOMY", 32, 50], ["respiratory tract", "ANATOMY", 58, 75], ["respiratory", "ANATOMY", 99, 110], ["organs", "ANATOMY", 183, 189], ["alimentary tract", "ANATOMY", 254, 270], ["testes", "ANATOMY", 272, 278], ["oviduct", "ANATOMY", 280, 287], ["Harderian gland", "ANATOMY", 293, 308], ["respiratory disease", "DISEASE", 99, 118], ["IBV", "ORGANISM", 9, 12], ["ciliated epithelia", "TISSUE", 32, 50], ["respiratory tract", "ORGANISM_SUBDIVISION", 58, 75], ["chickens", "ORGANISM", 79, 87], ["IBV", "ORGANISM", 154, 157], ["organs", "ORGAN", 183, 189], ["chicken", "ORGANISM", 197, 204], ["alimentary tract", "ORGANISM_SUBDIVISION", 254, 270], ["testes", "ORGAN", 272, 278], ["oviduct", "ORGAN", 280, 287], ["Harderian gland", "ORGAN", 293, 308], ["chickens", "SPECIES", 79, 87], ["chicken", "SPECIES", 197, 204], ["IBV", "SPECIES", 9, 12], ["chickens", "SPECIES", 79, 87], ["IBV", "SPECIES", 154, 157], ["chicken", "SPECIES", 197, 204], ["IBV", "PROBLEM", 9, 12], ["respiratory disease", "PROBLEM", 99, 118], ["many studies", "TEST", 120, 132], ["IBV", "PROBLEM", 154, 157], ["pathology in other issues", "PROBLEM", 219, 244], ["ciliated", "OBSERVATION_MODIFIER", 32, 40], ["epithelia", "OBSERVATION_MODIFIER", 41, 50], ["respiratory tract", "ANATOMY", 58, 75], ["respiratory disease", "OBSERVATION", 99, 118], ["alimentary tract", "ANATOMY", 254, 270], ["testes", "ANATOMY", 272, 278], ["oviduct", "ANATOMY", 280, 287], ["Harderian gland", "ANATOMY", 293, 308]]], ["Clinical signs include coughing, sneezing, nasal discharge, loss of appetite, and reduction in egg laying (Saif, 2003) .", [["nasal", "ANATOMY", 43, 48], ["egg", "ANATOMY", 95, 98], ["coughing", "DISEASE", 23, 31], ["sneezing", "DISEASE", 33, 41], ["loss of appetite", "DISEASE", 60, 76], ["nasal", "ORGANISM_SUBDIVISION", 43, 48], ["egg", "ORGANISM_SUBDIVISION", 95, 98], ["Clinical signs", "TEST", 0, 14], ["coughing", "PROBLEM", 23, 31], ["sneezing", "PROBLEM", 33, 41], ["nasal discharge", "PROBLEM", 43, 58], ["loss of appetite", "PROBLEM", 60, 76], ["coughing", "OBSERVATION", 23, 31], ["nasal", "ANATOMY", 43, 48]]], ["In addition to the original Massachusetts serotype, dozens of serotypes and genotypes of IBV have now been detected (Meir et al., 2010) .", [["IBV", "ORGANISM", 89, 92], ["IBV", "SPECIES", 89, 92], ["serotypes", "TREATMENT", 62, 71], ["IBV", "TREATMENT", 89, 92]]], ["Many strains can cause major or minor nephritis in both naturally infected or experimentally infected chickens (Lambrechts et al., 1993) .IntroductionSusceptibility of virulent strains of IBV to different cell lines has been sporadically reported; e.g. chicken fibroblasts (Nazerian and Cunningham, 1968) , HeLa cells (Chen et al., 2007) , primary chicken tracheal epithelial cell (Shen et al., 2010) , but currently the only way to efficiently propagate IBV is by using embryonated chicken eggs.", [["cell lines", "ANATOMY", 205, 215], ["fibroblasts", "ANATOMY", 261, 272], ["HeLa cells", "ANATOMY", 307, 317], ["tracheal epithelial cell", "ANATOMY", 356, 380], ["eggs", "ANATOMY", 491, 495], ["nephritis", "DISEASE", 38, 47], ["naturally infected or experimentally infected", "DISEASE", 56, 101], ["chickens", "ORGANISM", 102, 110], ["IBV", "ORGANISM", 188, 191], ["cell lines", "CELL", 205, 215], ["chicken", "ORGANISM", 253, 260], ["fibroblasts", "CELL", 261, 272], ["Nazerian", "CELL", 274, 282], ["HeLa cells", "CELL", 307, 317], ["chicken", "ORGANISM", 348, 355], ["tracheal epithelial cell", "CELL", 356, 380], ["IBV", "ORGANISM", 455, 458], ["chicken", "ORGANISM", 483, 490], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 491, 495], ["cell lines", "CELL_LINE", 205, 215], ["chicken fibroblasts", "CELL_TYPE", 253, 272], ["HeLa cells", "CELL_LINE", 307, 317], ["primary chicken tracheal epithelial cell", "CELL_TYPE", 340, 380], ["chickens", "SPECIES", 102, 110], ["chicken", "SPECIES", 253, 260], ["chicken", "SPECIES", 348, 355], ["chicken", "SPECIES", 483, 490], ["chickens", "SPECIES", 102, 110], ["IBV", "SPECIES", 188, 191], ["chicken", "SPECIES", 253, 260], ["chicken", "SPECIES", 348, 355], ["IBV", "SPECIES", 455, 458], ["chicken", "SPECIES", 483, 490], ["Many strains", "PROBLEM", 0, 12], ["minor nephritis", "PROBLEM", 32, 47], ["virulent strains", "PROBLEM", 168, 184], ["IBV", "PROBLEM", 188, 191], ["different cell lines", "TREATMENT", 195, 215], ["primary chicken tracheal epithelial cell", "PROBLEM", 340, 380], ["embryonated chicken eggs", "TREATMENT", 471, 495], ["minor", "OBSERVATION_MODIFIER", 32, 37], ["nephritis", "OBSERVATION", 38, 47], ["naturally", "OBSERVATION_MODIFIER", 56, 65], ["infected", "OBSERVATION_MODIFIER", 66, 74], ["infected", "OBSERVATION_MODIFIER", 93, 101], ["virulent strains", "OBSERVATION", 168, 184], ["different cell lines", "OBSERVATION", 195, 215], ["tracheal", "ANATOMY", 356, 364], ["epithelial cell", "OBSERVATION", 365, 380], ["IBV", "OBSERVATION", 455, 458]]], ["In cell culture, while most field strains of IBV can infect primary chicken derived cells (e.g. chick kidney and tracheal cells), no cell lines are generally considered to be susceptible to IBV infection.", [["cell culture", "ANATOMY", 3, 15], ["cells", "ANATOMY", 84, 89], ["kidney", "ANATOMY", 102, 108], ["tracheal cells", "ANATOMY", 113, 127], ["cell lines", "ANATOMY", 133, 143], ["IBV infection", "DISEASE", 190, 203], ["cell", "CELL", 3, 7], ["IBV", "ORGANISM", 45, 48], ["chicken", "ORGANISM", 68, 75], ["cells", "CELL", 84, 89], ["chick", "ORGANISM", 96, 101], ["kidney", "ORGAN", 102, 108], ["tracheal cells", "CELL", 113, 127], ["cell lines", "CELL", 133, 143], ["IBV", "ORGANISM", 190, 193], ["primary chicken derived cells", "CELL_TYPE", 60, 89], ["chick kidney and tracheal cells", "CELL_TYPE", 96, 127], ["cell lines", "CELL_LINE", 133, 143], ["chicken", "SPECIES", 68, 75], ["chick", "SPECIES", 96, 101], ["IBV", "SPECIES", 45, 48], ["chicken", "SPECIES", 68, 75], ["IBV", "SPECIES", 190, 193], ["cell culture", "TEST", 3, 15], ["IBV", "PROBLEM", 45, 48], ["primary chicken derived cells", "PROBLEM", 60, 89], ["chick kidney and tracheal cells", "PROBLEM", 96, 127], ["cell lines", "PROBLEM", 133, 143], ["IBV infection", "PROBLEM", 190, 203], ["cell culture", "OBSERVATION", 3, 15], ["kidney", "ANATOMY", 102, 108], ["tracheal cells", "ANATOMY", 113, 127], ["no", "UNCERTAINTY", 130, 132], ["cell lines", "OBSERVATION", 133, 143], ["IBV", "OBSERVATION_MODIFIER", 190, 193], ["infection", "OBSERVATION", 194, 203]]], ["The exception to this is the Beaudette strain, which is a highly embryo-and cell-culture adapted non-virulent virus and can infect cell lines derived from a variety of mammalian species (Saif, 2003) .IntroductionThe ability of IBV to infect different tissues in chickens may be linked to the receptor distribution within these tissues.", [["embryo", "ANATOMY", 65, 71], ["cell", "ANATOMY", 76, 80], ["cell lines", "ANATOMY", 131, 141], ["tissues", "ANATOMY", 251, 258], ["tissues", "ANATOMY", 327, 334], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 65, 71], ["cell", "CELL", 76, 80], ["cell lines", "CELL", 131, 141], ["IBV", "ORGANISM", 227, 230], ["tissues", "TISSUE", 251, 258], ["chickens", "ORGANISM", 262, 270], ["tissues", "TISSUE", 327, 334], ["cell lines", "CELL_LINE", 131, 141], ["chickens", "SPECIES", 262, 270], ["IBV", "SPECIES", 227, 230], ["chickens", "SPECIES", 262, 270], ["the Beaudette strain", "PROBLEM", 25, 45], ["a highly embryo-and cell-culture", "PROBLEM", 56, 88], ["non-virulent virus", "PROBLEM", 97, 115], ["infect cell lines", "PROBLEM", 124, 141], ["mammalian species", "PROBLEM", 168, 185], ["IBV", "TREATMENT", 227, 230], ["infect cell lines", "OBSERVATION", 124, 141], ["mammalian species", "OBSERVATION", 168, 185], ["infect different", "OBSERVATION_MODIFIER", 234, 250], ["tissues", "ANATOMY", 327, 334]]], ["Although the virus was first identified almost 80 years ago, the primary receptor for IBV has not been identified.", [["IBV", "ORGANISM", 86, 89], ["IBV", "SPECIES", 86, 89], ["the virus", "PROBLEM", 9, 18], ["IBV", "PROBLEM", 86, 89], ["virus", "OBSERVATION", 13, 18], ["IBV", "OBSERVATION", 86, 89]]], ["There was speculation that feline aminopeptidase N (fAPN), which can serve as a common receptor for many Alphacoronaviruses, is a receptor for IBV (Miguel et al., 2002) .", [["N", "CHEMICAL", 49, 50], ["feline aminopeptidase N", "GENE_OR_GENE_PRODUCT", 27, 50], ["fAPN", "GENE_OR_GENE_PRODUCT", 52, 56], ["Alphacoronaviruses", "GENE_OR_GENE_PRODUCT", 105, 123], ["IBV", "ORGANISM", 143, 146], ["feline aminopeptidase N", "PROTEIN", 27, 50], ["fAPN", "PROTEIN", 52, 56], ["Alphacoronaviruses", "PROTEIN", 105, 123], ["IBV", "SPECIES", 143, 146], ["feline aminopeptidase N (fAPN)", "TREATMENT", 27, 57]]], ["This was based in part on the ability of the Ark99 strain of IBV to infect feline kidney cells (Miguel et al., 2002) .", [["kidney cells", "ANATOMY", 82, 94], ["Ark99", "GENE_OR_GENE_PRODUCT", 45, 50], ["IBV", "ORGANISM", 61, 64], ["feline", "ORGANISM", 75, 81], ["kidney cells", "CELL", 82, 94], ["feline kidney cells", "CELL_TYPE", 75, 94], ["feline", "SPECIES", 75, 81], ["IBV", "SPECIES", 61, 64], ["IBV", "TREATMENT", 61, 64], ["kidney", "ANATOMY", 82, 88]]], ["However, these studies were not confirmed with additional isolates of IBV and the current view is that APN is not a functional receptor utilized by IBV.", [["IBV", "ORGANISM", 70, 73], ["APN", "GENE_OR_GENE_PRODUCT", 103, 106], ["IBV", "ORGANISM", 148, 151], ["APN", "PROTEIN", 103, 106], ["IBV", "SPECIES", 70, 73], ["IBV", "SPECIES", 148, 151], ["these studies", "TEST", 9, 22], ["IBV", "TREATMENT", 70, 73], ["a functional receptor", "TREATMENT", 114, 135]]], ["There have also been studies showing that the tissue tropism of IBV may be linked to the use of sialic acid as an attachment factor, which is present on cell surface of various tissues (Winter et al., 2006) .", [["tissue", "ANATOMY", 46, 52], ["cell surface", "ANATOMY", 153, 165], ["tissues", "ANATOMY", 177, 184], ["sialic acid", "CHEMICAL", 96, 107], ["sialic acid", "CHEMICAL", 96, 107], ["tissue", "TISSUE", 46, 52], ["IBV", "ORGANISM", 64, 67], ["sialic acid", "SIMPLE_CHEMICAL", 96, 107], ["cell surface", "CELLULAR_COMPONENT", 153, 165], ["tissues", "TISSUE", 177, 184], ["attachment factor", "PROTEIN", 114, 131], ["IBV", "SPECIES", 64, 67], ["studies", "TEST", 21, 28], ["the tissue tropism of IBV", "PROBLEM", 42, 67], ["sialic acid", "PROBLEM", 96, 107], ["an attachment factor", "PROBLEM", 111, 131], ["IBV", "OBSERVATION", 64, 67], ["various tissues", "ANATOMY", 169, 184]]], ["In addition, heparin sulfate has been reported as an attachment factor specifically for the Beaudette strain of IBV (Madu et al., 2007) .IntroductionDendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing Non-integrin (DC-SIGN) and its closely relatedLiver/lymph node-specific ICAM-3 grabbing non-integrin (L-SIGN) are calcium-dependent lectins.", [["lymph node", "ANATOMY", 268, 278], ["heparin sulfate", "CHEMICAL", 13, 28], ["calcium", "CHEMICAL", 330, 337], ["sulfate", "CHEMICAL", 21, 28], ["calcium", "CHEMICAL", 330, 337], ["heparin sulfate", "SIMPLE_CHEMICAL", 13, 28], ["IBV", "ORGANISM", 112, 115], ["Dendritic Cell-Specific Intercellular adhesion molecule-3", "GENE_OR_GENE_PRODUCT", 149, 206], ["Grabbing Non-integrin", "GENE_OR_GENE_PRODUCT", 207, 228], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 230, 237], ["lymph node", "MULTI-TISSUE_STRUCTURE", 268, 278], ["ICAM-3", "GENE_OR_GENE_PRODUCT", 288, 294], ["non-integrin", "GENE_OR_GENE_PRODUCT", 304, 316], ["L-SIGN", "GENE_OR_GENE_PRODUCT", 318, 324], ["calcium", "SIMPLE_CHEMICAL", 330, 337], ["Dendritic Cell-Specific Intercellular adhesion molecule-3", "PROTEIN", 149, 206], ["Grabbing Non-integrin", "PROTEIN", 207, 228], ["DC", "PROTEIN", 230, 232], ["SIGN", "PROTEIN", 233, 237], ["ICAM-3", "PROTEIN", 288, 294], ["non-integrin", "PROTEIN", 304, 316], ["L", "PROTEIN", 318, 319], ["SIGN", "PROTEIN", 320, 324], ["calcium-dependent lectins", "PROTEIN", 330, 355], ["IBV", "SPECIES", 112, 115], ["heparin sulfate", "TREATMENT", 13, 28], ["IntroductionDendritic Cell", "TEST", 137, 163], ["Specific Intercellular adhesion molecule", "TEST", 164, 204], ["its closely relatedLiver/lymph node", "PROBLEM", 243, 278], ["specific ICAM", "TEST", 279, 292], ["non-integrin", "TEST", 304, 316], ["calcium", "TEST", 330, 337], ["Dendritic Cell", "OBSERVATION", 149, 163], ["Intercellular", "OBSERVATION_MODIFIER", 173, 186], ["adhesion molecule", "OBSERVATION", 187, 204], ["lymph node", "OBSERVATION", 268, 278], ["dependent lectins", "OBSERVATION_MODIFIER", 338, 355]]], ["DC-SIGN was first discovered to be important in human immunodeficiency virus type 1 (HIV-1) pathogenesis (Geijtenbeek et al., 2000) .", [["DC", "ANATOMY", 0, 2], ["human immunodeficiency virus type 1 (HIV-1) pathogenesis", "DISEASE", 48, 104], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 0, 7], ["human immunodeficiency virus type 1", "ORGANISM", 48, 83], ["HIV-1", "ORGANISM", 85, 90], ["DC", "CELL_TYPE", 0, 2], ["SIGN", "PROTEIN", 3, 7], ["human immunodeficiency virus type 1", "SPECIES", 48, 83], ["HIV-1", "SPECIES", 85, 90], ["human immunodeficiency virus type 1", "SPECIES", 48, 83], ["HIV-1", "SPECIES", 85, 90], ["human immunodeficiency virus type", "PROBLEM", 48, 81], ["pathogenesis", "PROBLEM", 92, 104]]], ["This lectin, expressed mainly on dendritic cells, is believed to interact with the HIV-1 surface glycoprotein gp120 and enable capturing and transporting of the virus particle from mucosal infection site to secondary lymphoid tissues (Geijtenbeek et al., 2000) .", [["dendritic cells", "ANATOMY", 33, 48], ["mucosal", "ANATOMY", 181, 188], ["lymphoid tissues", "ANATOMY", 217, 233], ["infection", "DISEASE", 189, 198], ["lectin", "GENE_OR_GENE_PRODUCT", 5, 11], ["dendritic cells", "CELL", 33, 48], ["HIV-1", "ORGANISM", 83, 88], ["gp120", "GENE_OR_GENE_PRODUCT", 110, 115], ["mucosal", "ORGAN", 181, 188], ["lymphoid tissues", "TISSUE", 217, 233], ["lectin", "PROTEIN", 5, 11], ["dendritic cells", "CELL_TYPE", 33, 48], ["HIV-1 surface glycoprotein gp120", "PROTEIN", 83, 115], ["HIV-1", "SPECIES", 83, 88], ["HIV-1", "SPECIES", 83, 88], ["the HIV-1 surface glycoprotein gp120", "TREATMENT", 79, 115], ["the virus particle", "PROBLEM", 157, 175], ["mucosal infection site", "PROBLEM", 181, 203], ["dendritic cells", "OBSERVATION", 33, 48], ["mucosal", "ANATOMY", 181, 188], ["infection", "OBSERVATION", 189, 198], ["secondary lymphoid tissues", "OBSERVATION", 207, 233]]], ["DC-SIGN is also able to enhance HIV-1 infection in cis as an attachment factor (Lee et al., 2001) .", [["DC", "ANATOMY", 0, 2], ["HIV-1 infection", "DISEASE", 32, 47], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 0, 7], ["HIV-1", "ORGANISM", 32, 37], ["DC", "CELL_TYPE", 0, 2], ["SIGN", "PROTEIN", 3, 7], ["HIV-1", "SPECIES", 32, 37], ["HIV-1", "SPECIES", 32, 37], ["HIV", "PROBLEM", 32, 35], ["1 infection in cis", "PROBLEM", 36, 54], ["infection", "OBSERVATION", 38, 47]]], ["With a similar structure to DC-SIGN, L-SIGN is able to capture HIV-1 in the same manner.", [["DC", "ANATOMY", 28, 30], ["L-SIGN", "GENE_OR_GENE_PRODUCT", 37, 43], ["HIV-1", "ORGANISM", 63, 68], ["DC", "CELL_TYPE", 28, 30], ["SIGN", "PROTEIN", 31, 35], ["L", "PROTEIN", 37, 38], ["SIGN", "PROTEIN", 39, 43], ["HIV-1", "SPECIES", 63, 68], ["HIV-1", "SPECIES", 63, 68], ["HIV", "TEST", 63, 66]]], ["Many enveloped viruses such as Ebola virus, hepatitis C virus, and Sindbis virus also have been shown to be interacting with DC-SIGN and/or L-SIGN presumably via interaction with high-mannose glycoproteins on the viral particles (Alvarez et al., 2002; Klimstra et al., 2003; Navarro-Sanchez et al., 2003; Pohlmann et al., 2003) .IntroductionFor coronaviruses, there have been increasing numbers of reports demonstrating a role for human DC-SIGN and/or L-SIGN in pathogenesis of SARS coronavirus, human coronavirus-229E, human coronavirus-NL63, as well as feline coronavirus by enhancement of infection (Hofmann et al., 2006; Marzi et al., 2004; Regan and Whittaker, 2008; Yang et al., 2004) .", [["DC", "ANATOMY", 125, 127], ["DC", "ANATOMY", 437, 439], ["Ebola virus", "DISEASE", 31, 42], ["hepatitis C", "DISEASE", 44, 55], ["SARS coronavirus", "DISEASE", 478, 494], ["feline coronavirus", "DISEASE", 555, 573], ["infection", "DISEASE", 592, 601], ["mannose", "CHEMICAL", 184, 191], ["Ebola virus", "ORGANISM", 31, 42], ["hepatitis C virus", "ORGANISM", 44, 61], ["Sindbis virus", "ORGANISM", 67, 80], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 125, 132], ["L-SIGN", "GENE_OR_GENE_PRODUCT", 140, 146], ["human", "ORGANISM", 431, 436], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 437, 444], ["L-SIGN", "GENE_OR_GENE_PRODUCT", 452, 458], ["SARS coronavirus", "ORGANISM", 478, 494], ["human coronavirus-229E", "ORGANISM", 496, 518], ["human", "ORGANISM", 520, 525], ["coronavirus-NL63", "ORGANISM", 526, 542], ["feline coronavirus", "ORGANISM", 555, 573], ["DC", "CELL_TYPE", 125, 127], ["SIGN", "PROTEIN", 128, 132], ["SIGN", "PROTEIN", 142, 146], ["high-mannose glycoproteins", "PROTEIN", 179, 205], ["human DC-SIGN and/or L-SIGN", "PROTEIN", 431, 458], ["Ebola virus", "SPECIES", 31, 42], ["hepatitis C virus", "SPECIES", 44, 61], ["Sindbis virus", "SPECIES", 67, 80], ["human", "SPECIES", 431, 436], ["coronavirus", "SPECIES", 483, 494], ["human", "SPECIES", 496, 501], ["coronavirus", "SPECIES", 502, 513], ["human", "SPECIES", 520, 525], ["coronavirus", "SPECIES", 526, 537], ["feline coronavirus", "SPECIES", 555, 573], ["Ebola virus", "SPECIES", 31, 42], ["hepatitis C virus", "SPECIES", 44, 61], ["Sindbis virus", "SPECIES", 67, 80], ["human", "SPECIES", 431, 436], ["SARS coronavirus", "SPECIES", 478, 494], ["human coronavirus-229E", "SPECIES", 496, 518], ["human coronavirus", "SPECIES", 520, 537], ["feline coronavirus", "SPECIES", 555, 573], ["Many enveloped viruses", "PROBLEM", 0, 22], ["Ebola virus", "PROBLEM", 31, 42], ["hepatitis C virus", "PROBLEM", 44, 61], ["Sindbis virus", "PROBLEM", 67, 80], ["coronaviruses", "PROBLEM", 345, 358], ["SARS coronavirus", "PROBLEM", 478, 494], ["human coronavirus", "TEST", 496, 513], ["human coronavirus", "TEST", 520, 537], ["infection", "PROBLEM", 592, 601], ["enveloped", "OBSERVATION_MODIFIER", 5, 14], ["viruses", "OBSERVATION", 15, 22], ["Ebola virus", "OBSERVATION", 31, 42], ["infection", "OBSERVATION", 592, 601]]], ["Based on the evidence that human DC-SIGN is able to promote infection of nonhuman viruses, i.e. feline immunodeficiency virus and feline coronavirus (de Parseval et al., 2004; Regan and Whittaker, 2008) , we were interested in whether human DC-SIGN or L-SIGN might be an entry determinant for IBV and whether they may function in combination with fAPN.IntroductionIn our study, we demonstrate that by introducing DC-SIGN or L-SIGN into non-permissive cells, infection of IBV strain M41 is dramatically increased.", [["DC", "ANATOMY", 33, 35], ["DC", "ANATOMY", 241, 243], ["DC", "ANATOMY", 413, 415], ["cells", "ANATOMY", 451, 456], ["infection", "DISEASE", 60, 69], ["feline immunodeficiency virus", "DISEASE", 96, 125], ["feline coronavirus", "DISEASE", 130, 148], ["fAPN", "CHEMICAL", 347, 351], ["L-", "CHEMICAL", 424, 426], ["infection", "DISEASE", 458, 467], ["human", "ORGANISM", 27, 32], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 33, 40], ["nonhuman viruses", "ORGANISM", 73, 89], ["feline immunodeficiency virus", "ORGANISM", 96, 125], ["feline coronavirus", "ORGANISM", 130, 148], ["human", "ORGANISM", 235, 240], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 241, 248], ["L-SIGN", "GENE_OR_GENE_PRODUCT", 252, 258], ["IBV", "ORGANISM", 293, 296], ["fAPN", "SIMPLE_CHEMICAL", 347, 351], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 413, 420], ["L-SIGN", "GENE_OR_GENE_PRODUCT", 424, 430], ["cells", "CELL", 451, 456], ["IBV strain M41", "ORGANISM", 471, 485], ["human DC", "CELL_TYPE", 27, 35], ["SIGN", "PROTEIN", 36, 40], ["human DC", "CELL_TYPE", 235, 243], ["SIGN or L-SIGN", "PROTEIN", 244, 258], ["fAPN", "PROTEIN", 347, 351], ["DC", "CELL_TYPE", 413, 415], ["SIGN", "PROTEIN", 416, 420], ["L-SIGN", "PROTEIN", 424, 430], ["human", "SPECIES", 27, 32], ["feline immunodeficiency virus", "SPECIES", 96, 125], ["feline coronavirus", "SPECIES", 130, 148], ["human", "SPECIES", 235, 240], ["human", "SPECIES", 27, 32], ["nonhuman viruses", "SPECIES", 73, 89], ["feline immunodeficiency virus", "SPECIES", 96, 125], ["feline coronavirus", "SPECIES", 130, 148], ["human", "SPECIES", 235, 240], ["IBV", "SPECIES", 293, 296], ["IBV strain M41", "SPECIES", 471, 485], ["human DC", "TREATMENT", 27, 35], ["infection of nonhuman viruses", "PROBLEM", 60, 89], ["feline immunodeficiency virus", "PROBLEM", 96, 125], ["IBV", "PROBLEM", 293, 296], ["fAPN", "TREATMENT", 347, 351], ["our study", "TEST", 367, 376], ["non-permissive cells", "PROBLEM", 436, 456], ["infection of IBV strain M41", "PROBLEM", 458, 485], ["infection", "OBSERVATION", 60, 69], ["non-permissive cells", "OBSERVATION", 436, 456], ["dramatically", "OBSERVATION_MODIFIER", 489, 501], ["increased", "OBSERVATION_MODIFIER", 502, 511]]], ["This enhancement of infection also applies to various field strains of virulent IBVs and is independent from the previous reported attachment factor sialic acid.", [["IBVs", "ANATOMY", 80, 84], ["infection", "DISEASE", 20, 29], ["IBVs", "DISEASE", 80, 84], ["sialic acid", "CHEMICAL", 149, 160], ["sialic acid", "CHEMICAL", 149, 160], ["IBVs", "CANCER", 80, 84], ["sialic acid", "SIMPLE_CHEMICAL", 149, 160], ["attachment factor", "PROTEIN", 131, 148], ["This enhancement of infection", "PROBLEM", 0, 29], ["virulent IBVs", "PROBLEM", 71, 84], ["sialic acid", "TEST", 149, 160], ["infection", "OBSERVATION", 20, 29], ["virulent IBVs", "OBSERVATION", 71, 84]]], ["Our findings indicate that there may be a role for DC-SIGN for IBV spread from one organ to another, but that an additional receptor is involved in the infection of epithelial cell types, which is likely to be distinct from APN.Virus strainsIBV strains used in this study were M41, Cal99, Conn46, Iowa609, Gray, Iowa97, and JMK.", [["DC", "ANATOMY", 51, 53], ["organ", "ANATOMY", 83, 88], ["epithelial cell", "ANATOMY", 165, 180], ["infection", "DISEASE", 152, 161], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 51, 58], ["IBV", "ORGANISM", 63, 66], ["organ", "ORGAN", 83, 88], ["epithelial cell", "CELL", 165, 180], ["APN", "GENE_OR_GENE_PRODUCT", 224, 227], ["Virus strainsIBV strains", "ORGANISM", 228, 252], ["Cal99", "GENE_OR_GENE_PRODUCT", 282, 287], ["Conn46", "GENE_OR_GENE_PRODUCT", 289, 295], ["Iowa609", "GENE_OR_GENE_PRODUCT", 297, 304], ["Gray", "GENE_OR_GENE_PRODUCT", 306, 310], ["Iowa97", "GENE_OR_GENE_PRODUCT", 312, 318], ["JMK", "GENE_OR_GENE_PRODUCT", 324, 327], ["DC", "CELL_TYPE", 51, 53], ["SIGN", "PROTEIN", 54, 58], ["epithelial cell types", "CELL_TYPE", 165, 186], ["APN", "PROTEIN", 224, 227], ["IBV", "SPECIES", 63, 66], ["IBV spread", "PROBLEM", 63, 73], ["epithelial cell types", "PROBLEM", 165, 186], ["Virus strainsIBV strains", "PROBLEM", 228, 252], ["this study", "TEST", 261, 271], ["Cal99", "TEST", 282, 287], ["Gray", "TEST", 306, 310], ["Iowa97", "TEST", 312, 318], ["JMK", "TEST", 324, 327], ["infection", "OBSERVATION", 152, 161], ["epithelial cell types", "OBSERVATION", 165, 186], ["likely to be", "UNCERTAINTY", 197, 209], ["distinct", "OBSERVATION_MODIFIER", 210, 218]]], ["For preparation of virus stocks, approximately 10 2 EID50 of IBV was inoculated into 10day-old specific-pathogen-free chicken embryos.Virus strainsAllantoic fluid from infected embryos was collected 48 h post inoculation, and subjected to clarification by centrifugation at 1800 \u00d7 g for 15 minutes at 4\u00b0C. For concentrated IBV-M41 virus preparation, the allantoic fluid was further centrifugated at 34500 \u00d7 g for 60 minutes at 4\u00b0C using a Ti45 rotor (Beckman Coulter).", [["embryos", "ANATOMY", 126, 133], ["Allantoic fluid", "ANATOMY", 147, 162], ["embryos", "ANATOMY", 177, 184], ["allantoic fluid", "ANATOMY", 354, 369], ["IBV", "ORGANISM", 61, 64], ["chicken", "ORGANISM", 118, 125], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 126, 133], ["Virus strains", "ORGANISM", 134, 147], ["Allantoic fluid", "ORGANISM_SUBSTANCE", 147, 162], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 177, 184], ["IBV-M41 virus", "ORGANISM", 323, 336], ["allantoic fluid", "ORGANISM_SUBSTANCE", 354, 369], ["chicken", "SPECIES", 118, 125], ["IBV", "SPECIES", 61, 64], ["chicken", "SPECIES", 118, 125], ["IBV-M41 virus", "SPECIES", 323, 336], ["preparation of virus stocks", "TREATMENT", 4, 31], ["IBV", "TREATMENT", 61, 64], ["pathogen", "PROBLEM", 104, 112], ["free chicken embryos", "TREATMENT", 113, 133], ["Virus strains", "PROBLEM", 134, 147], ["Allantoic fluid", "TREATMENT", 147, 162], ["infected embryos", "PROBLEM", 168, 184], ["concentrated IBV-M41 virus preparation", "TREATMENT", 310, 348], ["the allantoic fluid", "TREATMENT", 350, 369], ["a Ti45 rotor (Beckman Coulter)", "TREATMENT", 437, 467], ["virus stocks", "OBSERVATION", 19, 31], ["free chicken embryos", "OBSERVATION", 113, 133], ["fluid", "OBSERVATION", 157, 162], ["infected embryos", "OBSERVATION", 168, 184]]], ["The virus pellet was resuspended in phosphate buffered saline (Cellgro).", [["phosphate", "CHEMICAL", 36, 45], ["phosphate", "CHEMICAL", 36, 45], ["phosphate buffered saline", "SIMPLE_CHEMICAL", 36, 61], ["Cellgro", "SIMPLE_CHEMICAL", 63, 70], ["The virus pellet", "TREATMENT", 0, 16], ["phosphate buffered saline (Cellgro", "TREATMENT", 36, 70], ["virus pellet", "OBSERVATION", 4, 16]]], ["IBV allantoic fluid was titered by egg infectious dose 50 assay.", [["allantoic fluid", "ANATOMY", 4, 19], ["IBV", "ORGANISM", 0, 3], ["allantoic fluid", "ORGANISM_SUBSTANCE", 4, 19], ["IBV", "SPECIES", 0, 3], ["IBV allantoic fluid", "TREATMENT", 0, 19], ["allantoic", "OBSERVATION_MODIFIER", 4, 13], ["fluid", "OBSERVATION", 14, 19]]], ["IBV concentrated preparation was titered by tissue culture infectious dose 50 assay.", [["tissue", "ANATOMY", 44, 50], ["IBV", "ORGANISM", 0, 3], ["tissue", "TISSUE", 44, 50], ["IBV", "SPECIES", 0, 3], ["IBV concentrated preparation", "TREATMENT", 0, 28]]], ["Influenza virus strain A/WSN/33 was propagated in MDBK cells and supernatant was collected 48 h post infection.", [["MDBK cells", "ANATOMY", 50, 60], ["supernatant", "ANATOMY", 65, 76], ["infection", "DISEASE", 101, 110], ["Influenza virus strain A", "ORGANISM", 0, 24], ["WSN/33", "ORGANISM", 25, 31], ["MDBK cells", "CELL", 50, 60], ["MDBK cells", "CELL_LINE", 50, 60], ["Influenza virus", "SPECIES", 0, 15], ["Influenza virus strain A/WSN/33", "SPECIES", 0, 31], ["MDBK", "SPECIES", 50, 54], ["Influenza virus strain", "PROBLEM", 0, 22], ["infection", "PROBLEM", 101, 110], ["infection", "OBSERVATION", 101, 110]]], ["Influenza virus preparation was titered by plaque assay.3T3-DCSIGN cells were obtained from the NIAID AIDS Research and Reference ReagentProgram.", [["plaque", "ANATOMY", 43, 49], ["3T3-DCSIGN cells", "ANATOMY", 56, 72], ["AIDS", "DISEASE", 102, 106], ["Influenza virus", "ORGANISM", 0, 15], ["3T3-DCSIGN cells", "CELL", 56, 72], ["3T3", "CELL_LINE", 56, 59], ["DCSIGN cells", "CELL_LINE", 60, 72], ["Influenza virus", "SPECIES", 0, 15], ["Influenza virus", "SPECIES", 0, 15], ["Influenza virus preparation", "TREATMENT", 0, 27], ["3T3-DCSIGN cells", "TEST", 56, 72]]], ["NIH3T3, CRFK, Vero E6, and BHK-21 cells were purchased from ATCC.", [["NIH3T3", "ANATOMY", 0, 6], ["Vero", "ANATOMY", 14, 18], ["BHK-21 cells", "ANATOMY", 27, 39], ["ATCC", "ANATOMY", 60, 64], ["NIH3T3", "CELL", 0, 6], ["CRFK", "GENE_OR_GENE_PRODUCT", 8, 12], ["Vero E6", "CELL", 14, 21], ["BHK-21 cells", "CELL", 27, 39], ["ATCC", "CELL", 60, 64], ["NIH3T3", "CELL_LINE", 0, 6], ["CRFK", "CELL_LINE", 8, 12], ["Vero E6", "CELL_LINE", 14, 21], ["BHK-21 cells", "CELL_LINE", 27, 39], ["ATCC", "SPECIES", 60, 64], ["NIH3T3", "TEST", 0, 6], ["CRFK", "TEST", 8, 12], ["Vero E6", "TEST", 14, 21], ["BHK", "TEST", 27, 30]]], ["3T3-fAPN, CRFK-fAPN, and CRFK-DCSIGN cells were kindly provided by Dr. Andrew D. Reagan, Cornell University.", [["3T3-fAPN", "ANATOMY", 0, 8], ["CRFK-DCSIGN cells", "ANATOMY", 25, 42], ["3T3-fAPN", "CELL", 0, 8], ["CRFK-fAPN", "GENE_OR_GENE_PRODUCT", 10, 19], ["CRFK-DCSIGN cells", "CELL", 25, 42], ["3T3", "CELL_LINE", 0, 3], ["fAPN", "CELL_LINE", 4, 8], ["CRFK", "CELL_LINE", 10, 14], ["fAPN", "CELL_LINE", 15, 19], ["CRFK-DCSIGN cells", "CELL_LINE", 25, 42], ["3T3", "TEST", 0, 3], ["CRFK", "TEST", 10, 14], ["fAPN", "PROBLEM", 15, 19], ["CRFK", "PROBLEM", 25, 29], ["DCSIGN cells", "PROBLEM", 30, 42]]], ["3T3, CRFK, Vero E6, and BHK-21 cells were grown in DMEM supplemented with 10% fetal bovine serum and 1% Penicillin/Streptomycin (Pen/Strep).", [["3T3", "ANATOMY", 0, 3], ["Vero", "ANATOMY", 11, 15], ["BHK-21 cells", "ANATOMY", 24, 36], ["fetal bovine serum", "ANATOMY", 78, 96], ["Penicillin", "CHEMICAL", 104, 114], ["Streptomycin", "CHEMICAL", 115, 127], ["Penicillin", "CHEMICAL", 104, 114], ["Streptomycin", "CHEMICAL", 115, 127], ["3T3", "CELL", 0, 3], ["CRFK", "CELL", 5, 9], ["Vero E6", "CELL", 11, 18], ["BHK-21 cells", "CELL", 24, 36], ["bovine", "ORGANISM", 84, 90], ["serum", "ORGANISM_SUBSTANCE", 91, 96], ["Penicillin", "SIMPLE_CHEMICAL", 104, 114], ["Streptomycin", "SIMPLE_CHEMICAL", 115, 127], ["3T3", "CELL_LINE", 0, 3], ["CRFK", "CELL_LINE", 5, 9], ["Vero E6", "CELL_LINE", 11, 18], ["BHK-21 cells", "CELL_LINE", 24, 36], ["bovine", "SPECIES", 84, 90], ["bovine", "SPECIES", 84, 90], ["3T3", "TEST", 0, 3], ["CRFK", "TEST", 5, 9], ["Vero E6", "TEST", 11, 18], ["BHK", "TEST", 24, 27], ["DMEM", "TEST", 51, 55], ["fetal bovine serum", "TEST", 78, 96], ["Penicillin", "TREATMENT", 104, 114], ["Streptomycin", "TREATMENT", 115, 127], ["Strep", "PROBLEM", 133, 138]]], ["The stable cell lines were grown in DMEM supplemented with 10% fetal bovine serum, 1% Penicillin/Streptomycin, and 400 \u03bcg/ml G418.", [["cell lines", "ANATOMY", 11, 21], ["fetal bovine serum", "ANATOMY", 63, 81], ["Penicillin", "CHEMICAL", 86, 96], ["Streptomycin", "CHEMICAL", 97, 109], ["G418", "CHEMICAL", 125, 129], ["Penicillin", "CHEMICAL", 86, 96], ["Streptomycin", "CHEMICAL", 97, 109], ["G418", "CHEMICAL", 125, 129], ["cell lines", "CELL", 11, 21], ["bovine", "ORGANISM", 69, 75], ["serum", "ORGANISM_SUBSTANCE", 76, 81], ["Penicillin", "SIMPLE_CHEMICAL", 86, 96], ["Streptomycin", "SIMPLE_CHEMICAL", 97, 109], ["stable cell lines", "CELL_LINE", 4, 21], ["bovine", "SPECIES", 69, 75], ["bovine", "SPECIES", 69, 75], ["The stable cell lines", "TREATMENT", 0, 21], ["10% fetal bovine serum", "TREATMENT", 59, 81], ["Penicillin", "TREATMENT", 86, 96], ["Streptomycin", "TREATMENT", 97, 109], ["stable", "OBSERVATION_MODIFIER", 4, 10], ["cell lines", "OBSERVATION", 11, 21]]], ["Chicken embryonic kidney cells were purchased from Charles River Laboratories and were cultured in basal media (Invitrogen) supplemented with 10% calf serum and 1% Pen/Strep.", [["embryonic kidney cells", "ANATOMY", 8, 30], ["serum", "ANATOMY", 151, 156], ["Chicken", "ORGANISM", 0, 7], ["embryonic kidney cells", "CELL", 8, 30], ["calf", "ORGANISM", 146, 150], ["serum", "ORGANISM_SUBSTANCE", 151, 156], ["Chicken embryonic kidney cells", "CELL_TYPE", 0, 30], ["Chicken", "SPECIES", 0, 7], ["calf", "SPECIES", 146, 150], ["Chicken", "SPECIES", 0, 7], ["Chicken embryonic kidney cells", "PROBLEM", 0, 30], ["calf serum", "TEST", 146, 156], ["Strep", "PROBLEM", 168, 173], ["embryonic kidney cells", "OBSERVATION", 8, 30], ["Strep", "OBSERVATION", 168, 173]]], ["Plasmids of hDC-SIGN and hL-SIGN were obtained from the NIAID AIDS Research and Reference Reagent Program.", [["AIDS", "DISEASE", 62, 66], ["hDC-SIGN", "GENE_OR_GENE_PRODUCT", 12, 20], ["hL-SIGN", "GENE_OR_GENE_PRODUCT", 25, 32], ["hDC", "DNA", 12, 15], ["SIGN", "DNA", 16, 20], ["hL", "DNA", 25, 27], ["SIGN", "DNA", 28, 32], ["hDC", "TEST", 12, 15]]], ["For transfection assays, 250 ng of plasmid DNA were mixed with 0.75\u03bcl of Lipofectamine 2000 (Invitrogen) in 50 \u03bcl of Opti-MEM (Gibco) at room temperature according to manufacturer's protocol.", [["plasmid", "ANATOMY", 35, 42], ["Lipofectamine", "CHEMICAL", 73, 86], ["DNA", "CELLULAR_COMPONENT", 43, 46], ["plasmid DNA", "DNA", 35, 46], ["transfection assays", "TEST", 4, 23], ["plasmid DNA", "TREATMENT", 35, 46], ["Lipofectamine", "TREATMENT", 73, 86], ["Opti-MEM", "TREATMENT", 117, 125], ["manufacturer's protocol", "TREATMENT", 167, 190]]], ["Cells seeded on glass cover slips were transfected at 37\u00b0C over night before viral infection.RT-PCR for viral infection detection10 6 3T3 or 3T3-DCSIGN cells were seeded onto 6 well plates and infected with different dilutions of allantoic fluid of IBV-M41.", [["Cells", "ANATOMY", 0, 5], ["detection10 6 3T3", "ANATOMY", 120, 137], ["3T3-DCSIGN cells", "ANATOMY", 141, 157], ["allantoic fluid", "ANATOMY", 230, 245], ["viral infection", "DISEASE", 77, 92], ["infection", "DISEASE", 110, 119], ["Cells", "CELL", 0, 5], ["C", "GENE_OR_GENE_PRODUCT", 57, 58], ["3T3-DCSIGN cells", "CELL", 141, 157], ["allantoic fluid", "ORGANISM_SUBSTANCE", 230, 245], ["IBV", "ORGANISM", 249, 252], ["3T3-DCSIGN cells", "CELL_LINE", 141, 157], ["IBV-M41", "SPECIES", 249, 256], ["glass cover slips", "TREATMENT", 16, 33], ["viral infection", "PROBLEM", 77, 92], ["RT-PCR", "TEST", 93, 99], ["viral infection detection10", "PROBLEM", 104, 131], ["3T3-DCSIGN cells", "TREATMENT", 141, 157], ["allantoic fluid of IBV", "TREATMENT", 230, 252], ["viral", "OBSERVATION_MODIFIER", 77, 82], ["infection", "OBSERVATION", 83, 92], ["infection", "OBSERVATION", 110, 119], ["infected", "OBSERVATION", 193, 201]]], ["Total RNA was extracted from IBV-M41 infected 3T3 or 3T3-DCSIGN cells 8 h post infection using a Qiagen RNeasy Mini Kit following manufacturer's protocols.", [["3T3", "ANATOMY", 46, 49], ["3T3-DCSIGN cells", "ANATOMY", 53, 69], ["infection", "DISEASE", 79, 88], ["IBV", "ORGANISM", 29, 32], ["-M41", "CELL", 32, 36], ["3T3", "CELL", 46, 49], ["3T3-DCSIGN cells", "CELL", 53, 69], ["IBV-M41 infected 3T3 or 3T3-DCSIGN cells", "CELL_LINE", 29, 69], ["IBV-M41", "SPECIES", 29, 36], ["Total RNA", "TEST", 0, 9], ["IBV", "TEST", 29, 32], ["DCSIGN cells", "PROBLEM", 57, 69], ["infection", "PROBLEM", 79, 88], ["a Qiagen RNeasy Mini Kit", "TREATMENT", 95, 119], ["manufacturer's protocols", "TREATMENT", 130, 154], ["infection", "OBSERVATION", 79, 88]]], ["Total RNA was reversed transcribed into cDNA by using SuperScript One-Step RT-PCR kit (Invitrogen).", [["cDNA", "DNA", 40, 44], ["Total RNA", "TREATMENT", 0, 9]]], ["Negative-strand RNA was reversed transcribed into cDNA using ThermoScript Reverse Transcriptase (Invitrogen) with antisense primer.", [["ThermoScript Reverse Transcriptase", "GENE_OR_GENE_PRODUCT", 61, 95], ["Invitrogen", "GENE_OR_GENE_PRODUCT", 97, 107], ["Negative-strand RNA", "RNA", 0, 19], ["cDNA", "DNA", 50, 54], ["ThermoScript Reverse Transcriptase", "PROTEIN", 61, 95], ["antisense primer", "DNA", 114, 130], ["strand RNA", "PROBLEM", 9, 19], ["ThermoScript Reverse Transcriptase (Invitrogen) with antisense primer", "TREATMENT", 61, 130], ["strand RNA", "OBSERVATION_MODIFIER", 9, 19]]], ["PCR reaction with High Fidelity Platinum Taq polymerase (Invitrogen) was conducted in a Bio-Rad DNA Engine Peltier Thermal Cycler with conditions of 1 cycle of 94\u00b0C for 2 minutes, 30 cycles at 94\u00b0C for 30 seconds, 48\u00b0C for 30 seconds, 72\u00b0C for 1 minute, and 1 cycle of 72\u00b0C for 5 minutes.", [["High Fidelity Platinum Taq polymerase", "PROTEIN", 18, 55], ["PCR reaction", "PROBLEM", 0, 12], ["High Fidelity Platinum Taq polymerase (Invitrogen)", "TREATMENT", 18, 68], ["Thermal Cycler", "TREATMENT", 115, 129], ["High Fidelity", "OBSERVATION_MODIFIER", 18, 31]]], ["Primers for detecting nucleocapsid protein (N) of IBV and host glyceraldehyde 3-phosphate dehydrogenase protein (GAPDH) were described by (Shen et al., 2010) .", [["glyceraldehyde 3-phosphate", "CHEMICAL", 63, 89], ["glyceraldehyde 3-phosphate", "CHEMICAL", 63, 89], ["nucleocapsid protein", "GENE_OR_GENE_PRODUCT", 22, 42], ["IBV", "ORGANISM", 50, 53], ["glyceraldehyde 3-phosphate dehydrogenase", "GENE_OR_GENE_PRODUCT", 63, 103], ["GAPDH", "GENE_OR_GENE_PRODUCT", 113, 118], ["nucleocapsid protein", "PROTEIN", 22, 42], ["N", "PROTEIN", 44, 45], ["IBV and host glyceraldehyde 3-phosphate dehydrogenase protein", "PROTEIN", 50, 111], ["GAPDH", "PROTEIN", 113, 118], ["IBV", "SPECIES", 50, 53], ["Primers", "TEST", 0, 7], ["nucleocapsid protein", "TEST", 22, 42], ["IBV", "TEST", 50, 53], ["host glyceraldehyde", "TEST", 58, 77], ["phosphate dehydrogenase protein (GAPDH)", "PROBLEM", 80, 119]]], ["10 \u03bcL of the PCR products were visualized on a 1% agarose gel.Virus infection and immunofluorescence assayVirus stocks were stored at \u221280\u00b0C, and for infection were diluted in RPMI 1680 medium containing 0.2% bovine serum albumin (Sigma) and adjusted pH to 6.8 with HEPES.", [["serum", "ANATOMY", 215, 220], ["Virus infection", "DISEASE", 62, 77], ["infection", "DISEASE", 149, 158], ["RPMI 1680", "CHEMICAL", 175, 184], ["HEPES", "CHEMICAL", 265, 270], ["agarose", "SIMPLE_CHEMICAL", 50, 57], ["Virus", "ORGANISM", 62, 67], ["bovine", "ORGANISM", 208, 214], ["serum", "ORGANISM_SUBSTANCE", 215, 220], ["albumin", "ORGANISM_SUBSTANCE", 221, 228], ["bovine", "SPECIES", 208, 214], ["bovine", "SPECIES", 208, 214], ["the PCR products", "TREATMENT", 9, 25], ["a 1% agarose gel", "TREATMENT", 45, 61], ["Virus infection", "PROBLEM", 62, 77], ["immunofluorescence assayVirus stocks", "PROBLEM", 82, 118], ["infection", "PROBLEM", 149, 158], ["bovine serum albumin", "TEST", 208, 228], ["adjusted pH", "TEST", 241, 252], ["HEPES", "TEST", 265, 270], ["infection", "OBSERVATION", 68, 77]]], ["Cells were infected for 1 h at 37\u00b0C without CO 2 on a rocking platform, and then were washed 3 times with PBS before incubating in 2% FBS/DMEM/1%Pen/Strep incubation medium.", [["Cells", "ANATOMY", 0, 5], ["CO 2", "CHEMICAL", 44, 48], ["Cells", "CELL", 0, 5], ["FBS", "ORGANISM_SUBSTANCE", 134, 137], ["a rocking platform", "TEST", 52, 70], ["PBS", "TREATMENT", 106, 109], ["DMEM", "TREATMENT", 138, 142], ["Strep incubation medium", "TREATMENT", 149, 172]]], ["For immunofluorescence assay, cells were seeded on glass cover slips for 24 h, infected or transfected and fixed with 100% methanol for detection of IBV viral antigens or 3% paraformaldehyde for other antigens.", [["cells", "ANATOMY", 30, 35], ["methanol", "CHEMICAL", 123, 131], ["methanol", "CHEMICAL", 123, 131], ["paraformaldehyde", "CHEMICAL", 174, 190], ["cells", "CELL", 30, 35], ["methanol", "SIMPLE_CHEMICAL", 123, 131], ["IBV", "ORGANISM", 149, 152], ["paraformaldehyde", "SIMPLE_CHEMICAL", 174, 190], ["IBV viral antigens", "PROTEIN", 149, 167], ["IBV", "SPECIES", 149, 152], ["immunofluorescence assay", "TEST", 4, 28], ["cells", "PROBLEM", 30, 35], ["IBV viral antigens", "PROBLEM", 149, 167], ["other antigens", "PROBLEM", 195, 209]]], ["For detection of IBV viral antigen, the anti-S1 monoclonal antibody 15:88 was used for IBV-M41.", [["IBV", "ORGANISM", 17, 20], ["IBV-M41", "ORGANISM", 87, 94], ["IBV viral antigen", "PROTEIN", 17, 34], ["anti-S1 monoclonal antibody 15:88", "PROTEIN", 40, 73], ["IBV", "SPECIES", 17, 20], ["IBV-M41", "SPECIES", 87, 94], ["IBV viral antigen", "TEST", 17, 34], ["the anti-S1 monoclonal antibody", "TEST", 36, 67], ["IBV", "TEST", 87, 90]]], ["The anti-M monoclonal antibody 9:19 was used for the panel of IBV isolates.", [["IBV", "ORGANISM", 62, 65], ["anti-M monoclonal antibody 9:19", "PROTEIN", 4, 35], ["IBV", "SPECIES", 62, 65], ["The anti-M monoclonal antibody", "TEST", 0, 30], ["the panel", "TEST", 49, 58], ["IBV isolates", "TREATMENT", 62, 74]]], ["The anti-NP monoclonal antibody H10, L16-4R5 was used for influenza infection detection (ATCC).", [["L16-4R5", "CHEMICAL", 37, 44], ["influenza infection", "DISEASE", 58, 77], ["L16-4R5", "CELL", 37, 44], ["anti-NP monoclonal antibody H10", "PROTEIN", 4, 35], ["L16", "PROTEIN", 37, 40], ["4R5", "PROTEIN", 41, 44], ["The anti-NP monoclonal antibody H10", "TEST", 0, 35], ["L16", "TEST", 37, 40], ["influenza infection detection", "PROBLEM", 58, 87]]], ["For detection of DC-SIGN, monoclonal antibody 14EG7 (NIAID AIDS Research and Reference Reagent Program) was used.", [["DC", "ANATOMY", 17, 19], ["AIDS", "DISEASE", 59, 63], ["DC", "CELL_TYPE", 17, 19], ["SIGN", "PROTEIN", 20, 24], ["monoclonal antibody 14EG7", "PROTEIN", 26, 51], ["DC", "TEST", 17, 19], ["monoclonal antibody", "TEST", 26, 45], ["Reference Reagent Program", "TREATMENT", 77, 102]]], ["The secondary antibodies AlexaFluor goat anti-mouse 488 or AlexaFluor goat anti-mouse 568 with isotype specificity against primary antibodies were purchased from Molecular Probes.", [["anti-mouse 568", "SIMPLE_CHEMICAL", 75, 89], ["secondary antibodies", "PROTEIN", 4, 24], ["AlexaFluor goat anti-mouse 488", "PROTEIN", 25, 55], ["AlexaFluor goat anti-mouse 568", "PROTEIN", 59, 89], ["primary antibodies", "PROTEIN", 123, 141], ["goat", "SPECIES", 36, 40], ["anti-mouse", "SPECIES", 41, 51], ["goat", "SPECIES", 70, 74], ["anti-mouse", "SPECIES", 75, 85], ["goat", "SPECIES", 36, 40], ["goat", "SPECIES", 70, 74], ["The secondary antibodies AlexaFluor goat anti-mouse", "TREATMENT", 0, 51], ["AlexaFluor goat anti-mouse", "TREATMENT", 59, 85], ["isotype specificity", "TEST", 95, 114], ["primary antibodies", "PROBLEM", 123, 141]]], ["Nuclei were stained with Hoechst 33258 (Molecular Probes).", [["Nuclei", "ANATOMY", 0, 6], ["Hoechst 33258", "CHEMICAL", 25, 38], ["Hoechst 33258", "CHEMICAL", 25, 38], ["Nuclei", "ORGANISM_SUBSTANCE", 0, 6], ["Hoechst 33258", "SIMPLE_CHEMICAL", 25, 38]]], ["Cover slips with cells were mounted on glass slides using Mowiol and were examined on a Nikon Eclipse E600 fluorescence microscope equipped with a SensiCam EM (Cooke Corp.).Treatment with mannan, DC-SIGN specific antibody, neuraminidase or sugarsCells were incubated with mannan at a concentration of 50\u03bcg/ml (Sigma), monoclonal antibody 9E9A8 specific for hDC-SIGN at 20mg/ml (NIAID AIDS Research and Reference Reagent Program), neuraminidase, or sugars in DMEM media for 1 h at 37\u00b0C before virus infection.", [["cells", "ANATOMY", 17, 22], ["Cells", "ANATOMY", 246, 251], ["sugars", "CHEMICAL", 240, 246], ["mannan", "CHEMICAL", 272, 278], ["hDC-SIGN", "CHEMICAL", 357, 365], ["AIDS", "DISEASE", 384, 388], ["infection", "DISEASE", 498, 507], ["sugars", "CHEMICAL", 240, 246], ["sugars", "CHEMICAL", 448, 454], ["cells", "CELL", 17, 22], ["Mowiol", "SIMPLE_CHEMICAL", 58, 64], ["mannan", "SIMPLE_CHEMICAL", 188, 194], ["DC-SIGN", "SIMPLE_CHEMICAL", 196, 203], ["neuraminidase", "SIMPLE_CHEMICAL", 223, 236], ["sugars", "SIMPLE_CHEMICAL", 240, 246], ["Cells", "CELL", 246, 251], ["mannan", "SIMPLE_CHEMICAL", 272, 278], ["hDC-SIGN", "SIMPLE_CHEMICAL", 357, 365], ["neuraminidase", "SIMPLE_CHEMICAL", 430, 443], ["sugars", "SIMPLE_CHEMICAL", 448, 454], ["C", "GENE_OR_GENE_PRODUCT", 483, 484], ["mannan, DC-SIGN specific antibody", "PROTEIN", 188, 221], ["neuraminidase", "PROTEIN", 223, 236], ["monoclonal antibody 9E9A8", "PROTEIN", 318, 343], ["hDC", "PROTEIN", 357, 360], ["mannan", "TREATMENT", 188, 194], ["neuraminidase", "TREATMENT", 223, 236], ["sugars", "TEST", 240, 246], ["mannan", "TREATMENT", 272, 278], ["monoclonal antibody", "TEST", 318, 337], ["hDC", "TEST", 357, 360], ["neuraminidase", "TREATMENT", 430, 443], ["virus infection", "PROBLEM", 492, 507], ["virus", "OBSERVATION_MODIFIER", 492, 497], ["infection", "OBSERVATION", 498, 507]]], ["Both mannose and galactose were purchased from Sigma and were used at a concentration of 0.01M.ResultsTo determine a role for C-type lectins in the entry of IBV into host cells, we transiently expressed either DC-SIGN or L-SIGN in cell lines that are known to be refractory to infection by clinical strains of IBV, such as M41, and examined these cells for virus infection.", [["cells", "ANATOMY", 171, 176], ["DC", "ANATOMY", 210, 212], ["cell lines", "ANATOMY", 231, 241], ["cells", "ANATOMY", 347, 352], ["mannose", "CHEMICAL", 5, 12], ["galactose", "CHEMICAL", 17, 26], ["L-", "CHEMICAL", 221, 223], ["infection", "DISEASE", 277, 286], ["infection", "DISEASE", 363, 372], ["mannose", "CHEMICAL", 5, 12], ["galactose", "CHEMICAL", 17, 26], ["mannose", "SIMPLE_CHEMICAL", 5, 12], ["galactose", "SIMPLE_CHEMICAL", 17, 26], ["C-type lectins", "GENE_OR_GENE_PRODUCT", 126, 140], ["IBV", "ORGANISM", 157, 160], ["host cells", "CELL", 166, 176], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 210, 217], ["L-SIGN", "GENE_OR_GENE_PRODUCT", 221, 227], ["cell lines", "CELL", 231, 241], ["IBV", "ORGANISM", 310, 313], ["cells", "CELL", 347, 352], ["C-type lectins", "PROTEIN", 126, 140], ["host cells", "CELL_TYPE", 166, 176], ["DC", "CELL_TYPE", 210, 212], ["SIGN", "PROTEIN", 213, 217], ["L-SIGN", "PROTEIN", 221, 227], ["cell lines", "CELL_LINE", 231, 241], ["IBV", "SPECIES", 157, 160], ["IBV", "SPECIES", 310, 313], ["galactose", "TREATMENT", 17, 26], ["C-type lectins", "TREATMENT", 126, 140], ["L-SIGN in cell lines", "PROBLEM", 221, 241], ["infection", "PROBLEM", 277, 286], ["IBV", "PROBLEM", 310, 313], ["virus infection", "PROBLEM", 357, 372], ["mannose", "ANATOMY_MODIFIER", 5, 12], ["cell lines", "OBSERVATION", 231, 241], ["infection", "OBSERVATION", 277, 286]]], ["Fig. 1 shows 3T3 (A) or CRFK cells (B) transfected with plasmids expressing DC-SIGN or L-SIGN, or with a control plasmid, and then infected with IBV M41.", [["3T3", "ANATOMY", 13, 16], ["CRFK cells", "ANATOMY", 24, 34], ["B", "ANATOMY", 36, 37], ["plasmids", "ANATOMY", 56, 64], ["DC", "ANATOMY", 76, 78], ["plasmid", "ANATOMY", 113, 120], ["3T3", "CELL", 13, 16], ["A", "CELL", 18, 19], ["CRFK cells", "CELL", 24, 34], ["B", "CELL", 36, 37], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 76, 83], ["L-SIGN", "GENE_OR_GENE_PRODUCT", 87, 93], ["IBV", "ORGANISM", 145, 148], ["M41", "ORGANISM", 149, 152], ["3T3", "CELL_LINE", 13, 16], ["CRFK cells", "CELL_LINE", 24, 34], ["plasmids", "DNA", 56, 64], ["DC", "CELL_TYPE", 76, 78], ["SIGN", "DNA", 79, 83], ["L", "DNA", 87, 88], ["SIGN", "DNA", 89, 93], ["control plasmid", "DNA", 105, 120], ["IBV M41", "SPECIES", 145, 152], ["CRFK cells", "PROBLEM", 24, 34], ["plasmids", "TREATMENT", 56, 64], ["a control plasmid", "TREATMENT", 103, 120], ["IBV M41", "TREATMENT", 145, 152]]], ["Cells expressing DC-SIGN or L-SIGN were identified with anti-lectin antibodies.", [["Cells", "ANATOMY", 0, 5], ["DC", "ANATOMY", 17, 19], ["Cells", "CELL", 0, 5], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 17, 24], ["L-SIGN", "GENE_OR_GENE_PRODUCT", 28, 34], ["anti-lectin antibodies", "GENE_OR_GENE_PRODUCT", 56, 78], ["DC", "CELL_TYPE", 17, 19], ["SIGN", "PROTEIN", 20, 24], ["L", "PROTEIN", 28, 29], ["SIGN", "PROTEIN", 30, 34], ["anti-lectin antibodies", "PROTEIN", 56, 78], ["anti-lectin antibodies", "PROBLEM", 56, 78]]], ["In the absence of lectin expression, we observed no infection with IBV M41.", [["infection", "DISEASE", 52, 61], ["lectin", "GENE_OR_GENE_PRODUCT", 18, 24], ["IBV", "ORGANISM", 67, 70], ["lectin", "PROTEIN", 18, 24], ["IBV M41", "SPECIES", 67, 74], ["infection", "PROBLEM", 52, 61], ["IBV M41", "TREATMENT", 67, 74], ["lectin expression", "OBSERVATION", 18, 35], ["no", "UNCERTAINTY", 49, 51], ["infection", "OBSERVATION", 52, 61]]], ["However, in the presence of DC-SIGN or L-SIGN expression, there was a strong correlation of IBV M41 infection in lectin-expressing cells.", [["DC", "ANATOMY", 28, 30], ["cells", "ANATOMY", 131, 136], ["infection", "DISEASE", 100, 109], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 28, 35], ["L-SIGN", "GENE_OR_GENE_PRODUCT", 39, 45], ["IBV", "ORGANISM", 92, 95], ["M41", "GENE_OR_GENE_PRODUCT", 96, 99], ["lectin", "GENE_OR_GENE_PRODUCT", 113, 119], ["cells", "CELL", 131, 136], ["DC", "CELL_TYPE", 28, 30], ["SIGN", "PROTEIN", 41, 45], ["lectin", "PROTEIN", 113, 119], ["expressing cells", "CELL_TYPE", 120, 136], ["IBV M41", "SPECIES", 92, 99], ["L-SIGN expression", "PROBLEM", 39, 56], ["IBV M41 infection", "PROBLEM", 92, 109], ["infection", "OBSERVATION", 100, 109], ["expressing cells", "OBSERVATION", 120, 136]]], ["Fig. 2 shows a quantification of the rescue of IBV infection, in this case using 3T3 and CRFK cells lines stably expressing DC-SIGN, as well as 3T3 and CRFK cells expressing feline aminopeptidase N (fAPN)-which has been previously proposed to be a receptor for IBV.", [["3T3", "ANATOMY", 81, 84], ["CRFK cells lines", "ANATOMY", 89, 105], ["DC-SIGN", "ANATOMY", 124, 131], ["3T3", "ANATOMY", 144, 147], ["CRFK cells", "ANATOMY", 152, 162], ["IBV infection", "DISEASE", 47, 60], ["IBV", "ORGANISM", 47, 50], ["3T3", "CELL", 81, 84], ["CRFK cells lines", "CELL", 89, 105], ["DC-SIGN", "CELL", 124, 131], ["3T3", "CELL", 144, 147], ["CRFK cells", "CELL", 152, 162], ["feline aminopeptidase N", "GENE_OR_GENE_PRODUCT", 174, 197], ["fAPN", "GENE_OR_GENE_PRODUCT", 199, 203], ["IBV", "ORGANISM", 261, 264], ["3T3", "CELL_LINE", 81, 84], ["CRFK cells lines", "CELL_LINE", 89, 105], ["DC", "CELL_TYPE", 124, 126], ["SIGN", "CELL_LINE", 127, 131], ["3T3", "CELL_LINE", 144, 147], ["CRFK cells", "CELL_LINE", 152, 162], ["feline aminopeptidase N", "PROTEIN", 174, 197], ["fAPN", "PROTEIN", 199, 203], ["IBV", "SPECIES", 47, 50], ["IBV", "SPECIES", 261, 264], ["IBV infection", "PROBLEM", 47, 60], ["3T3 and CRFK cells lines", "TREATMENT", 81, 105], ["feline aminopeptidase N (fAPN)", "PROBLEM", 174, 204], ["IBV", "PROBLEM", 261, 264], ["IBV", "OBSERVATION_MODIFIER", 47, 50], ["infection", "OBSERVATION", 51, 60]]], ["Both 3T3 and CRFK cells expressing DC-SIGN were efficiently infected with IBV M41, whereas there was no apparent rescue of infection in 3T3 or CRFK cells expressing fAPN.", [["3T3", "ANATOMY", 5, 8], ["CRFK cells", "ANATOMY", 13, 23], ["DC-SIGN", "ANATOMY", 35, 42], ["3T3", "ANATOMY", 136, 139], ["CRFK cells", "ANATOMY", 143, 153], ["infection", "DISEASE", 123, 132], ["3T3", "CELL", 5, 8], ["CRFK cells", "CELL", 13, 23], ["DC-SIGN", "CELL", 35, 42], ["IBV M41", "ORGANISM", 74, 81], ["3T3", "CELL", 136, 139], ["CRFK cells", "CELL", 143, 153], ["fAPN", "GENE_OR_GENE_PRODUCT", 165, 169], ["3T3", "CELL_LINE", 5, 8], ["CRFK cells", "CELL_LINE", 13, 23], ["DC", "CELL_TYPE", 35, 37], ["SIGN", "PROTEIN", 38, 42], ["3T3", "CELL_LINE", 136, 139], ["CRFK cells", "CELL_LINE", 143, 153], ["fAPN", "PROTEIN", 165, 169], ["IBV", "SPECIES", 74, 77], ["3T3", "SPECIES", 136, 139], ["IBV M41", "TREATMENT", 74, 81], ["infection in 3T3", "PROBLEM", 123, 139], ["CRFK cells", "PROBLEM", 143, 153], ["3T3", "ANATOMY", 5, 8], ["no apparent", "UNCERTAINTY", 101, 112], ["infection", "OBSERVATION", 123, 132]]], ["Overall, these data strongly suggest that over expression of the Ctype lectins L-SIGN or DC-SIGN can act as part of an IBV receptor complex and allow infection of 3T3 or CRFK cells that are otherwise resistant to IBV infection, and further support the idea that fAPN is not a functional receptor for IBV.ResultsTo further examine the role of C-type lectins for IBV entry, we treated DC-SIGN-expressing cells with either mannan or anti-DC-SIGN antibodies, and then infected the cells with IBV M41.", [["3T3", "ANATOMY", 163, 166], ["CRFK cells", "ANATOMY", 170, 180], ["DC-SIGN-expressing cells", "ANATOMY", 383, 407], ["cells", "ANATOMY", 477, 482], ["infection", "DISEASE", 150, 159], ["IBV infection", "DISEASE", 213, 226], ["L-SIGN", "GENE_OR_GENE_PRODUCT", 79, 85], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 89, 96], ["3T3", "CELL", 163, 166], ["CRFK cells", "CELL", 170, 180], ["IBV", "ORGANISM", 213, 216], ["fAPN", "GENE_OR_GENE_PRODUCT", 262, 266], ["IBV", "ORGANISM", 300, 303], ["C-type lectins", "GENE_OR_GENE_PRODUCT", 342, 356], ["IBV", "ORGANISM", 361, 364], ["DC-SIGN", "CELL", 383, 390], ["cells", "CELL", 402, 407], ["mannan", "SIMPLE_CHEMICAL", 420, 426], ["anti-DC-SIGN antibodies", "GENE_OR_GENE_PRODUCT", 430, 453], ["cells", "CELL", 477, 482], ["IBV", "ORGANISM", 488, 491], ["Ctype lectins L", "PROTEIN", 65, 80], ["SIGN", "PROTEIN", 81, 85], ["DC", "CELL_TYPE", 89, 91], ["SIGN", "PROTEIN", 92, 96], ["IBV receptor complex", "PROTEIN", 119, 139], ["3T3", "CELL_LINE", 163, 166], ["CRFK cells", "CELL_LINE", 170, 180], ["fAPN", "PROTEIN", 262, 266], ["C-type lectins", "PROTEIN", 342, 356], ["DC", "CELL_TYPE", 383, 385], ["SIGN-expressing cells", "CELL_LINE", 386, 407], ["mannan", "PROTEIN", 420, 426], ["anti-DC", "PROTEIN", 430, 437], ["SIGN antibodies", "PROTEIN", 438, 453], ["IBV", "SPECIES", 119, 122], ["IBV", "SPECIES", 213, 216], ["IBV", "SPECIES", 300, 303], ["IBV", "SPECIES", 361, 364], ["IBV M41", "SPECIES", 488, 495], ["the Ctype lectins", "TEST", 61, 78], ["an IBV receptor complex", "PROBLEM", 116, 139], ["infection of 3T3", "PROBLEM", 150, 166], ["CRFK cells", "PROBLEM", 170, 180], ["IBV infection", "PROBLEM", 213, 226], ["IBV", "PROBLEM", 300, 303], ["expressing cells", "PROBLEM", 391, 407], ["mannan", "TEST", 420, 426], ["SIGN antibodies", "PROBLEM", 438, 453], ["IBV M41", "TREATMENT", 488, 495], ["infection", "OBSERVATION", 217, 226]]], ["Mannan is a polymer of mannose that is well recognized to compete with mannosecontaining carbohydrates on glycoproteins and block interactions of viruses with C-type lectins.", [["Mannan", "CHEMICAL", 0, 6], ["mannose", "CHEMICAL", 23, 30], ["Mannan", "CHEMICAL", 0, 6], ["mannose", "CHEMICAL", 23, 30], ["carbohydrates", "CHEMICAL", 89, 102], ["Mannan", "SIMPLE_CHEMICAL", 0, 6], ["mannose", "SIMPLE_CHEMICAL", 23, 30], ["C-type lectins", "GENE_OR_GENE_PRODUCT", 159, 173], ["glycoproteins", "PROTEIN", 106, 119], ["C-type lectins", "PROTEIN", 159, 173], ["a polymer of mannose", "TREATMENT", 10, 30], ["glycoproteins", "TREATMENT", 106, 119], ["block interactions of viruses", "PROBLEM", 124, 153], ["C-type lectins", "PROBLEM", 159, 173]]], ["Both mannan and anti-DC-SIGN antibodies inhibited infection by IBV M41 (Fig. 3) , further supporting a specific role for DC-SIGN as part of the IBV receptor complex, and indicating that the interactions are mediated through mannose-containing carbohydrate residues present on the viral spike protein.", [["DC", "ANATOMY", 121, 123], ["infection", "DISEASE", 50, 59], ["mannose", "CHEMICAL", 224, 231], ["carbohydrate", "CHEMICAL", 243, 255], ["mannan", "SIMPLE_CHEMICAL", 5, 11], ["anti-DC-SIGN", "SIMPLE_CHEMICAL", 16, 28], ["IBV M41", "ORGANISM", 63, 70], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 121, 128], ["IBV", "ORGANISM", 144, 147], ["mannose", "SIMPLE_CHEMICAL", 224, 231], ["mannan and anti-DC-SIGN antibodies", "PROTEIN", 5, 39], ["DC", "CELL_TYPE", 121, 123], ["SIGN", "PROTEIN", 124, 128], ["IBV receptor complex", "PROTEIN", 144, 164], ["viral spike protein", "PROTEIN", 280, 299], ["IBV M41", "SPECIES", 63, 70], ["IBV", "SPECIES", 144, 147], ["Both mannan", "TREATMENT", 0, 11], ["SIGN antibodies inhibited infection", "PROBLEM", 24, 59], ["mannose", "TREATMENT", 224, 231], ["carbohydrate residues", "TREATMENT", 243, 264], ["the viral spike protein", "PROBLEM", 276, 299]]], ["In addition, infection was inhibited by the Ca 2+sequestering agent EGTA (data not shown), further indicating a specific role for C-type lectins, which are known to be Ca 2+ -dependent for their function.ResultsTo confirm that DC-SIGN-mediated entry of IBV M41 into cells allowed complete genome replication, we extracted total RNA from either 3T3 or 3T3-DC-SIGN cells infected with IBV M41 (Fig. 4) .", [["DC", "ANATOMY", 227, 229], ["cells", "ANATOMY", 266, 271], ["3T3", "ANATOMY", 344, 347], ["3T3-DC-SIGN cells", "ANATOMY", 351, 368], ["infection", "DISEASE", 13, 22], ["Ca", "CHEMICAL", 44, 46], ["EGTA", "CHEMICAL", 68, 72], ["Ca", "CHEMICAL", 168, 170], ["Ca 2+", "CHEMICAL", 44, 49], ["EGTA", "CHEMICAL", 68, 72], ["Ca 2+", "CHEMICAL", 168, 173], ["Ca 2+", "SIMPLE_CHEMICAL", 44, 49], ["EGTA", "SIMPLE_CHEMICAL", 68, 72], ["C-type lectins", "GENE_OR_GENE_PRODUCT", 130, 144], ["Ca 2+", "SIMPLE_CHEMICAL", 168, 173], ["SIGN", "GENE_OR_GENE_PRODUCT", 230, 234], ["IBV", "ORGANISM", 253, 256], ["M41", "CELL", 257, 260], ["cells", "CELL", 266, 271], ["3T3", "CELL", 344, 347], ["3T3-DC-SIGN cells", "CELL", 351, 368], ["IBV", "ORGANISM", 383, 386], ["C-type lectins", "PROTEIN", 130, 144], ["DC", "CELL_TYPE", 227, 229], ["SIGN", "PROTEIN", 230, 234], ["IBV M41", "DNA", 253, 260], ["3T3", "CELL_LINE", 344, 347], ["3T3-DC", "CELL_LINE", 351, 357], ["SIGN cells", "CELL_LINE", 358, 368], ["IBV", "SPECIES", 253, 256], ["IBV", "SPECIES", 383, 386], ["infection", "PROBLEM", 13, 22], ["the Ca", "TEST", 40, 46], ["C-type lectins", "PROBLEM", 130, 144], ["Ca", "TEST", 168, 170], ["IBV M41 into cells", "TREATMENT", 253, 271], ["complete genome replication", "TREATMENT", 280, 307], ["total RNA", "TEST", 322, 331], ["infection", "OBSERVATION", 13, 22]]], ["We then performed RT-PCR to detect the presence of both total and negative-sense viral RNA.", [["negative-sense viral RNA", "RNA", 66, 90], ["RT-PCR", "TEST", 18, 24], ["sense viral RNA", "PROBLEM", 75, 90], ["negative", "OBSERVATION", 66, 74], ["viral RNA", "OBSERVATION", 81, 90]]], ["In 3T3 cells, we could detect a low level of total viral RNA, but with no detectable negative-sense viral RNA.", [["3T3 cells", "ANATOMY", 3, 12], ["3T3 cells", "CELL", 3, 12], ["3T3 cells", "CELL_LINE", 3, 12], ["viral RNA", "RNA", 51, 60], ["viral RNA", "RNA", 100, 109], ["a low level of total viral RNA", "PROBLEM", 30, 60], ["sense viral RNA", "PROBLEM", 94, 109], ["3T3 cells", "OBSERVATION", 3, 12], ["low", "OBSERVATION_MODIFIER", 32, 35], ["viral RNA", "OBSERVATION", 51, 60], ["viral RNA", "OBSERVATION", 100, 109]]], ["This indicates that there was some of the original virus inoculum remaining in the sample, but that viral replication had not taken place.", [["sample", "ANATOMY", 83, 89], ["the original virus inoculum", "PROBLEM", 38, 65], ["viral replication", "PROBLEM", 100, 117], ["virus inoculum", "OBSERVATION", 51, 65], ["viral replication", "OBSERVATION", 100, 117]]], ["In contrast, 3T3-DC-SIGN cells showed a strong signal for both total and negativesense viral RNA confirming that DC-SIGN expression can rescue replication of IBV M41 in cells that are otherwise refractory to infection.ResultsSialic acid has been proposed to be part of the receptor complex for IBV M41 (Winter et al., 2006) , and so we examined whether there may be any interplay between sialic acid and Ctype lectins for entry of IBV M41 (Fig. 5) .", [["3T3-DC-SIGN cells", "ANATOMY", 13, 30], ["DC", "ANATOMY", 113, 115], ["cells", "ANATOMY", 169, 174], ["infection", "DISEASE", 208, 217], ["ResultsSialic acid", "CHEMICAL", 218, 236], ["sialic acid", "CHEMICAL", 388, 399], ["ResultsSialic acid", "CHEMICAL", 218, 236], ["sialic acid", "CHEMICAL", 388, 399], ["3T3-DC-SIGN cells", "CELL", 13, 30], ["negativesense", "GENE_OR_GENE_PRODUCT", 73, 86], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 113, 120], ["IBV M41", "ORGANISM", 158, 165], ["cells", "CELL", 169, 174], ["ResultsSialic acid", "SIMPLE_CHEMICAL", 218, 236], ["IBV M41", "ORGANISM", 294, 301], ["sialic acid", "SIMPLE_CHEMICAL", 388, 399], ["Ctype lectins", "GENE_OR_GENE_PRODUCT", 404, 417], ["IBV M41", "ORGANISM", 431, 438], ["Fig. 5", "ORGANISM", 440, 446], ["3T3-DC", "CELL_LINE", 13, 19], ["SIGN cells", "CELL_LINE", 20, 30], ["negativesense viral RNA", "RNA", 73, 96], ["DC", "CELL_TYPE", 113, 115], ["SIGN", "PROTEIN", 116, 120], ["receptor complex", "PROTEIN", 273, 289], ["Ctype lectins", "PROTEIN", 404, 417], ["IBV M41", "SPECIES", 158, 165], ["IBV", "SPECIES", 294, 297], ["IBV M41", "SPECIES", 431, 438], ["negativesense viral RNA", "PROBLEM", 73, 96], ["IBV M41 in cells", "TREATMENT", 158, 174], ["infection", "PROBLEM", 208, 217], ["sialic acid and Ctype lectins", "TREATMENT", 388, 417], ["IBV M41", "TREATMENT", 431, 438], ["refractory", "OBSERVATION_MODIFIER", 194, 204], ["infection", "OBSERVATION", 208, 217]]], ["3T3-DC-SIGN cells were infected with IBV M41 in the presence of varying concentrations of neuraminidase, which would cleave sialic acids on the cell surface but not affect C-type lectin function.", [["3T3-DC-SIGN cells", "ANATOMY", 0, 17], ["cell surface", "ANATOMY", 144, 156], ["sialic acids", "CHEMICAL", 124, 136], ["sialic acids", "CHEMICAL", 124, 136], ["3T3-DC-SIGN cells", "CELL", 0, 17], ["IBV", "ORGANISM", 37, 40], ["neuraminidase", "GENE_OR_GENE_PRODUCT", 90, 103], ["sialic acids", "SIMPLE_CHEMICAL", 124, 136], ["cell surface", "CELLULAR_COMPONENT", 144, 156], ["C-type lectin", "GENE_OR_GENE_PRODUCT", 172, 185], ["3T3-DC", "CELL_LINE", 0, 6], ["SIGN cells", "CELL_LINE", 7, 17], ["neuraminidase", "PROTEIN", 90, 103], ["lectin", "PROTEIN", 179, 185], ["IBV", "SPECIES", 37, 40], ["SIGN cells", "PROBLEM", 7, 17], ["IBV M41", "TREATMENT", 37, 44], ["varying concentrations of neuraminidase", "PROBLEM", 64, 103], ["sialic acids", "TEST", 124, 136], ["the cell surface", "TEST", 140, 156], ["varying", "OBSERVATION_MODIFIER", 64, 71], ["concentrations", "OBSERVATION_MODIFIER", 72, 86], ["neuraminidase", "OBSERVATION", 90, 103]]], ["As a control we used influenza virus, which is well established to use sialic acid as a functional receptor.", [["influenza virus", "DISEASE", 21, 36], ["sialic acid", "CHEMICAL", 71, 82], ["sialic acid", "CHEMICAL", 71, 82], ["influenza virus", "ORGANISM", 21, 36], ["sialic acid", "SIMPLE_CHEMICAL", 71, 82], ["influenza virus", "SPECIES", 21, 36], ["influenza virus", "SPECIES", 21, 36], ["influenza virus", "PROBLEM", 21, 36], ["sialic acid", "TREATMENT", 71, 82], ["a functional receptor", "TREATMENT", 86, 107]]], ["As expected, influenza infection was strongly inhibited by neuraminidase treatment in a dose-dependent manner.", [["influenza infection", "DISEASE", 13, 32], ["neuraminidase", "SIMPLE_CHEMICAL", 59, 72], ["neuraminidase", "PROTEIN", 59, 72], ["influenza infection", "PROBLEM", 13, 32], ["neuraminidase treatment", "TREATMENT", 59, 82], ["influenza", "OBSERVATION_MODIFIER", 13, 22], ["infection", "OBSERVATION", 23, 32]]], ["In contrast, there was no overall effect of neuraminidase treatment on IBV M41 infection.", [["infection", "DISEASE", 79, 88], ["neuraminidase", "SIMPLE_CHEMICAL", 44, 57], ["IBV", "ORGANISM", 71, 74], ["M41", "ORGANISM", 75, 78], ["neuraminidase", "PROTEIN", 44, 57], ["IBV M41", "SPECIES", 71, 78], ["neuraminidase treatment", "TREATMENT", 44, 67], ["IBV M41 infection", "PROBLEM", 71, 88], ["no", "UNCERTAINTY", 23, 25], ["infection", "OBSERVATION", 79, 88]]], ["These data indicate that there is no functional interplay between sialic acid and Ctype lectins as part of the IBV receptor complex, and that C-type lectin-mediated interactions dominate over sialic acid-mediated interactions for IBV M41 infection.ResultsIBV exists in several serotypes, which are antigenically distinct and so may differ in their receptor requirements.", [["sialic acid", "CHEMICAL", 66, 77], ["infection", "DISEASE", 238, 247], ["sialic acid", "CHEMICAL", 66, 77], ["sialic acid-mediated", "CHEMICAL", 192, 212], ["sialic acid", "SIMPLE_CHEMICAL", 66, 77], ["Ctype lectins", "GENE_OR_GENE_PRODUCT", 82, 95], ["C-type lectin", "GENE_OR_GENE_PRODUCT", 142, 155], ["sialic acid-mediated", "SIMPLE_CHEMICAL", 192, 212], ["IBV M41", "ORGANISM", 230, 237], ["ResultsIBV", "GENE_OR_GENE_PRODUCT", 248, 258], ["sialic acid and Ctype lectins", "PROTEIN", 66, 95], ["IBV receptor complex", "PROTEIN", 111, 131], ["C-type lectin", "PROTEIN", 142, 155], ["ResultsIBV", "PROTEIN", 248, 258], ["IBV", "SPECIES", 111, 114], ["IBV M41", "SPECIES", 230, 237], ["sialic acid and Ctype lectins", "TREATMENT", 66, 95], ["C-type lectin", "PROBLEM", 142, 155], ["sialic acid-mediated interactions", "TREATMENT", 192, 225], ["IBV M41 infection", "PROBLEM", 230, 247], ["several serotypes", "PROBLEM", 269, 286], ["no", "UNCERTAINTY", 34, 36], ["infection", "OBSERVATION", 238, 247], ["several", "OBSERVATION_MODIFIER", 269, 276], ["serotypes", "OBSERVATION", 277, 286]]], ["To determine whether C-type lectins can promote entry of a range of different IBVs, we infected 3T3 (not shown) or 3T3-DC-SIGN cells (Fig. 6) with the IBV strains Cal99, Conn46, Iowa609, Gray, Iowa97 and JMK, which cover the major virus serotypes.", [["IBVs", "ANATOMY", 78, 82], ["3T3", "ANATOMY", 96, 99], ["3T3-DC-SIGN cells", "ANATOMY", 115, 132], ["C-type lectins", "GENE_OR_GENE_PRODUCT", 21, 35], ["IBVs", "GENE_OR_GENE_PRODUCT", 78, 82], ["3T3", "CELL", 96, 99], ["3T3-DC-SIGN cells", "CELL", 115, 132], ["IBV", "ORGANISM", 151, 154], ["Cal99", "GENE_OR_GENE_PRODUCT", 163, 168], ["Conn46", "GENE_OR_GENE_PRODUCT", 170, 176], ["Iowa609", "GENE_OR_GENE_PRODUCT", 178, 185], ["Gray", "GENE_OR_GENE_PRODUCT", 187, 191], ["Iowa97", "GENE_OR_GENE_PRODUCT", 193, 199], ["JMK", "GENE_OR_GENE_PRODUCT", 204, 207], ["C-type lectins", "PROTEIN", 21, 35], ["3T3", "CELL_LINE", 96, 99], ["3T3-DC", "CELL_LINE", 115, 121], ["SIGN cells", "CELL_LINE", 122, 132], ["IBV", "SPECIES", 151, 154], ["C-type lectins", "PROBLEM", 21, 35], ["the IBV strains Cal99", "TEST", 147, 168], ["Gray", "TEST", 187, 191], ["JMK", "TEST", 204, 207], ["the major virus serotypes", "PROBLEM", 221, 246], ["virus serotypes", "OBSERVATION", 231, 246]]], ["In all cases we observed efficient infection of 3T3-DC-SIGN cells with the IBV strain used, confirming that C-type lectins such as DC-SIGN can promote entry of a wide range of distinct IBV strains.ResultsTo examine the role of C-type lectin in IBV infection in vivo, we used primary chicken kidney cells, a chicken cell type that is naturally susceptible to IBV infection.", [["3T3-DC-SIGN cells", "ANATOMY", 48, 65], ["kidney cells", "ANATOMY", 291, 303], ["cell", "ANATOMY", 315, 319], ["infection", "DISEASE", 35, 44], ["IBV infection", "DISEASE", 244, 257], ["IBV infection", "DISEASE", 358, 371], ["3T3-DC-SIGN cells", "CELL", 48, 65], ["IBV", "ORGANISM", 75, 78], ["C-type lectins", "GENE_OR_GENE_PRODUCT", 108, 122], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 131, 138], ["IBV", "ORGANISM", 185, 188], ["C-type lectin", "GENE_OR_GENE_PRODUCT", 227, 240], ["IBV", "ORGANISM", 244, 247], ["chicken", "ORGANISM", 283, 290], ["kidney cells", "CELL", 291, 303], ["chicken", "ORGANISM", 307, 314], ["cell type", "CELL", 315, 324], ["IBV", "ORGANISM", 358, 361], ["3T3-DC", "CELL_LINE", 48, 54], ["SIGN cells", "CELL_LINE", 55, 65], ["C-type lectins", "PROTEIN", 108, 122], ["DC", "CELL_TYPE", 131, 133], ["SIGN", "PROTEIN", 134, 138], ["C-type lectin", "PROTEIN", 227, 240], ["primary chicken kidney cells", "CELL_TYPE", 275, 303], ["chicken", "SPECIES", 283, 290], ["chicken", "SPECIES", 307, 314], ["IBV", "SPECIES", 75, 78], ["IBV", "SPECIES", 185, 188], ["IBV", "SPECIES", 244, 247], ["chicken", "SPECIES", 283, 290], ["chicken", "SPECIES", 307, 314], ["IBV", "SPECIES", 358, 361], ["efficient infection of 3T3", "PROBLEM", 25, 51], ["SIGN cells", "PROBLEM", 55, 65], ["the IBV strain", "PROBLEM", 71, 85], ["C-type lectins", "PROBLEM", 108, 122], ["distinct IBV strains", "PROBLEM", 176, 196], ["C-type lectin", "PROBLEM", 227, 240], ["IBV infection", "PROBLEM", 244, 257], ["primary chicken kidney cells", "TREATMENT", 275, 303], ["a chicken cell type", "TREATMENT", 305, 324], ["IBV infection", "PROBLEM", 358, 371], ["infection", "OBSERVATION", 35, 44], ["IBV strains", "OBSERVATION", 185, 196], ["infection", "OBSERVATION", 248, 257], ["kidney", "ANATOMY", 291, 297], ["cells", "OBSERVATION", 298, 303], ["chicken cell type", "OBSERVATION", 307, 324], ["IBV", "OBSERVATION_MODIFIER", 358, 361], ["infection", "OBSERVATION", 362, 371]]], ["While we were not able to inhibit the IBV-M41 strain infection in chicken kidney cells with mannan at 50 \u03bcg/ml concentration (data not shown), we observed notable reduction in infection with presence of 0.01M mannose, the sugar monomer enriched in mannan (Fig. 7) .", [["kidney cells", "ANATOMY", 74, 86], ["infection", "DISEASE", 53, 62], ["mannan", "CHEMICAL", 92, 98], ["infection", "DISEASE", 176, 185], ["mannose", "CHEMICAL", 209, 216], ["mannose", "CHEMICAL", 209, 216], ["sugar", "CHEMICAL", 222, 227], ["IBV-M41 strain", "ORGANISM", 38, 52], ["chicken", "ORGANISM", 66, 73], ["kidney cells", "CELL", 74, 86], ["mannan", "SIMPLE_CHEMICAL", 92, 98], ["mannose", "SIMPLE_CHEMICAL", 209, 216], ["sugar monomer", "SIMPLE_CHEMICAL", 222, 235], ["mannan", "SIMPLE_CHEMICAL", 248, 254], ["chicken kidney cells", "CELL_TYPE", 66, 86], ["mannan", "PROTEIN", 248, 254], ["chicken", "SPECIES", 66, 73], ["IBV-M41", "SPECIES", 38, 45], ["chicken", "SPECIES", 66, 73], ["strain infection in chicken kidney cells", "PROBLEM", 46, 86], ["mannan", "TREATMENT", 92, 98], ["notable reduction in infection", "PROBLEM", 155, 185], ["the sugar monomer", "TREATMENT", 218, 235], ["infection", "OBSERVATION", 53, 62], ["kidney", "ANATOMY", 74, 80], ["notable", "OBSERVATION_MODIFIER", 155, 162], ["reduction", "OBSERVATION_MODIFIER", 163, 172], ["infection", "OBSERVATION", 176, 185]]], ["As the control, galactose treatment at the same concentration did not render a similar decrease in infection.", [["galactose", "CHEMICAL", 16, 25], ["infection", "DISEASE", 99, 108], ["galactose", "CHEMICAL", 16, 25], ["galactose", "SIMPLE_CHEMICAL", 16, 25], ["galactose treatment", "TREATMENT", 16, 35], ["a similar decrease in infection", "PROBLEM", 77, 108], ["decrease", "OBSERVATION_MODIFIER", 87, 95], ["infection", "OBSERVATION", 99, 108]]], ["Our data suggest that there may be a role for a C-type mannose-binding lectin during IBV infection of the chicken host.DiscussionInfection of cells and cell lines in culture by field strains of the avian coronavirus infectious bronchitis virus (IBV) is typically restricted to primary chicken cells, such as chicken kidney (CK) cells.", [["cells", "ANATOMY", 142, 147], ["cell lines", "ANATOMY", 152, 162], ["cells", "ANATOMY", 293, 298], ["kidney (CK) cells", "ANATOMY", 316, 333], ["infection", "DISEASE", 89, 98], ["coronavirus infectious bronchitis", "DISEASE", 204, 237], ["mannose", "CHEMICAL", 55, 62], ["C-type mannose-binding lectin", "GENE_OR_GENE_PRODUCT", 48, 77], ["IBV", "ORGANISM", 85, 88], ["chicken", "ORGANISM", 106, 113], ["cells", "CELL", 142, 147], ["cell lines", "CELL", 152, 162], ["avian", "ORGANISM", 198, 203], ["coronavirus infectious bronchitis virus", "ORGANISM", 204, 243], ["IBV", "ORGANISM", 245, 248], ["chicken", "ORGANISM", 285, 292], ["cells", "CELL", 293, 298], ["chicken", "ORGANISM", 308, 315], ["kidney (CK) cells", "CELL", 316, 333], ["C-type mannose-binding lectin", "PROTEIN", 48, 77], ["cell lines", "CELL_LINE", 152, 162], ["primary chicken cells", "CELL_TYPE", 277, 298], ["chicken kidney (CK) cells", "CELL_TYPE", 308, 333], ["chicken", "SPECIES", 106, 113], ["avian coronavirus infectious bronchitis virus", "SPECIES", 198, 243], ["chicken", "SPECIES", 285, 292], ["chicken", "SPECIES", 308, 315], ["IBV", "SPECIES", 85, 88], ["chicken", "SPECIES", 106, 113], ["avian coronavirus infectious bronchitis virus", "SPECIES", 198, 243], ["IBV", "SPECIES", 245, 248], ["chicken", "SPECIES", 285, 292], ["chicken", "SPECIES", 308, 315], ["Our data", "TEST", 0, 8], ["a C-type mannose-binding lectin", "PROBLEM", 46, 77], ["IBV infection of the chicken host", "PROBLEM", 85, 118], ["cells", "PROBLEM", 142, 147], ["cell lines", "TREATMENT", 152, 162], ["culture", "TEST", 166, 173], ["the avian coronavirus infectious bronchitis virus", "PROBLEM", 194, 243], ["primary chicken cells", "PROBLEM", 277, 298], ["chicken kidney (CK) cells", "PROBLEM", 308, 333], ["infection", "OBSERVATION", 89, 98], ["cell lines", "OBSERVATION", 152, 162], ["chicken cells", "OBSERVATION", 285, 298], ["kidney", "ANATOMY", 316, 322]]], ["Here we show that two standard cell lines, mouse 3T3 and feline CRFK cells can be efficiently infected by the prototype IBV strain M41 when these cells lines express the Ctype lectins L-SIGN or DC-SIGN.", [["cell lines", "ANATOMY", 31, 41], ["3T3", "ANATOMY", 49, 52], ["CRFK cells", "ANATOMY", 64, 74], ["cells lines", "ANATOMY", 146, 157], ["cell lines", "CELL", 31, 41], ["mouse", "ORGANISM", 43, 48], ["3T3", "CELL", 49, 52], ["feline", "ORGANISM", 57, 63], ["CRFK cells", "CELL", 64, 74], ["IBV", "ORGANISM", 120, 123], ["M41", "CELL", 131, 134], ["cells lines", "CELL", 146, 157], ["L-SIGN", "GENE_OR_GENE_PRODUCT", 184, 190], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 194, 201], ["standard cell lines", "CELL_LINE", 22, 41], ["mouse 3T3", "CELL_LINE", 43, 52], ["feline CRFK cells", "CELL_LINE", 57, 74], ["Ctype lectins L", "PROTEIN", 170, 185], ["SIGN", "PROTEIN", 186, 190], ["DC", "CELL_TYPE", 194, 196], ["SIGN", "PROTEIN", 197, 201], ["mouse", "SPECIES", 43, 48], ["feline", "SPECIES", 57, 63], ["mouse", "SPECIES", 43, 48], ["IBV", "SPECIES", 120, 123], ["two standard cell lines", "TREATMENT", 18, 41], ["mouse 3T3", "TREATMENT", 43, 52], ["feline CRFK cells", "PROBLEM", 57, 74], ["the prototype IBV strain M41", "TREATMENT", 106, 134], ["these cells lines", "TREATMENT", 140, 157], ["cell lines", "OBSERVATION", 31, 41]]], ["Similar rescue of coronavirus infection has also been observed for a range of different coronaviruses, including SARS-CoV, HCoV-229E and feline coronaviruses (Jeffers et al., 2006; Jeffers et al., 2004; Regan and Whittaker, 2008) .", [["coronavirus infection", "DISEASE", 18, 39], ["feline coronaviruses", "DISEASE", 137, 157], ["coronavirus", "ORGANISM", 18, 29], ["coronaviruses", "ORGANISM", 88, 101], ["SARS-CoV", "ORGANISM", 113, 121], ["HCoV-229E", "ORGANISM", 123, 132], ["feline coronaviruses", "ORGANISM", 137, 157], ["feline", "SPECIES", 137, 143], ["SARS-CoV", "SPECIES", 113, 121], ["HCoV-229E", "SPECIES", 123, 132], ["feline coronaviruses", "SPECIES", 137, 157], ["coronavirus infection", "PROBLEM", 18, 39], ["different coronaviruses", "PROBLEM", 78, 101], ["SARS", "TEST", 113, 117], ["CoV", "TEST", 118, 121], ["HCoV", "TEST", 123, 127], ["coronavirus", "OBSERVATION_MODIFIER", 18, 29], ["infection", "OBSERVATION", 30, 39]]], ["While it is presently unclear whether L-SIGN and DC-SIGN act as coronavirus attachment factors or bone fide receptors, it is clear that the use of a C-type lectin during coronavirus entry can lead to a major shift in host cell tropism.", [["bone", "ANATOMY", 98, 102], ["cell", "ANATOMY", 222, 226], ["L-SIGN", "GENE_OR_GENE_PRODUCT", 38, 44], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 49, 56], ["coronavirus attachment factors", "GENE_OR_GENE_PRODUCT", 64, 94], ["bone", "TISSUE", 98, 102], ["C-type lectin", "GENE_OR_GENE_PRODUCT", 149, 162], ["coronavirus", "ORGANISM", 170, 181], ["host cell", "CELL", 217, 226], ["L-SIGN", "PROTEIN", 38, 44], ["DC", "CELL_TYPE", 49, 51], ["SIGN", "PROTEIN", 52, 56], ["coronavirus attachment factors", "PROTEIN", 64, 94], ["bone fide receptors", "PROTEIN", 98, 117], ["C-type lectin", "PROTEIN", 149, 162], ["coronavirus attachment factors", "PROBLEM", 64, 94], ["bone fide receptors", "PROBLEM", 98, 117], ["a C-type lectin", "PROBLEM", 147, 162], ["coronavirus entry", "PROBLEM", 170, 187], ["a major shift in host cell tropism", "PROBLEM", 200, 234], ["host cell tropism", "OBSERVATION", 217, 234]]], ["In the case of IBV, the data presented here show efficient infection of mouse or feline cells, and we expect that infection would not be limited to these cells, but would occur in many cell types.", [["cells", "ANATOMY", 88, 93], ["cells", "ANATOMY", 154, 159], ["cell", "ANATOMY", 185, 189], ["infection", "DISEASE", 59, 68], ["infection", "DISEASE", 114, 123], ["IBV", "ORGANISM", 15, 18], ["mouse", "ORGANISM", 72, 77], ["feline", "ORGANISM", 81, 87], ["cells", "CELL", 88, 93], ["cells", "CELL", 154, 159], ["cell", "CELL", 185, 189], ["mouse or feline cells", "CELL_TYPE", 72, 93], ["mouse", "SPECIES", 72, 77], ["feline", "SPECIES", 81, 87], ["IBV", "SPECIES", 15, 18], ["mouse", "SPECIES", 72, 77], ["IBV", "PROBLEM", 15, 18], ["the data", "TEST", 20, 28], ["efficient infection of mouse or feline cells", "PROBLEM", 49, 93], ["infection", "PROBLEM", 114, 123], ["these cells", "PROBLEM", 148, 159], ["efficient", "OBSERVATION_MODIFIER", 49, 58], ["infection", "OBSERVATION", 59, 68], ["feline cells", "OBSERVATION", 81, 93], ["infection", "OBSERVATION", 114, 123], ["many cell types", "OBSERVATION", 180, 195]]], ["It is possible the utilization of a C-type lectin may be involved in host range changes that are known to occur with coronavirus infections.", [["coronavirus infections", "DISEASE", 117, 139], ["C-type lectin", "GENE_OR_GENE_PRODUCT", 36, 49], ["coronavirus", "ORGANISM", 117, 128], ["C-type lectin", "PROTEIN", 36, 49], ["a C-type lectin", "TREATMENT", 34, 49], ["coronavirus infections", "PROBLEM", 117, 139], ["host range", "OBSERVATION_MODIFIER", 69, 79]]], ["Alternatively, use of L-SIGN and DC-SIGN may be involved in the spread of the virus to new cell types or target organs within an infected animal.", [["DC", "ANATOMY", 33, 35], ["cell", "ANATOMY", 91, 95], ["organs", "ANATOMY", 112, 118], ["L-SIGN", "GENE_OR_GENE_PRODUCT", 22, 28], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 33, 40], ["cell", "CELL", 91, 95], ["organs", "ORGAN", 112, 118], ["L-SIGN", "PROTEIN", 22, 28], ["DC", "CELL_TYPE", 33, 35], ["SIGN", "PROTEIN", 36, 40], ["the virus", "PROBLEM", 74, 83], ["target organs", "PROBLEM", 105, 118], ["infected", "OBSERVATION", 129, 137]]], ["Although it is evident that IBV viral replication took place in the mouse cell line expressing DC-SIGN, the level of released viruses into the infected cell culture supernatant was not observed, possibly due to defects in virus assembly or release in these mouse cells (data not shown).DiscussionOur studies rely on the use of a human lectin to rescue IBV infection.", [["cell line", "ANATOMY", 74, 83], ["DC-SIGN", "ANATOMY", 95, 102], ["cell culture supernatant", "ANATOMY", 152, 176], ["cells", "ANATOMY", 263, 268], ["IBV infection", "DISEASE", 352, 365], ["IBV viral", "ORGANISM", 28, 37], ["mouse", "ORGANISM", 68, 73], ["cell line", "CELL", 74, 83], ["DC-SIGN", "CELL", 95, 102], ["cell", "CELL", 152, 156], ["mouse", "ORGANISM", 257, 262], ["cells", "CELL", 263, 268], ["human", "ORGANISM", 329, 334], ["lectin", "GENE_OR_GENE_PRODUCT", 335, 341], ["IBV", "ORGANISM", 352, 355], ["mouse cell line", "CELL_LINE", 68, 83], ["DC", "CELL_TYPE", 95, 97], ["SIGN", "PROTEIN", 98, 102], ["mouse cells", "CELL_TYPE", 257, 268], ["human lectin", "PROTEIN", 329, 341], ["mouse", "SPECIES", 68, 73], ["mouse", "SPECIES", 257, 262], ["human", "SPECIES", 329, 334], ["IBV", "SPECIES", 28, 31], ["mouse", "SPECIES", 68, 73], ["mouse", "SPECIES", 257, 262], ["human", "SPECIES", 329, 334], ["IBV", "SPECIES", 352, 355], ["IBV viral replication", "TREATMENT", 28, 49], ["the infected cell culture", "TEST", 139, 164], ["defects in virus assembly", "PROBLEM", 211, 236], ["DiscussionOur studies", "TEST", 286, 307], ["a human lectin", "TREATMENT", 327, 341], ["IBV infection", "PROBLEM", 352, 365], ["viral replication", "OBSERVATION", 32, 49], ["cell line", "OBSERVATION", 74, 83], ["infected cell", "OBSERVATION", 143, 156], ["possibly due to", "UNCERTAINTY", 195, 210], ["defects", "OBSERVATION", 211, 218], ["virus", "OBSERVATION", 222, 227], ["infection", "OBSERVATION", 356, 365]]], ["A chicken holmolog of L-SIGN and DC-SIGN has not been identified and so it remains unclear what lectins might be involved in IBV infection in the chicken.", [["DC", "ANATOMY", 33, 35], ["IBV infection", "DISEASE", 125, 138], ["chicken", "ORGANISM", 2, 9], ["L-SIGN", "GENE_OR_GENE_PRODUCT", 22, 28], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 33, 40], ["IBV", "ORGANISM", 125, 128], ["chicken", "ORGANISM", 146, 153], ["SIGN", "PROTEIN", 24, 28], ["DC", "CELL_TYPE", 33, 35], ["SIGN", "PROTEIN", 36, 40], ["chicken", "SPECIES", 2, 9], ["chicken", "SPECIES", 146, 153], ["chicken", "SPECIES", 2, 9], ["IBV", "SPECIES", 125, 128], ["chicken", "SPECIES", 146, 153], ["IBV infection", "PROBLEM", 125, 138], ["IBV", "OBSERVATION_MODIFIER", 125, 128], ["infection", "OBSERVATION", 129, 138]]], ["We performed BLAST analysis of the chicken genome in an attempt to reveal potential chicken homologs of DC-SIGN.", [["DC", "ANATOMY", 104, 106], ["chicken", "ORGANISM", 35, 42], ["chicken", "ORGANISM", 84, 91], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 104, 111], ["chicken genome", "DNA", 35, 49], ["DC", "CELL_TYPE", 104, 106], ["SIGN", "PROTEIN", 107, 111], ["chicken", "SPECIES", 35, 42], ["chicken", "SPECIES", 84, 91], ["chicken", "SPECIES", 35, 42], ["chicken", "SPECIES", 84, 91], ["BLAST analysis", "TEST", 13, 27], ["the chicken genome", "TREATMENT", 31, 49]]], ["Three lectins, chicken hepatic lectin, the chicken C-type lectin receptor B-NK and chicken B-lec, were identified as the closest homologs to human DC-SIGN by amino acid sequence.", [["NK", "ANATOMY", 76, 78], ["DC", "ANATOMY", 147, 149], ["amino acid", "CHEMICAL", 158, 168], ["amino acid", "CHEMICAL", 158, 168], ["chicken", "ORGANISM", 15, 22], ["hepatic lectin", "GENE_OR_GENE_PRODUCT", 23, 37], ["chicken", "ORGANISM", 43, 50], ["C-type lectin receptor B-NK", "GENE_OR_GENE_PRODUCT", 51, 78], ["chicken B-lec", "GENE_OR_GENE_PRODUCT", 83, 96], ["human", "ORGANISM", 141, 146], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 147, 154], ["amino acid", "AMINO_ACID", 158, 168], ["lectins", "PROTEIN", 6, 13], ["chicken hepatic lectin", "PROTEIN", 15, 37], ["chicken C-type lectin receptor B", "PROTEIN", 43, 75], ["NK", "PROTEIN", 76, 78], ["chicken B", "PROTEIN", 83, 92], ["lec", "PROTEIN", 93, 96], ["human DC", "CELL_TYPE", 141, 149], ["SIGN", "PROTEIN", 150, 154], ["amino acid sequence", "PROTEIN", 158, 177], ["chicken", "SPECIES", 15, 22], ["chicken", "SPECIES", 43, 50], ["chicken", "SPECIES", 83, 90], ["human", "SPECIES", 141, 146], ["chicken", "SPECIES", 15, 22], ["chicken", "SPECIES", 43, 50], ["human", "SPECIES", 141, 146], ["Three lectins", "TREATMENT", 0, 13], ["chicken hepatic lectin", "TREATMENT", 15, 37], ["the chicken C", "TREATMENT", 39, 52], ["amino acid sequence", "TEST", 158, 177], ["hepatic", "ANATOMY", 23, 30], ["lectin", "ANATOMY_MODIFIER", 31, 37], ["NK", "ANATOMY", 76, 78]]], ["Each of these homologs was cloned and expressed in 3T3 cells, but in each case the expressed lectin was unable to rescue infection of IBV (data not shown).", [["3T3 cells", "ANATOMY", 51, 60], ["infection", "DISEASE", 121, 130], ["3T3 cells", "CELL", 51, 60], ["lectin", "GENE_OR_GENE_PRODUCT", 93, 99], ["IBV", "ORGANISM", 134, 137], ["3T3 cells", "CELL_LINE", 51, 60], ["lectin", "PROTEIN", 93, 99], ["IBV", "SPECIES", 134, 137], ["infection of IBV", "PROBLEM", 121, 137]]], ["The failure to rescue IBV infection may be due to differences in carbohydrate specificity.", [["IBV infection", "DISEASE", 22, 35], ["carbohydrate", "CHEMICAL", 65, 77], ["IBV", "ORGANISM", 22, 25], ["carbohydrate", "SIMPLE_CHEMICAL", 65, 77], ["IBV", "SPECIES", 22, 25], ["The failure", "PROBLEM", 0, 11], ["rescue IBV infection", "PROBLEM", 15, 35], ["carbohydrate specificity", "TEST", 65, 89], ["failure", "OBSERVATION", 4, 11], ["IBV", "OBSERVATION_MODIFIER", 22, 25], ["infection", "OBSERVATION", 26, 35], ["may be due to", "UNCERTAINTY", 36, 49]]], ["It is thought that DC-SIGN binds to high mannose and/or fucose residues on the glycoproteins (Guo et al., 2004) including the coronavirus spike protein (Khoo et al., 2008) and the potential chicken DC-SIGN homologs tested may have different carbohydrate-binding specificity.", [["DC", "ANATOMY", 19, 21], ["DC", "ANATOMY", 198, 200], ["mannose", "CHEMICAL", 41, 48], ["fucose", "CHEMICAL", 56, 62], ["carbohydrate", "CHEMICAL", 241, 253], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 19, 26], ["mannose", "SIMPLE_CHEMICAL", 41, 48], ["fucose", "AMINO_ACID", 56, 62], ["chicken", "ORGANISM", 190, 197], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 198, 205], ["DC", "CELL_TYPE", 19, 21], ["SIGN", "PROTEIN", 22, 26], ["coronavirus spike protein", "PROTEIN", 126, 151], ["chicken DC-SIGN homologs", "PROTEIN", 190, 214], ["chicken", "SPECIES", 190, 197], ["chicken", "SPECIES", 190, 197], ["high mannose", "PROBLEM", 36, 48], ["fucose residues", "PROBLEM", 56, 71], ["the coronavirus spike protein", "PROBLEM", 122, 151]]], ["For example, chicken hepatic lectin, which has the highest homology to human DC-SIGN, is known to be specific for terminal N-acetylglucosamine on glycoproteins (Kawasaki and Ashwell, 1977) .", [["hepatic", "ANATOMY", 21, 28], ["DC", "ANATOMY", 77, 79], ["N-acetylglucosamine", "CHEMICAL", 123, 142], ["chicken", "ORGANISM", 13, 20], ["hepatic lectin", "GENE_OR_GENE_PRODUCT", 21, 35], ["human", "ORGANISM", 71, 76], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 77, 84], ["terminal N-acetylglucosamine", "SIMPLE_CHEMICAL", 114, 142], ["chicken hepatic lectin", "PROTEIN", 13, 35], ["human DC", "CELL_TYPE", 71, 79], ["SIGN", "PROTEIN", 80, 84], ["chicken", "SPECIES", 13, 20], ["human", "SPECIES", 71, 76], ["chicken", "SPECIES", 13, 20], ["human", "SPECIES", 71, 76], ["chicken hepatic lectin", "PROBLEM", 13, 35], ["terminal N-acetylglucosamine on glycoproteins", "TREATMENT", 114, 159], ["hepatic", "ANATOMY", 21, 28], ["lectin", "ANATOMY_MODIFIER", 29, 35]]], ["Thus a functional equivalent to DC-SIGN remains to be identified in the chicken.DiscussionPrevious reports have indicated a low level of IBV infection in feline CRFK cells, suggesting that feline APN (fAPN) is a possible IBV receptor.", [["DC", "ANATOMY", 32, 34], ["CRFK cells", "ANATOMY", 161, 171], ["IBV infection", "DISEASE", 137, 150], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 32, 39], ["chicken", "ORGANISM", 72, 79], ["IBV", "ORGANISM", 137, 140], ["feline", "ORGANISM", 154, 160], ["CRFK cells", "CELL", 161, 171], ["feline", "ORGANISM", 189, 195], ["APN", "GENE_OR_GENE_PRODUCT", 196, 199], ["fAPN", "GENE_OR_GENE_PRODUCT", 201, 205], ["IBV", "ORGANISM", 221, 224], ["DC", "CELL_TYPE", 32, 34], ["SIGN", "PROTEIN", 35, 39], ["feline CRFK cells", "CELL_TYPE", 154, 171], ["feline APN", "PROTEIN", 189, 199], ["fAPN", "PROTEIN", 201, 205], ["IBV receptor", "PROTEIN", 221, 233], ["chicken", "SPECIES", 72, 79], ["feline", "SPECIES", 154, 160], ["chicken", "SPECIES", 72, 79], ["IBV", "SPECIES", 137, 140], ["IBV", "SPECIES", 221, 224], ["IBV infection in feline CRFK cells", "PROBLEM", 137, 171], ["IBV receptor", "TREATMENT", 221, 233], ["low level", "OBSERVATION_MODIFIER", 124, 133], ["IBV", "OBSERVATION_MODIFIER", 137, 140], ["infection", "OBSERVATION", 141, 150], ["possible", "UNCERTAINTY", 212, 220]]], ["While feline CRFK cells were rescued for IBV infection by DC-SIGN expression, the same situation occurred for mouse 3T3 cells.", [["CRFK cells", "ANATOMY", 13, 23], ["DC", "ANATOMY", 58, 60], ["3T3 cells", "ANATOMY", 116, 125], ["infection", "DISEASE", 45, 54], ["feline", "ORGANISM", 6, 12], ["CRFK cells", "CELL", 13, 23], ["IBV", "ORGANISM", 41, 44], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 58, 65], ["mouse", "ORGANISM", 110, 115], ["3T3 cells", "CELL", 116, 125], ["feline CRFK cells", "CELL_LINE", 6, 23], ["DC", "CELL_TYPE", 58, 60], ["SIGN", "PROTEIN", 61, 65], ["mouse 3T3 cells", "CELL_LINE", 110, 125], ["feline", "SPECIES", 6, 12], ["mouse", "SPECIES", 110, 115], ["IBV", "SPECIES", 41, 44], ["mouse", "SPECIES", 110, 115], ["feline CRFK cells", "PROBLEM", 6, 23], ["IBV infection", "PROBLEM", 41, 54], ["mouse 3T3 cells", "PROBLEM", 110, 125]]], ["Assuming that DC-SIGN is acting in concert with an additional IBV receptor, it appears that both mouse and feline homologs of this receptor are able to act, at least in the presence of high levels of DC-SIGN expression.", [["DC", "ANATOMY", 14, 16], ["DC", "ANATOMY", 200, 202], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 14, 21], ["mouse", "ORGANISM", 97, 102], ["feline", "ORGANISM", 107, 113], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 200, 207], ["DC", "CELL_TYPE", 14, 16], ["SIGN", "PROTEIN", 17, 21], ["IBV receptor", "PROTEIN", 62, 74], ["DC", "CELL_TYPE", 200, 202], ["SIGN", "PROTEIN", 203, 207], ["mouse", "SPECIES", 97, 102], ["IBV", "SPECIES", 62, 65], ["mouse", "SPECIES", 97, 102], ["an additional IBV receptor", "TREATMENT", 48, 74]]], ["In addition to testing for the function of over-expressed fAPN, we also cloned and expressed the chicken aminopeptidase N (chAPN).", [["fAPN", "GENE_OR_GENE_PRODUCT", 58, 62], ["chicken", "ORGANISM", 97, 104], ["aminopeptidase N", "GENE_OR_GENE_PRODUCT", 105, 121], ["chAPN", "GENE_OR_GENE_PRODUCT", 123, 128], ["fAPN", "PROTEIN", 58, 62], ["chicken aminopeptidase N", "PROTEIN", 97, 121], ["chAPN", "PROTEIN", 123, 128], ["chicken", "SPECIES", 97, 104], ["chicken", "SPECIES", 97, 104], ["testing", "TEST", 15, 22], ["the chicken aminopeptidase N (chAPN)", "TREATMENT", 93, 129]]], ["However, like fAPN, this potential receptor failed to rescue infection by IBV (data not shown).", [["infection", "DISEASE", 61, 70], ["fAPN", "GENE_OR_GENE_PRODUCT", 14, 18], ["IBV", "ORGANISM", 74, 77], ["fAPN", "PROTEIN", 14, 18], ["IBV", "SPECIES", 74, 77], ["rescue infection", "PROBLEM", 54, 70], ["IBV (data", "TEST", 74, 83], ["infection", "OBSERVATION", 61, 70]]], ["Cell lines in culture typically do not express C-type lectins such as DC-SIGN.", [["Cell lines", "ANATOMY", 0, 10], ["DC", "ANATOMY", 70, 72], ["Cell lines", "CELL", 0, 10], ["C-type lectins", "GENE_OR_GENE_PRODUCT", 47, 61], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 70, 77], ["C-type lectins", "PROTEIN", 47, 61], ["DC", "CELL_TYPE", 70, 72], ["SIGN", "PROTEIN", 73, 77], ["Cell lines in culture", "TEST", 0, 21]]], ["However we observed that there was is always a very low amount of infection observed in most avian and mammalian cell lines tested, perhaps due to a very low level of C-type lectin expression or the inefficient use of a homologous (non-chicken) receptor.DiscussionWhile C-type lectins can allow infection of cells by IBV, they are unlikely to be the sole component of the IBV receptor complex in chicken epithelial cells, since we were not able to find a critical role of mannose-binding molecules in the infection of chicken kidney cells by IBV.", [["cell lines", "ANATOMY", 113, 123], ["cells", "ANATOMY", 308, 313], ["epithelial cells", "ANATOMY", 404, 420], ["kidney cells", "ANATOMY", 526, 538], ["infection", "DISEASE", 66, 75], ["infection", "DISEASE", 295, 304], ["infection", "DISEASE", 505, 514], ["mannose", "CHEMICAL", 472, 479], ["mammalian cell lines", "CELL", 103, 123], ["C-type lectin", "GENE_OR_GENE_PRODUCT", 167, 180], ["non-chicken) receptor", "GENE_OR_GENE_PRODUCT", 232, 253], ["C-type lectins", "GENE_OR_GENE_PRODUCT", 270, 284], ["cells", "CELL", 308, 313], ["IBV", "ORGANISM", 317, 320], ["IBV", "ORGANISM", 372, 375], ["chicken", "ORGANISM", 396, 403], ["epithelial cells", "CELL", 404, 420], ["mannose-binding molecules", "GENE_OR_GENE_PRODUCT", 472, 497], ["chicken", "ORGANISM", 518, 525], ["kidney cells", "CELL", 526, 538], ["IBV", "ORGANISM", 542, 545], ["mammalian cell lines", "CELL_LINE", 103, 123], ["C-type lectin", "PROTEIN", 167, 180], ["homologous (non-chicken) receptor", "PROTEIN", 220, 253], ["C-type lectins", "PROTEIN", 270, 284], ["IBV receptor complex", "PROTEIN", 372, 392], ["chicken epithelial cells", "CELL_TYPE", 396, 420], ["mannose-binding molecules", "PROTEIN", 472, 497], ["chicken kidney cells", "CELL_TYPE", 518, 538], ["chicken", "SPECIES", 396, 403], ["chicken", "SPECIES", 518, 525], ["IBV", "SPECIES", 317, 320], ["IBV", "SPECIES", 372, 375], ["chicken", "SPECIES", 396, 403], ["chicken", "SPECIES", 518, 525], ["IBV", "SPECIES", 542, 545], ["a very low amount of infection", "PROBLEM", 45, 75], ["mammalian cell lines", "TREATMENT", 103, 123], ["a very low level of C-type lectin expression", "PROBLEM", 147, 191], ["a homologous (non-chicken) receptor", "TREATMENT", 218, 253], ["C-type lectins", "PROBLEM", 270, 284], ["infection of cells", "PROBLEM", 295, 313], ["IBV", "PROBLEM", 317, 320], ["the IBV receptor complex in chicken epithelial cells", "PROBLEM", 368, 420], ["mannose-binding molecules", "PROBLEM", 472, 497], ["the infection of chicken kidney cells", "PROBLEM", 501, 538], ["IBV", "PROBLEM", 542, 545], ["very", "OBSERVATION_MODIFIER", 47, 51], ["low amount", "OBSERVATION_MODIFIER", 52, 62], ["infection", "OBSERVATION", 66, 75], ["most avian", "OBSERVATION_MODIFIER", 88, 98], ["mammalian cell lines", "OBSERVATION", 103, 123], ["epithelial cells", "OBSERVATION", 404, 420], ["infection", "OBSERVATION", 505, 514], ["kidney", "ANATOMY", 526, 532]]], ["While in vivo infection with most IBV strains is primarily localized to the respiratory tract, it is known that certain strains can spread to other organs, e.g. kidney and oviduct.", [["respiratory tract", "ANATOMY", 76, 93], ["organs", "ANATOMY", 148, 154], ["kidney", "ANATOMY", 161, 167], ["oviduct", "ANATOMY", 172, 179], ["infection", "DISEASE", 14, 23], ["IBV", "ORGANISM", 34, 37], ["respiratory tract", "ORGANISM_SUBDIVISION", 76, 93], ["organs", "ORGAN", 148, 154], ["kidney", "ORGAN", 161, 167], ["oviduct", "ORGAN", 172, 179], ["IBV", "SPECIES", 34, 37], ["vivo infection", "PROBLEM", 9, 23], ["most IBV strains", "PROBLEM", 29, 45], ["certain strains", "PROBLEM", 112, 127], ["infection", "OBSERVATION", 14, 23], ["respiratory tract", "ANATOMY", 76, 93], ["kidney", "ANATOMY", 161, 167], ["oviduct", "ANATOMY", 172, 179]]], ["This in vivo spread is likely to be highly influenced by C-type lectin expression and distribution, especially in relation to the proposed role of hematopoetic cells, such as macrophages, which often express high levels of C-type lectins and can readily disseminate the virus to distant organs.", [["hematopoetic cells", "ANATOMY", 147, 165], ["macrophages", "ANATOMY", 175, 186], ["organs", "ANATOMY", 287, 293], ["C-type lectin", "GENE_OR_GENE_PRODUCT", 57, 70], ["hematopoetic cells", "CELL", 147, 165], ["macrophages", "CELL", 175, 186], ["C-type lectins", "GENE_OR_GENE_PRODUCT", 223, 237], ["organs", "ORGAN", 287, 293], ["lectin", "PROTEIN", 64, 70], ["hematopoetic cells", "CELL_TYPE", 147, 165], ["macrophages", "CELL_TYPE", 175, 186], ["C-type lectins", "PROTEIN", 223, 237], ["hematopoetic cells", "PROBLEM", 147, 165], ["macrophages", "PROBLEM", 175, 186], ["high levels of C-type lectins", "PROBLEM", 208, 237], ["likely to be", "UNCERTAINTY", 23, 35], ["distribution", "OBSERVATION_MODIFIER", 86, 98], ["hematopoetic cells", "OBSERVATION", 147, 165], ["macrophages", "OBSERVATION", 175, 186]]], ["Nevertheless, the C-type lectin molecules DC-/L-SIGN are able to mediate efficient IBV infection even in the absence of a chicken -specific receptor.", [["IBV infection", "DISEASE", 83, 96], ["C-type lectin", "GENE_OR_GENE_PRODUCT", 18, 31], ["L-SIGN", "GENE_OR_GENE_PRODUCT", 46, 52], ["IBV", "ORGANISM", 83, 86], ["chicken", "ORGANISM", 122, 129], ["C-type lectin molecules", "PROTEIN", 18, 41], ["DC", "PROTEIN", 42, 44], ["L-SIGN", "PROTEIN", 46, 52], ["chicken -specific receptor", "PROTEIN", 122, 148], ["chicken", "SPECIES", 122, 129], ["IBV", "SPECIES", 83, 86], ["chicken", "SPECIES", 122, 129], ["efficient IBV infection", "PROBLEM", 73, 96], ["IBV", "OBSERVATION_MODIFIER", 83, 86], ["infection", "OBSERVATION", 87, 96]]], ["Overall, our findings on lectin-virus interactions reveal important parts of the IBV receptor complex, the full intricacy of which remains to be determined.Figure 1.", [["lectin", "GENE_OR_GENE_PRODUCT", 25, 31], ["IBV", "ORGANISM", 81, 84], ["lectin", "PROTEIN", 25, 31], ["IBV receptor complex", "PROTEIN", 81, 101], ["IBV", "SPECIES", 81, 84], ["lectin-virus interactions", "TREATMENT", 25, 50], ["the IBV receptor complex", "TREATMENT", 77, 101]]], ["IBV-M41 infection of 3T3 and CRFK cells is enhanced by introduction of hDC-SIGN or hL-SIGN3T3 (A) or CRFK (B) cells were transfected with expression plasmids for hDC-SIGN or hL-SIGN and infected with 10 3 TCID50/ml of IBV-M41 for 1 h at 37\u00b0C. Cells were washed 3 times with sterile PBS and further incubated for 12 h before fixing with methanol.", [["3T3", "ANATOMY", 21, 24], ["CRFK cells", "ANATOMY", 29, 39], ["hDC-SIGN", "ANATOMY", 71, 79], ["hL-SIGN3T3 (A", "ANATOMY", 83, 96], ["CRFK (B) cells", "ANATOMY", 101, 115], ["plasmids", "ANATOMY", 149, 157], ["Cells", "ANATOMY", 243, 248], ["infection", "DISEASE", 8, 17], ["methanol", "CHEMICAL", 336, 344], ["methanol", "CHEMICAL", 336, 344], ["IBV-M41", "ORGANISM", 0, 7], ["3T3", "CELL", 21, 24], ["CRFK cells", "CELL", 29, 39], ["hDC-SIGN", "GENE_OR_GENE_PRODUCT", 71, 79], ["hL-SIGN3T3", "GENE_OR_GENE_PRODUCT", 83, 93], ["A", "CELL", 95, 96], ["CRFK (B) cells", "CELL", 101, 115], ["hDC-SIGN", "GENE_OR_GENE_PRODUCT", 162, 170], ["hL-SIGN", "CELL", 174, 181], ["IBV", "ORGANISM", 218, 221], ["Cells", "CELL", 243, 248], ["methanol", "SIMPLE_CHEMICAL", 336, 344], ["3T3", "CELL_LINE", 21, 24], ["CRFK cells", "CELL_LINE", 29, 39], ["hDC-SIGN or hL-SIGN3T3 (A) or CRFK (B) cells", "CELL_LINE", 71, 115], ["expression plasmids", "DNA", 138, 157], ["hDC", "PROTEIN", 162, 165], ["SIGN", "PROTEIN", 166, 170], ["hL", "DNA", 174, 176], ["SIGN", "DNA", 177, 181], ["IBV-M41", "SPECIES", 0, 7], ["IBV-M41", "SPECIES", 218, 225], ["IBV", "TEST", 0, 3], ["M41 infection of 3T3 and CRFK cells", "PROBLEM", 4, 39], ["hDC", "TEST", 71, 74], ["hL", "PROBLEM", 83, 85], ["CRFK (B) cells", "PROBLEM", 101, 115], ["expression plasmids", "TREATMENT", 138, 157], ["hDC", "TEST", 162, 165], ["hL", "PROBLEM", 174, 176], ["IBV", "TREATMENT", 218, 221], ["sterile PBS", "TREATMENT", 274, 285], ["methanol", "TREATMENT", 336, 344], ["infection", "OBSERVATION", 8, 17]]], ["Viral S protein was detected by immunofluorescence microscopy using the anti-S1 mouse monoclonal antibody 15:88 following by goat anti-mouse AlexaFluor-568.", [["AlexaFluor-568", "CHEMICAL", 141, 155], ["AlexaFluor-568", "CHEMICAL", 141, 155], ["Viral S protein", "GENE_OR_GENE_PRODUCT", 0, 15], ["mouse", "ORGANISM", 80, 85], ["goat", "ORGANISM", 125, 129], ["AlexaFluor-568", "SIMPLE_CHEMICAL", 141, 155], ["Viral S protein", "PROTEIN", 0, 15], ["anti-S1 mouse monoclonal antibody 15:88", "PROTEIN", 72, 111], ["goat anti-mouse AlexaFluor-568", "PROTEIN", 125, 155], ["mouse", "SPECIES", 80, 85], ["goat", "SPECIES", 125, 129], ["anti-mouse", "SPECIES", 130, 140], ["mouse", "SPECIES", 80, 85], ["goat", "SPECIES", 125, 129], ["Viral S protein", "TEST", 0, 15], ["immunofluorescence microscopy", "TEST", 32, 61], ["the anti-S1 mouse monoclonal antibody", "TEST", 68, 105]]], ["Lectin expression was detected using the 14EG7 monoclonal antibody.", [["Lectin", "GENE_OR_GENE_PRODUCT", 0, 6], ["Lectin", "PROTEIN", 0, 6], ["14EG7 monoclonal antibody", "PROTEIN", 41, 66], ["Lectin expression", "PROBLEM", 0, 17]]], ["Cell nuclei were counterstained with Hoechst 33258.Figure 2.", [["Cell nuclei", "ANATOMY", 0, 11], ["Hoechst 33258", "CHEMICAL", 37, 50], ["Hoechst 33258", "CHEMICAL", 37, 50], ["Cell nuclei", "CELL", 0, 11], ["Hoechst 33258", "SIMPLE_CHEMICAL", 37, 50]]], ["IBV-M41 infection is enhanced on 3T3 or CRFK cells stably expressing DCSIGN3T3 or CRFK cells stably expressing DCSIGN cells were infected with 10 3 TCID50/ml of IBV-M41 for 1 h at 37\u00b0C. Cells were washed 3 times with sterile PBS and further incubated for 12 h before fixing with methanol.", [["3T3", "ANATOMY", 33, 36], ["CRFK cells", "ANATOMY", 40, 50], ["DCSIGN3T3", "ANATOMY", 69, 78], ["CRFK cells", "ANATOMY", 82, 92], ["DCSIGN cells", "ANATOMY", 111, 123], ["Cells", "ANATOMY", 186, 191], ["infection", "DISEASE", 8, 17], ["methanol", "CHEMICAL", 279, 287], ["methanol", "CHEMICAL", 279, 287], ["IBV-M41", "ORGANISM", 0, 7], ["3T3", "CELL", 33, 36], ["CRFK cells", "CELL", 40, 50], ["DCSIGN3T3", "CELL", 69, 78], ["CRFK cells", "CELL", 82, 92], ["DCSIGN cells", "CELL", 111, 123], ["IBV", "ORGANISM", 161, 164], ["-M41", "ORGANISM", 164, 168], ["Cells", "CELL", 186, 191], ["methanol", "SIMPLE_CHEMICAL", 279, 287], ["3T3", "CELL_LINE", 33, 36], ["CRFK cells", "CELL_LINE", 40, 50], ["DCSIGN3T3", "CELL_LINE", 69, 78], ["CRFK cells", "CELL_LINE", 82, 92], ["DCSIGN cells", "CELL_LINE", 111, 123], ["IBV-M41", "SPECIES", 0, 7], ["IBV-M41", "SPECIES", 161, 168], ["IBV", "PROBLEM", 0, 3], ["M41 infection", "PROBLEM", 4, 17], ["CRFK cells", "PROBLEM", 40, 50], ["CRFK cells", "PROBLEM", 82, 92], ["DCSIGN cells", "PROBLEM", 111, 123], ["IBV", "TREATMENT", 161, 164], ["sterile PBS", "TREATMENT", 217, 228], ["methanol", "TREATMENT", 279, 287], ["infection", "OBSERVATION", 8, 17]]], ["Viral S protein was detected by immunofluorescence microscopy using the anti-S1 mouse monoclonal antibody 15:88 following by goat antimouse AlexaFluor-568.", [["AlexaFluor-568", "CHEMICAL", 140, 154], ["AlexaFluor-568", "CHEMICAL", 140, 154], ["Viral S protein", "GENE_OR_GENE_PRODUCT", 0, 15], ["mouse", "ORGANISM", 80, 85], ["goat", "ORGANISM", 125, 129], ["AlexaFluor-568", "SIMPLE_CHEMICAL", 140, 154], ["Viral S protein", "PROTEIN", 0, 15], ["anti-S1 mouse monoclonal antibody 15:88", "PROTEIN", 72, 111], ["goat antimouse AlexaFluor-568", "PROTEIN", 125, 154], ["mouse", "SPECIES", 80, 85], ["goat", "SPECIES", 125, 129], ["mouse", "SPECIES", 80, 85], ["goat", "SPECIES", 125, 129], ["Viral S protein", "TEST", 0, 15], ["immunofluorescence microscopy", "TEST", 32, 61], ["the anti-S1 mouse monoclonal antibody", "TREATMENT", 68, 105]]], ["Cells were quantified by scoring the percentage of cells positive for viral antigen. >200 cells were quantified from three independent experiments.", [["Cells", "ANATOMY", 0, 5], ["cells", "ANATOMY", 51, 56], ["cells", "ANATOMY", 90, 95], ["Cells", "CELL", 0, 5], ["cells", "CELL", 51, 56], ["viral antigen", "GENE_OR_GENE_PRODUCT", 70, 83], ["cells", "CELL", 90, 95], ["viral antigen", "PROTEIN", 70, 83], ["viral antigen", "PROBLEM", 70, 83]]], ["Error bars represent the standard deviation from the mean.", [["the standard deviation", "PROBLEM", 21, 43], ["standard deviation", "OBSERVATION", 25, 43]]], ["3T3-DCSIGN cells were treated with 50\u03bcg/ml mannan (A) or 20mg/ml anti-DC-SIGN antibody 9E9A8 (C) prior to infection with 10 3 TCID50/ml of IBV-M41.", [["3T3-DCSIGN cells", "ANATOMY", 0, 16], ["infection", "DISEASE", 106, 115], ["3T3-DCSIGN cells", "CELL", 0, 16], ["mannan", "SIMPLE_CHEMICAL", 43, 49], ["A", "SIMPLE_CHEMICAL", 51, 52], ["anti-DC-SIGN", "SIMPLE_CHEMICAL", 65, 77], ["C", "SIMPLE_CHEMICAL", 94, 95], ["IBV", "ORGANISM", 139, 142], ["-M41", "ORGANISM", 142, 146], ["3T3", "CELL_LINE", 0, 3], ["DCSIGN cells", "CELL_LINE", 4, 16], ["anti-DC", "PROTEIN", 65, 72], ["SIGN antibody 9E9A8 (C)", "PROTEIN", 73, 96], ["IBV-M41", "SPECIES", 139, 146], ["anti-DC", "TEST", 65, 72], ["SIGN antibody", "TEST", 73, 86], ["infection", "PROBLEM", 106, 115], ["IBV", "TREATMENT", 139, 142], ["infection", "OBSERVATION", 106, 115]]], ["Cells were fixed at 24 h post infection and analyzed by immunofluorescence microscopy.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["Cells", "TEST", 0, 5], ["infection", "PROBLEM", 30, 39], ["immunofluorescence microscopy", "TEST", 56, 85], ["infection", "OBSERVATION", 30, 39]]], ["Cell nuclei were counterstained with Hoechst 33258.", [["Cell nuclei", "ANATOMY", 0, 11], ["Hoechst 33258", "CHEMICAL", 37, 50], ["Hoechst 33258", "CHEMICAL", 37, 50], ["Cell nuclei", "CELL", 0, 11], ["Hoechst 33258", "SIMPLE_CHEMICAL", 37, 50]]], ["For each treatment, cells were quantified by scoring the percentage of cells positive for viral antigen (B and D). >200 cells were quantified from three independent experiments.", [["cells", "ANATOMY", 20, 25], ["cells", "ANATOMY", 71, 76], ["cells", "ANATOMY", 120, 125], ["cells", "CELL", 20, 25], ["cells", "CELL", 71, 76], ["viral antigen", "GENE_OR_GENE_PRODUCT", 90, 103], ["B", "GENE_OR_GENE_PRODUCT", 105, 106], ["cells", "CELL", 120, 125], ["viral antigen", "PROTEIN", 90, 103], ["each treatment", "TREATMENT", 4, 18], ["viral antigen", "TEST", 90, 103]]], ["Error bars represent the standard deviation from the mean.Figure 5.", [["the standard deviation", "PROBLEM", 21, 43], ["standard deviation", "OBSERVATION", 25, 43]]], ["Effect of neuraminidase treatment on 3T3-DCSIGN cells infected by IBV-M413T3-DCSIGN cells were pre-treated with neuraminidase and then were infected by M41 (10 3 TCID50/ml), or a control virus, influenza A/WSN/33 (MOI of 5).", [["3T3-DCSIGN cells", "ANATOMY", 37, 53], ["IBV-M413T3-DCSIGN cells", "ANATOMY", 66, 89], ["M41", "CHEMICAL", 152, 155], ["neuraminidase", "SIMPLE_CHEMICAL", 10, 23], ["3T3-DCSIGN cells", "CELL", 37, 53], ["IBV", "ORGANISM", 66, 69], ["M413T3-DCSIGN cells", "CELL", 70, 89], ["neuraminidase", "PROTEIN", 10, 23], ["3T3-DCSIGN cells", "CELL_LINE", 37, 53], ["IBV-M413T3-DCSIGN cells", "CELL_LINE", 66, 89], ["neuraminidase", "PROTEIN", 112, 125], ["IBV", "SPECIES", 66, 69], ["influenza A/WSN/33", "SPECIES", 194, 212], ["neuraminidase treatment", "TREATMENT", 10, 33], ["3T3-DCSIGN cells", "TREATMENT", 37, 53], ["IBV", "TEST", 66, 69], ["DCSIGN cells", "PROBLEM", 77, 89], ["neuraminidase", "TREATMENT", 112, 125], ["a control virus", "PROBLEM", 177, 192], ["influenza", "PROBLEM", 194, 203]]], ["At 12 h post infection (M41) or 5 h post infection (WSN), cells were fixed and stained for immunofluorescence microscopy with 15:88 anti-S1 mouse monoclonal antibody (M41) or anti-NP mouse monoclonal antibody (WSN/33).", [["cells", "ANATOMY", 58, 63], ["infection", "DISEASE", 13, 22], ["infection", "DISEASE", 41, 50], ["cells", "CELL", 58, 63], ["mouse", "ORGANISM", 140, 145], ["M41", "CANCER", 167, 170], ["mouse", "ORGANISM", 183, 188], ["15:88 anti-S1 mouse monoclonal antibody", "PROTEIN", 126, 165], ["M41", "PROTEIN", 167, 170], ["anti-NP mouse monoclonal antibody", "PROTEIN", 175, 208], ["WSN/33", "PROTEIN", 210, 216], ["mouse", "SPECIES", 140, 145], ["mouse", "SPECIES", 183, 188], ["mouse", "SPECIES", 140, 145], ["mouse", "SPECIES", 183, 188], ["infection", "PROBLEM", 13, 22], ["infection", "PROBLEM", 41, 50], ["cells", "TEST", 58, 63], ["immunofluorescence microscopy", "TEST", 91, 120], ["anti", "TEST", 132, 136], ["S1 mouse monoclonal antibody", "TEST", 137, 165], ["anti-NP mouse monoclonal antibody", "TEST", 175, 208], ["infection", "OBSERVATION", 13, 22], ["infection", "OBSERVATION", 41, 50]]], ["Cells were quantified by scoring the percentage of cells positive for viral antigen. >200 cells were quantified from three independent experiments.", [["Cells", "ANATOMY", 0, 5], ["cells", "ANATOMY", 51, 56], ["cells", "ANATOMY", 90, 95], ["Cells", "CELL", 0, 5], ["cells", "CELL", 51, 56], ["viral antigen", "GENE_OR_GENE_PRODUCT", 70, 83], ["cells", "CELL", 90, 95], ["viral antigen", "PROTEIN", 70, 83], ["viral antigen", "PROBLEM", 70, 83]]], ["Error bars represent the standard deviation from the mean.", [["the standard deviation", "PROBLEM", 21, 43], ["standard deviation", "OBSERVATION", 25, 43]]]]}